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Due to the growing number of patients being treated for colorectal cancer (CRC), 
frequent specialist visits will no longer be logistically feasible as a result of the 
increased number of patients attending busy clinics.[17] Therefore, addressing patients’ 
needs and maintaining continuity of care will require strategies that supplement and 
support existing services. Various solutions have been explored by hospitals to support 
cancer patients, such as telephone support, especially following surgery. However, no 
conclusive evidence demonstrates the long-term outcomes of these solutions for 
supporting patients. 
 
Most people with CRC are now living beyond five years post treatment and have other 
chronic conditions for which they visit their general practitioner (GP) on a regular 
basis.[18] As the survival rate improves, GPs will find that patients with CRC will 
occupy a larger proportion of their practices, and hence GPs will need additional 
support. In Australia, GPs are the first point of contact for patients in the health system. 
Based on these factors, there is potential for GPs to support CRC patients together with 
ongoing specialist care. 
 
This thesis explores the use of general practice as a setting to support CRC patients in 
the long term. The purpose of this thesis is to develop and assess the feasibility of a 
needs-assessment tool (self-assessment tool for patients—SATp) to support patients 
that seek health advice from their GPs regarding CRC-related health problems. Further, 
this thesis assesses GPs’ approaches to treating common CRC related problems. 
 
The theoretical base for this study was the Glasziou and Haynes model of evidence-
based medicine, which outlines the path from research to improved health outcomes. 
Various techniques were employed to collect data specifically, the Delphi technique, 
surveys and video vignettes. The data collection instruments included the SATp 
questionnaire, Theory of Planned Behaviour and internet-based GP questionnaires, as 
well as review of clinical notes. 
 
xviii 
The major outcomes of the thesis were as follows: 
 
 The valid needs-assessment measure (SATp) in Study 1: The SATp 
demonstrated internal consistency (Cronbach’s alpha 0.70–0.97), readability 
(reading ease 82.5%) and test–retest reliability (kappa 0.689–1.000). A total of 
30 patients piloted the SATp. Participants were on average 69.2 (standard 
deviation [SD] 9.9) years old, while 26.7 months (range 6–92, median 28) was 
the median follow-up period at the outpatient cancer clinic. A total of 149 
issues associated with CRC treatment were identified by the SATp, with an 
average of 8.1 needs per patient (median 7; interquartile range [IQR] 3–12.25). 
The identified needs were in the physical (53, 36%), psychological (53, 36%) 
and social (48, 32%) domains. The SATp contained 25 questions. 
 
 Trialling of the SATp in Study 3: A trial with a cohort of 66 patients with CRC 
in general practice over a five month period revealed a statistically significant 
reduction in the number of patient-reported psychological CRC problems. Of 
the 66 participants who completed this cohort study, 86% visited a GP during 
the five-month study period. A total of 547 problems were identified (median 
7; IQR 3–12.25). Participants with physical problems were more likely to 
consult their GP (p = 0.05) compared to those with social or psychological 
problems. This trend was demonstrated in participants with diarrhoea (odds 
ratio [OR] 1.84, 95% confidence interval (CI) 1.05–3.21, p = 0.03). The 
number of problems experienced by participants did not appear to have any 
influence on the decision to visit a GP. Self-reported psychological problems 
(p < 0.01) significantly reduced over the five-month study period. There were 
no statistically significant reductions in the number of physical or social 
problems. GP consultations (n = 117) resulted in a total of 78 management 
actions. Of these, 25 of 78 (32%) were prescriptions, 17 (22%) were 
investigations and nine (11.5%) were referrals. Prescriptions were mostly for 
antidepressants (9 of 25, 36%), sedatives (6 of 25, 24%) and analgesics (3 of 
25, 12%). 
 
 Study 2 assessed patients’ decisions to seek health advice from a GP about 
their CRC-related problems. In this study, there were higher patient intentions 
xix 
to visit a GP for CRC support, especially among those with another chronic 
illness. Patient attitude (believing their GP has the skills and knowledge to 
detect a recurrence) and the presence of other comorbidities significantly 
affected future intention to visit a GP (attitude: R2 = 0.233, F [1, 65] = 4.345, 
p < 0.01; comorbidity: R2 = 0.128, F [1, 65] = 3.019, p < 0.05). 
 
 Study 4 explored the effect of a variety of clinical and respondent 
characteristics on GPs’ decisions to treat patients with treatment side-effects or 
symptoms of recurrence of CRC. The results revealed that management by GPs 
of most CRC-related problems was consistent with expert opinion. In total, 52 
GPs consented and 40 (77%) completed the study. Most GPs completed 
diagnoses of CRC treatment side-effects or symptoms of recurrence that were 
consistent with the experts’ opinions. However, correct diagnosis was 
dependent on the type of case viewed. Compared to radiation proctitis, GPs 
were more likely to recognise peripheral neuropathy (OR 12.55, 95% CI 1.38–
2.74) and erectile dysfunction (OR 21.98, 95% CI 2.24–36.84) and less likely 
to identify chemotherapy induced fatigue (OR 0.02, 95% CI 0.09–0.46). GPs 
who had more hours of direct patient care (OR 8.67, 95% CI 1.23–70.70, p = 
0.03) or were experienced in general (OR 9.78, 95% CI 1.18–8.84, p = 0.02] 
suggested management plans consistent with the expert opinion. 
 
Overall, this thesis has demonstrated that using a screening tool (SATp) with 
appropriate support in place (general practice) is a viable method to support CRC 
patients with problems following cancer treatment. The reports of Study 3 showed that 
GPs can recognise and offer appropriate treatment for most of the side-effects of CRC 
treatment and for the symptoms of recurrence. However, more training is required for 









Colorectal cancer (CRC) is the second most commonly diagnosed adult cancer in 
Australia.[12-14] From 1980 to 2007, 105,144 people were diagnosed with CRC in 
Australia, with approximately 12,600 new cases diagnosed each year.[12-14] The 
number of new cases of all cancers is expected to grow by 319 cases per year.[14] 
According to age-standardised rates by the Australian Institute of Health and 
Welfare (AIHW), one in 21 Australians is likely to develop CRC during his or her 
lifetime, with the risk increasing after 40 years of age, and rising sharply and 
progressively from the age of 50.[12] The lifetime risk of CRC before the age of 75 
years is about one in 17 for males and one in 26 for females, with incidence and 
mortality increasing progressively with age for both genders. 
 
Improved treatment modalities (surgical techniques and neo-adjuvant therapy) 
mean that more people with CRC are surviving for longer periods.[15, 16] Based on 
United States surveillance, epidemiology and end results data for colorectal cancer, 
it is estimated that the 15-year survival for CRC in that country is 47%.[17] In 
Australia, there is no uniform national database for CRC survival based on clinical 
pathological stages.[12] However, the hospital-based register for South Australian 
teaching hospitals shows a five-year CRC case survival of 88% for Stage A 
(mucosal and sub-mucosal involvement), 70% for Stage B (muscular involvement), 
43% for Stage C (regional nodal involvement) and 7% for Stage D (distance 
metastases).[12-14] Overall, the five-year survival rate for people treated for CRC in 
Australia is 89%.[14] 
 
Treatment for CRC includes surgery and, in some cases, chemotherapy and/or 
radiotherapy. This may result in long-term physical problems, such as bowel 
dysfunction, urinary problems and neurological deficits.[1, 18] In addition, 
psychological effects, such as anxiety,[19] depression[7] and fear of recurrence,[1, 20, 
2 
21] plus social problems, such as financial difficulties[22] and activity limitation,[1, 
23] may continue to affect patients for many years following treatment.[1, 24-28] 
 
There is evidence that problems related to CRC treatment are not always identified 
during routine doctor–patient consultations. The reasons for non-identification 
include patients’ reluctance to initiate discussions about these problems, and health 
professionals’ failure to prompt discussion about these issues during a clinical 
consultation.[29] Consequently, problems may go unresolved and result in delayed 
diagnosis and treatment. Clinical practice guidelines often recommend that care of 
patients with CRC must incorporate all aspects of patient care, including physical, 
psychological and social care; however, this is often not integrated in the follow-up 
clinical care.[30] 
 
With the significant increase in patients treated for CRC, frequent specialist visits 
are not logistically feasible due to the sheer number of patients attending a limited 
number of busy clinics.[31] Therefore, addressing patients’ needs and maintaining 
continuity of care will require strategies that supplement and support existing 
services. In addition, most people with CRC are now living beyond five years post-
treatment and have other chronic conditions for which they visit their general 
practitioner (GP) on a regular basis.[32] As the survival rate improves, GPs will find 
that patients with CRC occupy a larger proportion of their practices, and that 
supporting them is going to become a significant part of their workload. In Australia, 
GPs are the first point of contact for patients in the health system. Based on this, 
there is potential for GPs to support CRC patients in conjunction with ongoing 
specialist care. 
 
One potential solution to address patient problems related to CRC treatment is to 
assist patients to identify issues as they arise and seek timely help from the clinician 
(GP) they usually visit for other health conditions. This project provides an insight 
to this integrated approach through a series of studies that assist patients to identify 
CRC-related problems and, where appropriate, consult their GP. This project 
developed a self-administered needs-assessment tool (self-assessment tool for 
patients—SATp) and offered it to patients post-surgery for CRC to help them 
monitor their treatment-related problems through consultation with their GP. This 
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intervention was offered alongside scheduled specialist visits. Further, this project 
evaluated GPs’ management approaches to treating CRC-related problems using 
standardised patients (actor-patients). 
 
1.2 Research Questions and Intentions 
 
Although problems associated with CRC treatment are documented in the literature, 
there is a lack of collated information on their management that is easily accessible 
by patients and clinicians for use in practice.[33] Specifically, there is a paucity of 
information on general practice, where many people living with CRC are seen 
occasionally for various reasons. The initial research question of this study emerged 
from a motivation to outline the most common issues experienced by patients 
following treatment for CRC, and to provide this information to both clinicians and 
CRC patients. First, it was important to examine the existing literature and identify 
these issues: 
 
RQ 1. What are the most common problems associated with CRC 
treatment, as reported in the literature? 
 
Second, it was essential to examine the current literature to determine whether 
patients with CRC would benefit from accessing additional support from a GP 
while still receiving specialist care. The literature provides details regarding the 
organisation of patient care and flow of information between the specialist and GP. 
Thus, it was important to explore the literature to assess which issues are routinely 
addressed during patient visits with a GP and also those that are not routinely 
addressed. This prompted the second research question: 
 
RQ 2. Do patients benefit from involving a GP in their ongoing care 
following initial cancer treatment? 
 
After identifying the most common CRC treatment–related problems and 
examining whether patients benefit from GP support, the subsequent intention of 
this project was to develop an instrument that could be used by patients to direct 
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discussions during GP consultation and to provide information to supplement their 
records. This motivation led to the following questions: 
 
RQ 3. Could a user-friendly, patient completed data collection tool 
(SATp) be developed to assess problems that patients may experience 
following treatment for CRC? 
 
RQ 4. Is the SATp a reliable and valid data collection tool for assisting 
patients to discuss issues associated with their CRC treatment with 
their GP? 
 
Before testing the SATp, it was important to identify factors that may influence 
CRC patients’ intentions to seek health advice from a GP regarding their treatment-
related problems. Most patients with CRC have at least one chronic illness for 
which they regularly visit their GP.[34] Recent efforts to report patients’ preferences 
for cancer care have indicated that GP support in managing their care is 
preferred.[35] However, exploration of these preferences has only been in the context 
of perceived satisfaction with the organisation of the care provided.[36] More 
evidence is required regarding the role of chronic illnesses and other factors that 
may influence patients’ decisions to attend a GP for CRC health advice. This led to 
the following research questions: 
 
RQ 5. Are personal attitude, perceived control/barriers and the 
influence of other people independently associated with CRC patients’ 
intentions to attend a GP for future health advice about their CRC 
problems? 
 
RQ 6. Do patients’ demographics and clinical characteristics, such as 
the presence of an existing chronic conditions, influence their 
intentions to visit a GP for health advice about their CRC problems? 
 
After developing the SATp (RQ 3), it was vital to test whether this tool could be 
used in general practice to identify common issues experienced by patients with 
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CRC following treatment (RQ 4). This led to the following research questions to 
test the SATp: 
 
RQ 7. Can the SATp help identify physical, psychological and social 
problems related to CRC treatment? 
 
RQ 8. If patients present the SATp to their GP, would this facilitate 
discussions about any physical, psychological and social problems 
associated with their CRC treatment? 
 
Finally, it was important to assess whether GPs would diagnose and treat the 
identified CRC treatment–related problems or recurrence. Previous studies have 
demonstrated that patients consult their GPs during the months and years after 
treatment for CRC, even for patients with scheduled specialist visits at hospital.[35] 
In order to address the needs of patients treated for CRC, GPs must be 
knowledgeable about the recommended treatment for the side-effects of CRC 
treatment, and the signs and symptoms that merit referral for further specialist 
treatment. This led to the final research questions: 
 
RQ 9. Can GPs recognise the side-effects of CRC treatment, and the 
recurrence of CRC? 
 
RQ 10. Can GPs manage the side-effects of CRC treatment and 
recurrence in accordance with expert opinion? 
 
1.3 Significance of the Project 
 
In Western Australia (WA), follow-up visits with specialists for patients who have 
received treatment for CRC are scheduled every six months for the first five years 
post treatment.[31] However, CRC follow-up regimens may vary for each case, 
depending on patient or clinician preferences, clinical indications, geography and 
convenience.[31, 37-39] CRC survival is improving; thus, the follow-up workload is 
continuously increasing and burdening existing specialist services.[31] As such, 
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more frequent specialist visits for patients may not be feasible due to the increasing 
number of patients attending outpatient cancer clinics. There is growing recognition 
that people with CRC have complex physical and psychosocial needs that are not 
always met in specialist clinics.[40] This is due to workload pressures and/or lack of 
expertise identifying and managing some of the psychosocial problems that patients 
present.[41] Given this situation, alternative strategies to support existing specialist 
services are needed. 
 
GPs are well placed to provide this support because they are the first point of contact 
in the Australian health system. In most cases, GPs are aware of patients’ CRC 
history before diagnosis because most patients first consult a GP before being 
referred to the specialist for further treatment.[42] GPs are in an ideal position to 
support CRC patients following completion of treatment. However, several studies 
have indicated that survivors of CRC have significant physical, psychological and 
social problems that are not addressed during regular doctor–patient visits.[43-45] 
Most patients who have completed cancer treatment are treated as hospital 
outpatients.[46] In between these outpatient visits, they often consult their GP for 
further advice.[46] This contact places GPs in a key position, which requires them to 
have specific knowledge of CRC treatment–related side-effects.[46] However, some 
GPs do not have access to patients’ current clinical information related to their CRC 
treatment,[47] and sometimes do not have the specific knowledge to identity and treat 
CRC problems.[48] 
 
The need to support patients and GPs in identifying and discussing CRC treatment–
related problems is integral to effective management. The active involvement of 
patients’ GPs following their CRC treatment could enhance continuity of care and 
patient satisfaction,[49-51] both prerequisites for high quality care. This engagement 
would also facilitate identification of problems that could be given appropriate 
attention prior to scheduled specialist visits. 
 
There is evidence that interventions aimed at addressing cancer-related problems 
(such as telephone support, alongside usual management strategies) may address 
patient problems following initial surgical treatment.[52] These interventions have 
also been reported to be effective in addressing cancer patients’ problems when 
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offered alongside specialist visits.[53] Most of these supportive approaches are 
offered to cancer patients immediately following discharge from hospital, when 
treatment-related symptoms may be highly distressing.[41] There is evidence that 
additional support is effective in reducing emergency department presentations of 
patients with CRC treatment–related problems.[52] To date, most of these additional 
support interventions have been implemented in a hospital setting and are clinician 
driven. The sustainability of these supportive interventions may require such 
initiatives to be patient driven, with measures implemented to assist patients to 
identify their needs and seek health advice.[53] 
 
This project developed and tested a tailored assessment tool for use by patients with 
CRC to aid them to identify problems and issues when consulting a GP (SATp). 
This approach is patient driven and offered alongside specialist visits. Using such a 
tool may assist clinicians and patients to identify issues of concern that would 
otherwise be missed during consultations. Overall, the routine, systematic and 
regular use of a patient-administered assessment tool during general practice may 
facilitate the timely provision of needs-based care. 
 
1.4 Theoretical Framework Guiding the Development of the Thesis 
 
This thesis was guided by the Glasziou and Haynes model of evidence-based 
medicine that outlines the path from research to improved health outcomes.[54] 
According to Glasziou and Haynes, research must be synthesised by: 
 framing the research question 
 tracking down the best evidence 
 critically appraising the evidence for validity, effect and applicability 
 integrating the results to be used by clinicians. 
 
Further, Glasziou and Haynes stated that, even with the best evidence available, 
there are substantial gaps between the evidence and the management patients 
receive. To achieve better clinical outcomes for patients, clinicians must (i) be 
aware of, (ii) accept, (iii) apply, (iv) be available and able, (v) act on, (vi) be 
agreeable to and (vii) adhere to the evidence. However, even with high rates of 
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transfer of information between these stages, there may be little effect on patient 
outcomes. Hence, there must be strategies for increased uptake at each stage. 
 
1.4.1 Stages of the Glasziou and Haynes Model 
 
The Glasziou and Haynes model has seven stages being: awareness; acceptance; 
application; availability; action; agreement and adherence. 
 
1. Awareness: Given the plethora of published papers, clinicians may find it 
difficult to be aware of all relevant and valid information. After identifying the 
best available evidence, this evidence must be collated and made available to 
clinicians. This would enable clinicians to locate only relevant information for 
specific clinical problems. 
2. Acceptance: While clinicians may have heard of the benefits of the evidence, 
they may not be persuaded to change management based on this evidence. 
Hence, more work is needed to identify the methods that can best persuade them. 
3. Applicable: Even if the evidence is accepted, clinicians and guidelines may not 
target the correct group of patients. 
4. Available and able: Undertaking an intervention requires both access and 
knowledge. For complex interventions, the learning curve is steeper and hence 
is a greater barrier to changing practice. Clinicians may require additional 
training before undertaking complex interventions competently. 
5. Act: Even when people know and accept what to do, they often forget to act on 
the evidence. Omissions are more frequent for long-term and preventive issues 
because they are not the pressing focus of a consultation. A reminder is often 
sufficient for such omissions to be addressed. 
6. Agree: When clinicians remember to suggest applicable evidence, the above 
steps may begin all over again for the patient. For patients to agree, they must 
be aware of the options, accept them and be able to undertake the required action. 
This may involve a complex mixture of the patients’ values and beliefs, which 
needs to be explored. 
7. Adhere: Patients must also contend with conflicting advice, adverse effects and 
sometimes a lack of ability to pay for the tests and treatments. Strategies must 
be trialled to encourage concordance. 
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A graphic presentation of the Glasziou and Haynes model of evidence-based 
medicine is presented in Figure 1.1. 
 
 
Figure 1.1: Sequential Phases of Paths from Research to Improved Health 
Outcomes Adapted From Glasziou P, Haynes B. 2005 [54] 
 
In this model, depending on the clinical questions and application, not all stages 
may be relevant. Thus, this framework is best viewed as an example of ‘flexible 
guidance’ for applying evidence-based medicine. Depending on the nature of the 
intervention, particular stages may be combined or other theoretical models may 




Overall, the design of this thesis sought to: 
 critically appraise the available literature to identify problems that patients 
experience following CRC treatment 
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 develop a patient-completed needs-assessment tool (i.e. the SATp) based on 
the identified problems 
 apply this tool in a healthcare setting (general practice) to assess its 
usefulness in identifying and addressing the problems of patients following 
CRC treatment 
 assess GPs’ approaches to managing these problems. 
The Glasziou and Haynes framework of stages from research to improved health 
outcomes facilitated the design of this project. Table 1.1 presents a comparison of 
the Glasziou and Haynes framework and this thesis. 
 




Synopsis Glasziou and Haynes Framework 
Chapter 1 Introduction: Identify scope of 
the problem and thesis 
justification. 
Research synthesis: Frame the research 
questions. 
Chapter 2 Review of the literature. Research synthesis: Appraise evidence for 
validity, effect and applicability. 
Chapter 3 Study 1: Develop the SATp. Awareness: Make the evidence available to 
clinicians and patients. 
Chapter 4 Study 2: Assess factors that 
influence CRC patients’ 
decisions to visit a GP. 
Applicable: Support clinicians to target the 
correct group of patients. 
Agree and adhere: Patients must be aware of 
the options and must accept and be able to 
undertake the required actions. This may 
involve a complex mixture of the patients’ 
values and beliefs, which thus needs to be 
explored. 
Chapter 5 Study 3: Trial the SATp in 
general practice. 
Applicable: Support clinicians to target the 
correct group of patients. 
Act: Patients should be aware of the options 
for them to act, and should accept and be able 
to undertake the options. 
Chapter 6 Study 4: Assess GPs’ 
approach to managing CRC 
problems (video vignette 
study). 
Available and able: Undertaking an 
intervention requires both access and 
knowledge. 
Act: Clinicians must have the ability to use 
the available evidence to improve patient 
outcomes. 
Chapter 7 Thesis discussion and 
conclusions. 






1.5 Overview of Thesis Chapters and Study Method 
 
This thesis is presented in seven chapters, as follows. 
 
Chapter 1 discusses the research background, questions and intentions, 
significance of the study, and theoretical frameworks guiding the development of 
the study. 
 
Chapter 2 presents a review of the literature relating to CRC as a public health 
problem. The problems experienced by patients following CRC treatment are also 
reviewed. Finally, the importance of GPs’ support of and involvement in patient 
care following CRC treatment is reviewed. 
 
Chapter 3 outlines the steps involved in developing a self-assessment tool for CRC 
patients (SATp) (Study 1). The study’s aims, methodology, results and findings are 
discussed. The primary aim of Study 1 was to develop a patient-completed needs-
screening tool to identify physical, psychological and social needs among patients 
treated for CRC. The existing literature was evaluated to identity problems 
experienced by patients with CRC post-treatment. Through a series of validation 
processes, a list of common problems experienced by patients following treatment 
was generated and tested for its reliability and ability to identify common problems 
experienced by CRC patients. Study 1 employed a Delphi method[55] as the 
conceptual framework to validate the questionnaire. 
 
A purposive sample of 17 panellists (patients with CRC and health professionals 
involved in CRC follow-up care) was invited to validate the questions to be 
included in the SATp. The researcher sent out the draft SATp to consenting experts 
via email for them to provide their level of agreement with each item using a Likert 
scale on a questionnaire developed for this purpose. The researcher coordinated the 
responses of the panel of experts until a consensus of 70% was achieved. The 
developed questionnaire was pre-tested for reliability and usability by a group of 
30 consenting patients with CRC. The result of Study 1 was a 25-item 
questionnaire—the SATp that was deployed in Chapter 5 of this thesis. 
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Chapter 4 presents the study participants’ intentions to visit a GP (Study 2). It 
details the factors that may influence patients’ decisions to seek health advice from 
their GP. The study design, methodology and results are presented. Study 2 was a 
cross-sectional study that employed a questionnaire based on the theory of planned 
behaviour (TPB). The TPB outlines three constructs (personal attitudes, social 
norms and perceived barriers and controls) that influence a person’s intention to 
perform a certain action.[56] In this study, the influence of TPB constructs on 
patients’ decisions to seek health advice from a GP was assessed. Further, the role 
of clinical and respondent characteristics on the TPB constructs was explored. 
 
A convenience sample of 66 patients was recruited from an outpatient cancer centre 
of Sir Charles Gairdner Hospital (SCGH)—a tertiary referral teaching hospital 
located in Perth, Western Australia. The consenting participants were invited to 
complete a demographic survey and the TPB questionnaire. The TPB questions 
were adapted from various cancer studies,[57-62] and validated via the process 
outlined in a manual on constructing questionnaires based on the TPB.[62] These 
questions were then piloted by a group of five patients to assess for readability, as 
the assembled items were from various studies conducted in different countries. A 
regression analysis of the collected data was computed to identify predictors of 
participants’ intentions to seek health advice from a GP about CRC-related 
problems 
 
Chapter 5 describes trialling the SATp in general practice (Study 3)—the SATp 
intervention. The study design, methods and findings are discussed. The main aims 
of Study 3 were to test whether the SATp developed in Study 1 would identify 
physical, psychological and social problems related to CRC treatment, and whether 
SATp-identified problems would be addressed in a GP consultation. 
 
A convenience sample of 66 participants (recruited in Study 2) was invited to 
participate in a prospective study. At the beginning of the study, the participants 
were asked to nominate their regular GP, who was then contacted and advised that 
the patient was participating in the study and that a researcher had consent to access 
their records and survey their GP. The participants were provided with a booklet of 
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SATp questionnaires (developed in Study 1), which they completed at six time 
points (at the baseline and then monthly for five months). The participants were 
also invited to take the booklet whenever they consulted their GP. 
 
At the end of the study follow-up period (at five months), the clinical notes 
(integrated notes) were reviewed by a team of trained researchers. Data from the 
clinical notes were extracted using a data abstraction pro-forma developed for this 
purpose. The data were analysed using the generalised estimating equation model 
(logistic regression) to control for the correlations between the responses on 
multiple responses from each participant. 
 
Chapter 6 describes GPs’ approach to managing the problems experienced by 
patients following CRC treatment (Study 4). This was a video vignette study. This 
chapter presents the study design, methods and results. The primary aim of Study 4 
was to assess the factors that affect GPs’ decisions to treat patients with CRC-
related problems or symptoms of recurrence. 
 
Participants were recruited from a convenience sample of 100 GPs across Australia 
who were members of the Curtin Health Innovation Research Network. The video 
vignettes were acted from six scenarios developed by panel of experts, who were 
selected based on their expertise in the follow-up of CRC patients. These scenarios 
were developed through a Delphi method. The experts viewed the vignettes and 
outlined the management of such cases and the relevant physical examination they 
would undertake if reviewing such a case. For each vignette, clear indications for 
specific management—including referral, prescription, reassurance and/or 
investigation—were requested. The survey was administered via web-based 
software (https://www.qualtrics.com/) approved by Curtin University. The six 
video vignettes were presented to each participant. The data were analysed using 
the generalised estimating equation model (logistic regression) to control for 
correlations between the responses on multiple vignettes from each participant. 
 
Chapter 7 discusses the issues pertaining to the findings from all three studies 
(Studies 2, 3 and 4). Recommendations related to the study findings and areas for 
further research are identified, and conclusions are drawn. 
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Chapter 2: Literature Review 
 
 
This chapter presents the epidemiological perspective of CRC. Further, this chapter 
summarises the various treatment modalities for CRC, including surgery, 
chemotherapy and radiotherapy. It also discusses the range of adverse issues 
experienced by patients following treatment. The remainder of the chapter describes 
the benefits patients may derive by having a GP involved in their care following 
treatment. 
 
2.1 CRC: General Epidemiology 
 
CRC is a major health burden worldwide. Internationally, 1.2 million people were 
expected to be diagnosed with bowel cancer in 2007, making it the fourth most 
common cancer in the world that year. A comparison of the United States, the United 
Kingdom and Australia shows that CRC is ranked in the top four most frequently 
occurring cancers,[14, 63, 64] highlighting the significant effect of this cancer in these 
populations. 
 
In Australia, CRC was the second most common cancer diagnosed and the second 
most common cause of cancer death between 2006 and 2010.[14] By 2007, 105,144 
people had been diagnosed with CRC during the previous 26 years, and, each year, 
there are approximately 12,600 newly diagnosed cases of CRC and 4,700 deaths 
directly related to this cancer.[65] The number of new cases of cancer is expected to 
grow by 3,090 cases per year. The greatest increase in cancers is projected for prostate 
cancer (939 extra cases per year), followed by melanoma of the skin (392), CRC (319), 
breast cancer (314) and lung cancer (190).[65] 
 
CRC is the most common cancer diagnosis in patients older than 75 years.[66] More 
than 90% of invasive CRCs are diagnosed in patients older than 50 years, with 67% 
being diagnosed in patients older than 65 years. In these cases, both genders are equally 
affected by this disease; however, there is a higher incidence among males over 50 
years than among females.[7] 
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Clinical pathological staging/classification is currently the most important determinant 
of prognosis, and is widely used to classify CRC.[38, 67-69] The Australian classification 
(Australian Clinical Pathological Staging [ACPS]) is comparable to the Tumour, 
Node, Metastasis classification of the American Joint Committee on Cancer and the 
Union for International Cancer Control (UICC) Fifth Edition (UICC stage)[68] that is 
currently recommended for daily routine use and for use in clinical trials.[70] Table 2.1 
shows the descriptors of clinical pathological staging and how they relate to each other. 
This thesis uses the UICC stage descriptor. 
 
Table 2.1: Various Clinical Pathological Staging for Colorectal Cancer 
ACPS[38] UICC Stage 
UICC—Fifth Edition[68] 
Tumour, Node, Metastasis[68] 
A0 + A Stage I T1, T2, N0, M0 
B Stage II T3, N0, M0 
T4, N0, M0 
C Stage III T1, T2, N1, M0 
T3, T4 N1, M0 
Any, N2, M0 
D Stage IV Any T, any N, M1 
T1: tumour invades submucosa; T2: tumour invades muscularis propria; T3: tumour invades through 
muscularis propria into subserosa or into non-peritonealised pericolic or perirectal tissues; T4: tumour 
directly invades other organs or structures and/or perforates visceral peritoneum.[68] 
 
2.2 CRC Survival 
 
Due to early diagnosis and treatment for CRC (surgery, chemotherapy and 
radiotherapy), overall survival rates have improved from 48.0 to 66.2% during the last 
two decades.[71] Population-based studies show that approximately 50% of CRC cases 
are diagnosed while the cancer is still confined to the primary site (Stages I, II and III), 
while the rest of patients are diagnosed when the cancer has spread (Stage IV).[70-72] 
 
The survival rates are dependent on the stage of the disease. Patients with Stage I can 
be expected to have a five-year relative survival of 80 to 95%, Stage II of 60 to 80%, 
Stage III of 30 to 55%, and Stage IV of < 3%, as defined by the UICC five-year stage-
specific survival rates.[68] In ACPS, hospital-based registries for teaching hospitals in 
some states show that the five-year CRC case survival varies with ACPS: 88% for 
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Stage A, 70% for Stage B, 43% for Stage C (regional nodal involvement) and 7% for 





Figure 2.1: Five-year CRC Case Survival by ACPS[14] 
 
Although survival rates are dependent on the stage of the cancer, significant 
differences have been observed among patients operated on as emergencies and those 
treated as elective cases. Emergency surgery for CRC is associated with a high 
postoperative morbidity and mortality, and both short- and long-term survival are 
impaired.[73] 
 
The increase in the use of chemotherapeutic agents to treat CRC—such as fluorouracil 
and a combination of this agent with others, such as leucovorin and folinic acid—
during the last decade has showed a 10% reduction in the risk of death and an increase 
of 2.3% in the five-year survival rate.[71] Sequential exposure of patients to 
combinations of fluorouracil, irinotecan and oxaliplatin is documented to extend 
median overall survival by approximately 20 months.[74] 
 
Similarly, the incidence of recurrence is dependent on the stage of the disease. In the 
1990s, of the two thirds of patients undergoing resection with curative intent at the 
time of initial diagnosis, about 30 to 50% would relapse and die of their disease.[75] 























example, five-year follow-up data from the Swedish Rectal Cancer Trial of patients 
treated with preoperative irradiation show a 4% recurrence rate in Stage I disease, 10% 
in Stage II and 20% in Stage III for rectal cancer patients.[76] While early detection and 
improved treatment of CRC have led to more people surviving for longer periods,[14, 
16] many survivors of CRC live with long-term side-effects of treatment, which affects 
their quality of life (QoL).[14] 
 
2.3 Management of CRC 
2.3.1 Overview of Cancer Management 
 
Managing colon and rectal cancers is somewhat similar because surgery is the primary 
mode of treatment for localised disease (Stages I to III CRC) for both cancers.[37, 38, 67, 
70, 77] Approximately 98% of patients with CRC undergo surgery.[18, 38, 78-84] Due to the 
increased risk of local recurrence, the management of rectal cancer varies to that of 
colon cancer.[18, 38, 79, 81, 82, 85] Differences include surgical technique, the use of 
radiation therapy, and the method of chemotherapy administration.[18, 38, 79, 81, 82, 85] For 
rectal cancers in Stage I at low risk (< 3 cm, < 30% circumference of the bowel, 
moderately or well differentiated, localised), local excision is usually indicated. 
However, for Stage I at high risk (not fulfilling the low-risk criteria), surgical resection 
and preoperative radiotherapy are offered. For Stage II to III rectal cancers, surgical 
resection, preoperative chemo-radiotherapy and postoperative chemotherapy are the 
standard treatments.[38] For patients with colon cancer who are surgical candidates, 
treatment entails surgical resection and postoperative chemo-radiotherapy.[38] Using 
adjuvant chemotherapy as a standard treatment for all patients with Stage II colon 
cancer is debated;[86-89] however, certain subgroups in this stage that are at higher risk 
of recurrence (including those with bowel obstruction, lymphovascular or perineural 
invasion, perforation, or tumours that have abnormal DNA content) and who may 
benefit from adjuvant therapy should be considered for chemotherapy.[38, 90-93] 
 
Although radiotherapy has a limited role in colon cancer,[38, 67, 94] chemo-radiotherapy 
is used for Stage I and II rectal cancer and in all cases of Stage III colon and rectal 
cancers[2, 38, 67, 90, 95, 96] because there are added survival benefits.[88, 92, 97] In some cases, 
chemo-radiation is used for Stage I rectal tumours with lymph node positivity 
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(19.6 %).[98] Overall, at least 20% of patients at Stage II and 70% at Stage III receive 
chemotherapy.[71, 97] 
 
2.3.1.1 Surgical Management 
 
The main aim of surgical treatment for CRC is to excise the tumour and its margin and 
surrounding tissue (resection), which may contain cancer cells that pose a risk to 
patients.[99, 100] Surgery significantly minimises the risk of cancer recurrence and is a 
major curative treatment option. The type of surgery performed for colon cancer is 
largely dependent on where the cancer is located in the bowel. For example, a right 
hemi-colectomy is performed for cancers of the caecum, ascending colon or hepatic 
flexure; a left hemi-colectomy for transverse, splenic flexure descending colon 
cancers; and a sigmoid colectomy for cancer of the sigmoid. For colon cancer, the most 
recent advancement in surgical treatment is the development of laparoscopic-assisted 
or keyhole surgery. Meta-analytic evidence confirms that laparoscopy has comparable 
recurrence and survival rates to open surgery.[77] 
 
For rectal cancers, surgical treatment historically involved formation of a colostomy 
(part of the colon is brought out of the abdominal wall to allow passage of faecal 
matter), which is still indicated today for all abdominal peritoneal resection (APR). 
APR is an extensive surgical procedure that involves removal of the anus, the rectum, 
part of the sigmoid colon and the regional lymph nodes through incisions to the 
abdomen and perineum.[79] APR is reserved for cancers typically found in the lower 
third segment of the rectum.[79, 100] Other surgical procedures for rectal cancer include 
anterior resections, which preserve the sphincter.[100] The type of resection is 
determined by where the malignancy is found in the rectum. For example, high anterior 
resection is indicated for tumours in the recto-sigmoid, and low anterior resections for 
those in the upper, middle or lower segments.[79, 100] For ultra-low or low anterior 
resection, a temporary ileostomy (part of the small bowel is brought to surface of the 
abdomen, bypassing the rectum) is performed to allow the anastomosis to heal.[79] 
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2.3.1.2 Neo-adjuvant Therapy and Adjuvant Therapy 
 
Neo-adjuvant therapy can be defined as any treatment given before a first treatment 
(such as surgery or radiotherapy) for a primary tumour, when the first treatment was 
aimed at completely eradicating all visible tumour.[79] When such treatment is offered 
post–primary treatment, it is referred to as ‘adjuvant therapy’.[79] 
 
In addition to surgery, chemotherapy and radiotherapy can be administered to treat 
CRC. Chemotherapy and radiotherapy are usually indicated for people with more 
advanced disease. For patients with Stage III colon cancer, chemotherapy—usually a 
combination of CapeOx (Capecitabine and oxaliplatin), FOLFOX (5-FU, leucovorin, 
and oxaliplatin) are indicated to be administered post-operatively.[38, 85] For patients 
with Stage II colon cancer, chemotherapy is not usually offered, and guidelines 
recommend that clinicians and patients should discuss the relative merits of this. 
Radiotherapy is generally not required for colon cancer and is limited to patients with 
specific disease characteristics.[38, 94] For rectal cancer, radiotherapy is recommended 
in preoperative or postoperative setting for Stage II tumours.[38, 94] Evidence exists that 
radiotherapy reduces the risk of local recurrence and, when offered post-operatively, 
shrinks the tumour and lowers the incidence of long-term morbidity.[38, 94] 
 
2.4 Effects of CRC Treatment: A Review of Literature 
2.4.1 Overview of Treatment Side-effects 
 
While treatment has added survival benefits, a myriad of associated side-effects may 
affect the patient’s QoL. Normally, the acute effects diminish after completion of 
treatment; however, some symptoms persist even years after therapy. Although issues 
and symptoms are most prominent during the first three years, the effects of treatment 
can persist long after this, and include fatigue, sleep difficulty, fear of recurrence, 
anxiety, depression, negative body image, sensory neuropathy, gastrointestinal 
problems, urinary incontinence, and sexual dysfunction.[1, 20] Estimates from a 
population-based study by Schneider et al.[3] show that the most commonly reported 
symptoms are fatigue (23%), negative feelings about body appearance (14%), 
diarrhoea (13%) and constipation (7%). In this study, higher percentages of 
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respondents attributed health effects to cancer or its treatment, including worries about 
health (24%), physical discomfort (19%) and activity limitations (15%).[3] 
 
 
2.4.2 Aims of the Review 
 
The aims of this literature review were to describe the long-term effects of CRC 
following treatment, and outline the implications of these CRC treatment effects. 
 
2.4.3 Methods 
2.4.3.1 Search Strategy 
 
A search strategy was developed to electronically source studies published in English 
from four academic databases: PubMed/Medline, CINAHL, Web of Science and 
Cochrane Reviews/Trials. These were searched in January 2013 by employing the 
following strategy using medical subject headings: 
1. colorectal cancer (MH) OR bowel cancer (MH) AND 
2. *side-effects as topic (MH) OR needs as topic (MH) OR quality of life* (MH) 
AND 
3. treatment (MH) 
4. randomised control trial (MH) 
5. *projects (MH) 
6. various combinations (1 AND 2, 1 AND 3 AND 4, 1 AND 5, 2 AND 3, 2 AND 
4, and 2 AND 5). 
 
2.4.3.2 Eligibility of Studies, and Outcomes Assessed 
 
For inclusion, studies had to describe CRC or have CRC among the cancers being 
described. Studies that included CRC, regardless of the site or stage of the disease, 
were eligible for review. All studies that outlined the needs assessment for cancer in 
which CRC was included were integrated in the review. A total of 3,218 references 
with relevant titles were identified. These were complemented by a search of grey 
literature sourced from both the Curtin University library catalogue and the AIHW 
website. Eight references were found using this latter strategy. All duplicates (2,018) 
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and articles without full-text versions (550) were removed, yielding a total of 650 
references. 
 
The titles and abstracts of the 650 references were independently reviewed by two 
reviewers (IN and MJ) using the selected inclusion criteria, from which 69 studies 
were included for the review (Figure 2.3). Studies that had been evaluated by the 
included systematic reviews were not reconsidered for critical evaluation in this review 
of literature. However, the main findings of these systematic reviews were considered 
for this literature review. Details of other studies that were not assessed by identified 
systematic reviews have been outlined in Appendix 2:1. The literature reviewed 
suggested that physical, psychological and social problems should be considered when 





Figure 2.2: Flow Diagram of the Results of a Literature Review of CRC 
Treatment Effects 
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2.4.4 Results 
2.4.4.1 Physical Effects 
 
Physical side-effects of treatment relating to the bowel, the urinary bladder, sexual 
dysfunction, peripheral neuropathy and fatigue were reported by 50 of the 69 papers. 
Long-term bowel and urinary problems, such as impaired continence and increased 
urgency, were more common among those who had invasive surgery, such as total 
mesorectal excision,[18, 78, 79, 81-83] with rectal cancer,[18, 78, 79, 81-83] and those treated with 
adjuvant radiotherapy.[70, 86, 102-106] 
 
Functional bowel problems caused by reduced storage capacity of the bowel and 
adjuvant treatment—such as frequent and incomplete bowel movements, abdominal 
pain, urgency, leakage and incontinence, constipation, diarrhoea and flatus[1, 3]—were 
reported as long-term effects. Studies that examined these outcomes showed that 
approximately 20% of patients who received chemo-radiation continued to experience 
increased bowel movements per day, with 20 to 30% reporting some form of 
incontinence and the inability to defer bowel movement.[1, 3] Additionally, patients 
with a permanent or temporary stoma reported several ostomy issues, such as prolapse, 
skin-related problems, leakage or stenosis of stoma opening.[4, 6, 38, 107] Patients who 
received radiation followed by APR reported urinary dysfunction, such as urinary 
incontinence (38%), difficulties in bladder emptying (31%), the need to void within 
two hours of voiding (70%) and the use of continence aids (57%) up to five years after 
treatment completion.[1, 108] 
 
In a cohort study examining the long-term effects (40 months) of chemo-radiation 
between survivors of rectal cancer who had and had not received chemo-radiotherapy, 
in the group that received chemotherapy, only nine of 41 patients (22%) had less than 
four bowel movements per day, while 15 (37%) had five bowel movements per day 
and 17 (42%) reported clustering - (numerous bowel movements over a few hours) (p 
< 0.001). Compared to the non-radiation group, of those who received chemo-
radiotherapy, 19 (46%, p < 0.001) needed to wake at night to pass a bowel movement, 
16 (39%) reported occasional incontinence, 7 (17%) reported frequent incontinence, 




Other physical symptoms identified in this review included sexual dysfunction, 
peripheral neuropathy, loss of weight and abdominal pain.[1, 109] Sexual dysfunction 
was reported as both a physical and psychological effect.[1, 110] In both cases, sexual 
dysfunction was associated with the effects of surgery, adjuvant therapy or indirectly 
to the psychological effects of a stoma that may cause negative body image.[6, 8] 
Patients with a stoma reported psychosocial issues, such as fear of leakage, concerns 
about appearance, odour, negative body image, smell, impotence and decreased 
libido.[6, 8] One study reported that 43% of sexually active men with CRC and 69% of 
men overall have International Index of Erectile Function scores that are considered 
abnormal.[6, 8] Similarly, 39% of sexually active women and 62% of all women 
respondents in this study had Female Sexual Function Index scores that were 
considered abnormal,[6, 8] despite the fact that nerve-sparing surgery was used 
routinely.[6] Overall, 26% of the bowel cancer patients continued to report at least one 
form of sexual dysfunction three years after treatment.[1] 
 
Approximately 92% of patients offered adjuvant chemotherapy (oxaliplatin and 
infusional 5-fluororuacil [FOLFOX] or bolus 5-fluorouracil [FLOX]) develop some 
degree of sensory neuropathy,[111] with 8 to 12% developing Grade 3 neuropathy 
(severe neuropathy interfering with function—defined as being severe enough to 
interfere with daily living) and 22% requiring premature discontinuation of oxaliplatin 
for severe neuropathy.[111] The acute nerve effects reduce within one month of 
treatment discontinuation; however, the median time for resolving these symptoms is 
approximately nine months.[10] Although only 1% of patients have residual Grade 3 
neuropathy at 12 months after completing therapy, approximately 20% of survivors 
may experience worsening of symptoms after treatment discontinuation, and up to 
12% have persistent symptoms for four years after completing adjuvant treatment, 
when all grades are combined.[1] 
 
2.4.4.2 Psychological and Social Effects 
 
The psychological effects of treatment—such as anxiety,[19] depression,[7] fear of 
recurrence [21] and fatigue [1, 5, 20, 112, 113]—are commonly reported many years after 
diagnosis. Estimates from a population-based study by Schneider et al. showed that 
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the most commonly reported symptoms three years after diagnosis are fatigue (23%), 
negative feelings about body appearance (14%), worries about health (24%), physical 
discomfort (19%) and activity limitations (15%).[3] Other studies that describe the 
long-term psychological effects of CRC indicate that 26 to 44% of long-term survivors 
continue to worry about cancer recurrence, and 48% have sleep difficulties.[9] Similar 
high rates of 68% have been reported by other studies that assessed the long-term 
effects of CRC treatment.[114] 
 
Some studies included in this review reported health concerns linked to anxiety and 
depression, with 24% of patients showing depression scores high enough to require 
evaluation for clinical depression.[1] Other reports showed that both the anxiety and 
depression subscales of the Hospital Anxiety and Depression Scale significantly 
predicted QoL scores.[110] Long-term (more than one year) negative feelings about 
body appearance are more common among stoma survivors than non-stoma survivors. 
Up to four years after treatment, 25% of stoma patients report negative body image. 
 
Social factors such as financial problems,[22] information needs,[115] activity limitation 
and social function issues[1, 23] have also been reported by patients years after treatment 
completion. Social function and activity limitation among stoma patients can be 
negatively affected up to one year after diagnosis; however, the presence of a 
permanent stoma has a minimal effect on social and activity functioning two years 
after diagnosis.[1, 23] Stoma patients complain of more financial difficulties than do 
non-stoma patients. A 2005 cross-sectional study by Sideris et al that compared the 
effect of a permanent colostomy on the QoL of patients who underwent operations for 
low rectal cancer showed that stoma patients have more financial difficulties than do 
non-stoma patients.[23] Additional studies included in this review demonstrated that 
gastrointestinal cancer survivors, including CRC, are at a higher risk of unemployment 
than are healthy adults (48.8 v. 33.4%).[116] 
 
2.4.5 Implications of CRC Treatment Effects 
 
The implications of treatment effects are that people have multiple and unique sets of 
needs that require holistic management. This includes clinical, social and 
psychological needs related to treatment, as described above, and other co-occurring 
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chronic illnesses. Given that the median age for CRC is 69 years, more than 30% of 
this group have an existing chronic illness[117] that requires ongoing management. 
Meeting patients’ needs is a central tenet to the delivery of quality healthcare, and 
clinicians who are the most accessible to CRC patients on a regular basis must be 
involved in the management of these patients. The following section explores the 
potential for GPs’ involvement in the management of these problems. 
 
2.5 Benefits of Involving a GP Following Cancer Care: A Literature 
Review 
 
2.5.1 Overview of GP Involvement in the Care of Cancer Patients Following 
Treatment 
 
Due to the improved survival rates of cancer patients following treatment, greater  
attention needs to paid to the ongoing physical and psychosocial needs of this 
population.[65] Long-term physical problems and psychological morbidity—such as 
anxiety,[19] depression[7, 118] and fear of recurrence,[21] and social factors,[1, 20] such as 
financial problems[22] and activity limitation[1, 23]—continue to affect patients for many 
years following treatment. 
 
Cancer patients are now living longer, and many have coexisting health conditions.[34, 
119] For example, around 50% of people with CRC are now living beyond 10 years 
after treatment[32] and between 30 to 60% of CRC survivors aged 70 years or older 
have other concomitant health conditions and are more likely to die of other causes.[117] 
As the survival rate of cancer patients improves, GPs will find that these people occupy 
a larger proportion of their practice. In addition, with the increasing number of cancer 
patients accessing specialist cancer clinics, strategies that supplement these services 
will be required to support patients with long-term treatment side-effects. 
 
In Australia, cancer patients attend a GP for multiple reasons,[34] including for care of 
health conditions and to receive preventive health services, such as screening, health 
promotion advice and vaccinations.[120] Given that GP services are a cornerstone of the 
Australian health system, there is potential for GPs to support cancer patients with 
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ongoing specialist care. Moreover, there is evidence that cancer patients first present 
to a GP with cancer-related side-effects or symptoms of recurrence, even when 
receiving ongoing management from a specialist.[35] There is empirical evidence that 
a GP-led follow-up model for cancer patients would be ideal; however, oncologists 
must still play a fundamental role in managing these patients.[121] Studies have shown 
that cancer patients who are supported by both oncologists and GPs receive better 
preventive healthcare and cancer care than do those who are managed by either of the 
specialties independently.[120] In addition, some patients still value access to specialist 
services, especially during the early stages after treatment.[121] 
 
To date, most of the literature reviews that report on interventions provided by a GP 
concurrent with a specialist only provide details regarding the organisation of patient 
care and flow of information between the specialist and GP.[122-125] Although these 
reviews offer recommendations regarding communication between the GP and 
specialist,[122-125] patients’ outcome data regarding the issues addressed during patient 
visits with the GP are limited.[123] Given these findings and the potential benefits of 
support that patients may receive by having a GP involved in their cancer care, this 
study conducted a literature review to assess the care of patients in the context of 
ongoing specialist care, with particular reference to GP involvement. This review 
focused on all types of cancer studies that met the inclusion criteria, thereby assessing 
integrated approaches to care for multiple cancer types. 
 
2.5.2 Aims of the Review 
 
The aims of this literature review were to: 
1. describe the proactive management of patients with long-term needs following 
cancer treatment, including surveillance for recurrence; 
2. describe the effectiveness of GP support in post-treatment cancer care; 





2.5.3.1 Search Strategy 
 
A search strategy was developed to electronically source studies published in English 
from six academic databases: AustHealth, CINAHL, the Cochrane Online Library 
Reviews/Trials, Embase, PHCRIS and PubMed/Medline. These were searched in 
January 2014 employing the following strategy using medical subject headings: 
1. family practice (MH) OR primary health care (MH) or general practice AND 
2. parallel care as topic (MH) OR shared care as topic (MH) OR cancer follow 
up* care (MH) AND 
3. evaluation research (MH) 
4. randomised control trial (MH) 
5. feasibility projects (MH) 
6. various combinations (1 AND 2, 1 AND 3 AND 4, 1 AND 5, 2 AND 3, 2 AND 
4 and 2 AND 5). 
 
2.5.3.2 Eligibility of Studies, Types of Participants and Outcomes Assessed 
 
For inclusion, studies had to describe delivery of interventions by a GP, and care had 
to be delivered alongside specialist care. Studies that included adult cancer patients, 
regardless of the site or stage of the disease, were also eligible for review. For inclusion 
in the review, patients should have completed treatment for cancer. Given that terms 
such as ‘shared care’, ‘complementary care’ and ‘parallel care’ were poorly 
standardised in the taxonomy and nomenclature of the electronic databases, the search 
strategy was kept as broad as possible. All papers with such terms were included for 
the review. The cancer follow-up phase was poorly defined regarding when this period 
began; hence, all studies in which patients had completed the indicated treatment were 
included in the review. 
 
2.5.3.3 Identification of Studies 
 
A total of 1,802 papers were identified from the six academic databases: AustHealth 
(n = 202), CINAHL (n = 500), the Cochrane Library Reviews/Trials (n = 200), Embase 
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(n = 368), PHCRIS (n = 132) and PubMed/Medline (n = 410). Potentially relevant 
titles and abstracts of 533 references were reviewed using the following inclusion 
criteria: 
1. the study represents a research article (rather than a letter or commentary) 
2. the research context is primary care—that is, settings in which health 
practitioners are primary health physicians, family practice doctors or GPs 
3. the primary focus is to describe interventions or evaluate care provided by a 
GP alongside hospital care for patients who have completed cancer treatment. 
The primary researcher author (IN) and two other reviewers (MJ and AM) 
independently reviewed 143 studies. Studies that included other models of post-
treatment cancer care were excluded. In total, 20 studies were eligible to be included 






Figure 2.3: Flow Diagram of the Results of a Literature Review of GP-led 
Supportive Care Interventions 
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2.5.3.4 Data Extraction 
 
One reviewer (IN) extracted articles and assessed the methodological quality of the 
studies using Consolidated Standards of Reporting Trials (CONSORT)[126] for 
randomised control trials (RCTs), Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) [127] for cohort and cross-sectional studies, and 
Walsh and Downe criteria[128] for qualitative studies. 
 
CONSORT is an evidence-based, minimum set of recommendations for reporting 
RCTs. It offers a standard way for authors to prepare reports of trial findings, thereby 
facilitating their complete and transparent reporting and aiding their critical appraisal 
and interpretation. The CONSORT statement comprises a 25-item checklist, with the 
items focusing on reporting how the trial was designed, analysed and interpreted.[126] 
See Appendix 2.3. 
 
STROBE is an international, collaborative initiative of epidemiologists, 
methodologists, statisticians, researchers and journal editors involved in the conduct 
and dissemination of observational studies, with the common aim of strengthening the 
reporting of observational studies in epidemiology. STROBE offers a standard way to 
report study design, results and interpretation of cohort, case control and cross-
sectional studies. The checklist comprises 20 items that offer a basis for evaluating 
observational studies.[127] See Appendix 2.4. 
 
The Walsh and Downie recommendations are a set of iterative criteria that create a 
working framework for qualitative research appraisal. This checklist comprises eight 
stages that aid with critical appraisal of study designs, methodology, interpretation and 
transferability of results.[128] See Appendix 2.5. Selected articles were also reviewed 
by two other researchers (MJ and AM) as a measure of inter-rater reliability. 
Differences in assessments by the reviewers were resolved by consensus when the full-
text articles were reviewed. The intervention, outcome details and main conclusions 
were collected on a standard data sheet that included the type of study, author, data, 





The reviewers reached consensus on the remaining 20 articles, all of which were 
included in the review (Figure 2.3). There were three RCTs, five cohort studies, five 
cross-sectional studies, four qualitative studies and three systematic reviews. Due to 
variation in the studies’ methodology and how the findings were reported and analysed, 
a meta-analysis was not feasible even for studies with similar outcome measures. 
Additionally, all studies included in this review were conducted in different countries 
with very different healthcare arrangements. The results of these studies are 
summarised in Appendix 2.1. 
 
2.5.4.1 Interventions and Evaluation of GP Involvement 
 
Studies in which an intervention occurred or was evaluated are described below. In 
summary, 10 studies were based on a framework that sought information from patients 
about the rehabilitation care (psychological, physical and social care) provided by their 
GP. Patients’ rehabilitation needs were either assessed directly by the GP or by cancer 
nurses or specialists, and then relayed to the GP in a letter. 
 
1. In the Bergholdt et al. study, patients were invited to participate in an interview 
about their rehabilitation needs with a rehabilitation coordinator at the hospital. 
The information from the hospital was sent to the GP about patients’ individual 
needs for rehabilitation, and the GP was encouraged to contact the patients to offer 
support with rehabilitation.[36] 
 
2. In the Holtedahl et al. study, cancer patients were invited to a 30-minute 
consultation with their GP, who was asked to let the patients discuss their 
experiences as cancer patients, and to tell the patients explicitly that they would be 
welcome to contact the GP whenever they had a question or problem related to 
their disease. [42] 
 
3. Two studies described a shared care programme between the GP and specialist. In 
Nielsen et al.’s study, a discharge summary letter detailing patients’ physical, 
psychological and social problems was posted to the GP. The summary also 
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contained information about what the oncologists expected the GP to do; specific 
information about each patient’s type of cancer, treatment plans and prognosis; and 
general information about treating common side-effects and pain. The names and 
telephone numbers of the doctors and nurses responsible for the patient were also 
attached.[46] In the Hall et al. study, patients were asked to attend GPs for follow-
up appointments. Follow-up protocols and a system of specialist support were sent 
to the GPs by the treating specialist. The GPs were given an opportunity to shadow 
specialists as they conducted follow-up appointments at the hospital.[41] 
 
4. In the Sisler et al. study, cancer survivors who had a GP were sent a survey 
assessing the patients’ perceptions of continuity of care around the time of 
discharge from the cancer centre. Health-related QoL (HRQol) was also assessed 
as long-term patients stated they had seen a GP during their survivorship care.[129] 
 
5. Bowman et al. assessed primary care provider (PCP) involvement in key activities 
measured by cancer survivors’ reports. It examined whether PCPs discussed 
cancer-related problems with patients, and whether these discussions resulted in 
tests and procedures.[130] 
 
6. In five other studies, patients completed a survey or data were analysed on one of 
the following: the number of visits to the family physician during the prior year; 
the family physician’s, specialist’s and oncology team’s responsibility for cancer 
care; the family physician’s involvement in cancer care; the perceived family 
physician’s actual and expected roles in various aspects of care (coordination, 
psychosocial support, information transmission, symptom relief and preventive 
health); and the family physician’s pattern of care.[50, 131-134] 
 




2.5.4.2 Critical Appraisal of the Studies 
2.5.4.2.1 Recruitment, Randomisation and Methods 
 
Three RCTs with GP interventions were identified.[36, 42, 46] All three studies fulfilled 
at least 22 of the 25 items in CONSORT and provided background details about the 
study objectives, eligible participants and outcomes of interest. Reporting of the 
randomisation process was generally poor, with details of the allocation concealment 
not fully provided. Strategies used to generate allocation sequences were only fully 
described by Bergholdt et al.[36] and Holtedahl et al.[42] A critical appraisal of the 
studies is presented in Appendix 2.3. 
 
Of the five cohort and four cross-sectional studies, none fulfilled all criteria of the 
STROBE statement.[128] Seven studies[129, 131-136] provided clear information regarding 
the participants’ eligibility criteria, study setting, locations and relevant dates, 
including periods of recruitment. In all nine studies, descriptions of the study methods 
were often sparse or were either missing or only partially satisfied. A critical appraisal 
of these studies is presented in Appendix 2.4. For the four qualitative studies,[41, 130, 137, 
138] nearly all criteria outlined by Walsh and Downe[128] were met. The studies were 
contextualised with the existing literature, the details of the methods/design were 
consistent with research intent, and the data collection strategies were apparent and 
appropriate. The authors also provided data to support interpretation and elements of 
study relevance and transferability. However, the descriptions of the analytical 
approach in these studies were unclear. They were missing details of how the 
subjective meanings of participants were portrayed and handled, and in what ways the 
deviant data were sought. A critical appraisal of the studies is presented in Appendix 
2.5. 
 
2.5.4.3 Overview of Research Findings 
 
The outcomes and results of the type of interventions are summarised in Table 1 for 
RCTs and cohort and cross-sectional studies. The following two main themes emerged 
when the data were synthesised: 
1. Care outcomes were generally reported as any progress in patients’ 
psychosocial and physical functioning (or an overall improvement in patients’ 
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QoL), detection of recurrence, management of comorbidities and preventive 
health. 
2. Perspectives of care were reported as patients’ satisfaction with the care 
provided by the GP, or health professionals’ views of the GPs’ role in providing 
post-treatment care. 
 
2.5.4.3.1 Physical and Psychological Outcomes and QoL 
 
Six studies reported GPs’ supportive role in providing post-treatment cancer care in 
the context of ongoing specialist care.[36, 41, 42, 46, 132] There were mixed results reported 
regarding the QoL benefits to patients. In a randomised control trial investigating 
whether patients benefit from contact with a GP after cancer treatment, Holtedahl et 
al.[42]  showed no significant effect of GPs’ involvement for the 81 patients who 
answered two sets of QoL questionnaires. However, there was a significant 
improvement at six months in physical and social function status (p = 0.032, and 0.004, 
respectively); when frequent contact occurred.  
 
Bergholdt et al.[36] examined the involvement of GPs in cancer rehabilitation, with the 
primary outcome being the global health status of patients after six months. They 
allocated 281 patients to the intervention group and 297 to the control group (hospital 
care only), and found that the intervention had no statistically significant effect on the 
primary outcome. Adjustment for age and gender showed results similar to the 
unadjusted analysis. Overall, this intervention had a limited effect on the QoL and 
psychological distress of patients, but had a positive effect on patients’ evaluation of 
cooperation between primary and secondary healthcare sectors.[36] A quality analysis 
of this study based on CONSORT revealed an adequate sample size. Although this 
study was powered (80%, ἀ = 0.05, n = 144) to detect the differences between the 
groups in terms of the primary outcome, process evaluation measures—such as GP 
proactivity and patient participation—were not undertaken, which may have affected 
the QoL results. To improve the QoL outcome, Bergholdt et al.[36] recommended the 
development of screening tools that support identification of patients with special 




Nielsen et al.[46] reported similar results to Bergholdt et al.[36] In this study, a discharge 
summary letter detailing patients’ potential or current physical, psychological and 
social problems was sent to the GP at the end of the treatment period by the 
oncologists. Patients in the intervention group were encouraged to visit their GP. 
Patients’ attitudes towards healthcare services, reports about contact with the GP, 
HRQoL and performance status were evaluated at the baseline and then three and six 
months later. The results of patients’ assessments of their HRQoL using the European 
Organisation for Research and Treatment of Cancer (EORTC) Quality of Life 
Questionnaire (QLQ)-C30 measure showed no statistically significant differences 
between the intervention and control groups; however, there were improvements in the 
quality of care offered in the intervention group.[46] 
 
2.5.4.3.2 Preventive Health and Management of Other Chronic Illnesses 
 
In a retrospective cohort study, Earle analysed chronic comorbidities and preventive 
healthcare of cancer patients managed by both primary care physicians and specialists. 
In this study, 50% of survivors (7,465 patients) continued to see an oncologist during 
follow-up, and 8% of those (587 patients) saw only an oncologist. In all categories of 
care, patients who were supported by both oncologists and primary care physicians 
received the highest proportion of recommended care for the management of cancer, 
chronic illness and preventive health, followed by patients who were supported by 
primary care physicians. Patients who were supported only by oncologists received 
significantly worse preventive care than did patients who also had a primary care 
physician. Survivors who did not receive care from an oncologist were less likely to 
undergo the cancer-related procedures of surveillance colonoscopy (27.6 v. 46.7%) 
and mammography (26.5 v. 31.3%) compared to patients who saw an oncologist. 
Conversely, the subset of patients who were seen only by primary care physicians were 
more likely to receive influenza vaccination (55.2 v. 43.6%), cervical screening (14.7 
v. 8.2%) and bone densitometry (3.9 v. 1.1%) than were patients who were supported 
only by an oncologist.[139] 
 
In an analysis by Haggstrom et al. of the type of doctor specialist most frequently 
visited by cancer patients during follow-up care (other than an oncologist), 16% (n = 
303) reported visiting a GP. Of these, 70% had two or three other medical conditions 
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followed up in primary care.[50] In this study, survivors were asked whether they 
received follow-up medical tests to check for signs of other health conditions, and 
whether their doctor discussed preventive health issues, such as lifestyle changes, diet 
and exercise. The results of this study indicated that survivors of CRC who most often 
saw oncologists were still significantly more likely than those who saw PCPs to report 
seeing a doctor for follow-up tests, and less likely to receive a physical exam. In terms 
of health promotion activities, CRC survivors who most often saw primary care 
physicians for follow-up cancer care were significantly more likely than survivors who 
saw specialists to report that their follow-up doctor helped with lifestyle (83 v. 63%, p 
= 0.015) and discussed diet (70 v. 48%, p = 0.005). In models adjusting for patient 
characteristics, oncologists were significantly less likely than PCPs to discuss disease 
prevention, provide help with lifestyle and discuss diet.[50] 
 
Anvik et al. (2006) explored the role of the GP in the post-treatment cancer care of 
patients recently treated, and reported that patients trusted their GP to provide 
competent care, especially when they had more complex healthcare needs in addition 
to cancer.[140] 
 
2.5.4.3.3 Perspectives of Care: Patients’ Perspectives 
 
Satisfaction with care was reported both qualitatively and quantitatively in six 
studies.[41, 42, 46, 130, 137, 140] Holtedahl et al.[42] reported that there was a non-significant 
tendency towards higher satisfaction among patients whose GPs were involved in their 
care. The improvement in scores for perceptions of patients regarding their overall 
cancer care was evident between randomisation and six months (score from 55.2 to 
58.9, p = 0.060). Further, when the authors conducted a subgroup analysis comparing 
those patients treated with curative intent and those offered palliative treatment, this 
tendency was confirmed for patients treated with curative intent (62.15 v. 46.38, p = 
0.035).[42] 
 
In an analysis by Aubin et al.[132] of patients’ perceived gap between actual and 
expected family physician involvement in cancer care during all phases of cancer, 
patients preferred their family doctor to be involved in all aspects of care.[132] Nielsen 
et al.[46] reported a statistically significant difference between intervention and control 
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groups at three months when patients’ attitudes towards cooperation (between GP and 
oncologist) and their feeling of ‘not being left in limbo’ were assessed (p = 0.025). A 
subgroup analysis of these variables showed that men in the GP-integrated programme 
felt less ‘left in limbo’ (p = 0.031), as did the younger age group (18 to 49 years) at 
both three and six months (p = 0.024 and p = 0.031).[46] In this study, being male (p = 
0.007) or younger (p = 0.029) were predictors of increased contact visits with a GP 
and of the ability of the GP to manage post-treatment cancer care. 
 
Qualitative studies also reported comparable results. Hall et al.[41] modelled a shared 
care model and explored the views of potential patients and the opinions and 
experiences of patients and doctors in the model,[41] while Hudson et al. explored 
survivor preferences of the shared care model.[137] Hall et al.[41] and Hudson et al.[41] 
revealed that patients were more receptive to GP involvement in post-treatment cancer 
care if they were confident that the GP had received extra training and support from 
the hospital.[137] The shared care model was also seen as favourable to participants 
because of reduced waiting time and parking fees. In particular, this model was 
reported to be valuable to those living in regional areas because of the reduced number 
of hospital visits and travel logistics.[41] 
 
Five studies reported continued patient contact with a GP while patients were 
undergoing follow-up at their hospital.[46, 50, 131, 132] Aubin et al.,[132] Bowman et al.[130] 
and Lundstrom et al.[135] assessed family physician involvement in cancer care and 
found that large proportions (88%, 62% and 35%, respectively) of patients continued 
to visit their GP informally throughout their cancer journey, despite being supported 
in the hospital by a specialist. Similarly, Nielsen et al.[46] noted that patients 
randomised to the shared care group had an increased number of visits to their GP at 
three and six months (p = 0.049 and p = 0.042, respectively). 
 
2.5.4.3.4 Health Professionals’ Perspectives 
 
Three studies[41, 133, 140] in this review evaluated health professionals’ views and 
experiences of GP involvement in post-treatment cancer care. In a survey of 
oncologists and GPs, Forsythe et al. examined perceptions of shared responsibility for 
the psychological follow-up of cancer patients.[133] In this study, GPs were more likely 
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to report shared provision for the management of physical symptoms and sole 
provision for health promotion and psychosocial care, compared to oncologists. In 
contrast, oncologists reported a shared approach for provision of patient psychosocial 
care (p < 0.001). Among the aspects of psychosocial care provided by GPs were 
treatment of sexual dysfunction, depression and anxiety.[133] Similarly, Wind et al.[141] 
explored the experiences of surgeons addressing cancer-related psychosocial problems 
and other non-cancer-related physical problems and reported that over 40% of 
surgeons felt that these issues were beyond their field of experience. 
 
Wind et al.[141] and Anvik et al.[140] reported that both GPs and surgeons are confident 
that GPs can handle post-treatment cancer care among patients with a low risk of 
recurrence (p = 0.004)[141] and that GPs have a role in the follow-up of many patients 
with cancer, including during initial phase after treatment.[140] In a qualitative study 
exploring GPs’ and patients’ experiences and opinions of GP involvement in post-
treatment care, Hall et al. found that GPs felt that their own clinical skills were 
improved when they received support and training.[41] In this study, the clinical skills 
of GPs were enhanced by attending training seminars and shadowing specialists at 
cancer clinics.[41] 
 
2.6 Discussion and Conclusion 
 
This review of the literature reported the outcomes of GP involvement in post-
treatment care alongside hospital care for cancer. Nearly all reviewed studies indicated 
that involving GPs in the care of patients alongside specialist visits is possible and 
acceptable to patients. Emerging evidence suggests that it is feasible to involve GPs in 
the care of cancer patients, provided that GPs are equipped with the necessary skills. 
 
This review indicated that both specialists and GPs were confident that GPs are able 
to assume a role in post-treatment cancer care. Most GPs are prepared to undertake a 
more prominent role in post-treatment cancer, contingent on good specialist support. 
The reviewed studies showed no differences between the GP and specialist in 
managing patients’ physical health, and GPs were more skilled at recognising 
psychosocial issues. Patient contact with the GP for supportive care was significantly 
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associated with identification and management of psychosocial issues. Overall, GPs 
reported greater involvement in the management of psychosocial issues, and shared 
management with specialists for physical symptoms. 
 
There were various results from the studies that examined QoL, with some studies 
reporting non–statistically significant improvements in patients’ QoL, and vice versa. 
Overall, GP involvement in follow-up care was associated with improvement in the 
physical and social wellbeing of patients following cancer treatment. In studies in 
which GP follow-up did not result in statistically significant improvement in QoL, 
patients reported enhanced quality and coordination of care. Patients who had their GP 
involved and had other concomitant health conditions reported greater continuity of 
care and a less fragmented approach to managing their health. 
 
However, caution should be exercised when interpreting these results because the 
study periods were relatively short in some of the reports, the measures used to assess 
QoL were different, and the reporting quality of each study was variable. For all studies, 
there were many aspects of methodological quality identified. Overall, regarding QoL, 
the quality of data was generally poor and no conclusive evidence can be drawn from 
the collated data or narratives. In addition, given that not all studies included in this 
review performed a subgroup analysis on the effect of GP involvement for patient 
outcomes with different types of cancer, it is plausible that the effects may differ if this 
model was applied to specific cancers. Most studies reported an overall effect of GP 
involvement patient on outcomes (physical, psychological and social) for all cancers 
combined. 
 
The reviewed studies did not provide strong evidence of the patient’s role in driving 
the delivery of care. Most studies either mentioned patient proactive approaches as a 
recommendation in their summary of findings or in the methodology. In some studies, 
patients were encouraged to visit their GP if they perceived a need to do so, and, in 
others, the GP was provided an assessment of the patient’s condition and encouraged 
to invite the patient for a consultation. The quality of measures used to aid GP 
consultation was not standardised. In some studies, GPs used broad questions to assess 
the general wellbeing of the patient, while, in others, the nurse coordinator assessed 
the needs of the patients, sent the report to the GP and encouraged the GP to contact 
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the patients. The deployment of a validated questionnaire detailing the possible needs 
of the patients and how this assessment was used to encourage a consultation with the 
GP was limited. Bergholdt et al.[36] recommended using a screening tool or decision 
support tool to identify and address patient needs. 
 
2.6.1 Study Strengths and Limitations 
 
The small number of studies identified for this review may arise from a variety of 
reasons. The ongoing involvement of GPs in post-treatment cancer care is not clearly 
described in the literature. In some cases, this was described as ‘formal’ shared care, 
in which the different roles of the GP and specialist were clearly delineated, while 
other studies described this as ‘informal’ shared care, in which patients continued to 
visit their GP informally, while still attending scheduled visits with a specialist. 
However, database searches were supplemented by a hand search from the list of 
references of the identified papers and systematic reviews. Finally, the heterogeneity 
of the study methods, outcome measures and analytical approach of various studies 




To improve patient outcomes in this approach, it would be helpful to design and test 
validated measures that support identifying patients who may benefit from GP 
involvement while still receiving ongoing care from a specialist. Additionally, it is 
useful to consider devising and deploying initiatives that encourage and facilitate 
patients to first consult their GP about what they believe are their needs or symptoms 
of recurrence. Applying this model of post-treatment cancer care to patients with a 
specified cancer would clarify whether the outcomes would be different. 
 
This review of the literature demonstrates that GP involvement alongside specialist 
care for cancer patients has not been robustly explored, despite some studies 
concluding that this is feasible and acceptable to patients. Therefore, the following two 
chapters explore the development and application of a patient-completed assessment 
tool—an initiative that encourages and facilitates patients to consult their GP regarding 
post-treatment cancer care. 
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Chapter 3: Developing the SATp for use by CRC Patients 
in General Practice (Study 1) 
 
 
A paper describing the study in this chapter has been accepted for publication in the 
journal Quality in Primary Care: 
Ngune I, Jiwa M, McManus A, Parsons R, Hodder R, Entriken F. 
Development of a patient-administered self-assessment tool (SATp) for 
follow-up of CRC patients in general practice. Qual Prim Care. 2015. 
Details of the letter of acceptance are shown in Appendix 3.6. 
 
This chapter outlines the steps involved in developing a self-assessment tool for CRC 
patients (SATp) to help them to articulate problems associated with their CRC 




Background: Treatment for CRC may result in physical, social and psychological 
issues that affect patients’ post-treatment QoL. A comprehensive assessment 
conducted to identify these needs noted a lack of tools and processes available in 
general practice to facilitate identification and discussion of patients’ problems post–
CRC treatment with a GP. 
 
Aims: The aim of Study 1 was to develop a patient-completed needs-screening tool 
( SATp) that identifies the potentially unmet physical, psychological and social needs 
of patients treated for CRC. 
 
Methods: The development of the SATp included a review of the literature; ensuring 
face and content validity with reference to an expert panel; psychometric testing, 
including readability, internal consistency and test–retest reliability; and ensuring 
usability in clinical practice. 
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Results: The SATp contained 25 questions. It indicated internal consistency 
(Cronbach’s alpha 0.70–0.97), readability (reading ease 82.5%) and test–retest 
reliability (kappa 0.689–1.000). A total of 30 patients piloted the SATp. Participants 
were an average of 69.2 (SD 9.9) years old, while 26.7 months (range 6–92, median 
28) was the median follow-up period at the outpatient cancer clinic. A total of 149 
issues associated with CRC treatment were identified by SATp, with an average of 8.1 
needs per patient (median 7, IQR [3–12.25]). Identified needs were in the physical (53, 
36%), psychological (53, 36%) and social (48, 32%) domains. 
 
Conclusions: The SATp is a reliable and valid self-assessment tool that is useful for 
identifying CRC patient needs. Further testing of this tool for validity and usability is 
outlined in Chapter 5—Study 3. 
 
3.2 Summary Statement 
3.2.1 What Do We Know? 
 
The following knowledge was used as the basis of this study: 
 the treatment for CRC often results in long-term side-effects 
 assessment of CRC-related needs and side-effects is important in determining 
ongoing care for CRC patients 
 the available needs-assessment tools do not adequately capture long-term CRC 
side-effects 
 there is no documented CRC needs-assessment tool used in general practice to 
assess the long-term side-effects of treatment. 
 
3.2.2 Contributions of Study 1 
 
This study reports the development of a reliable and valid needs-assessment tool 






Treatment for CRC is associated with physical, social and psychological side-effects 
that can affect patients’ QoL many years after completing treatment. Although acute 
side-effects diminish after treatment completion, some problems persist for years, 
including fatigue, sleep difficulty, fear of recurrence, anxiety, depression, negative 
body image, activity limitation, sensory neuropathy, gastrointestinal problems, urinary 
complications and sexual dysfunction.[1, 3] There is evidence that these problems are 
not always identified during routine doctor–patient consultations. The reasons for non-
identification include patients’ reluctance to initiate a discussion about their needs, and 
health professionals’ failure to prompt patients to discuss these needs during 
consultation.[29] Consequently, issues may go unchecked, thereby resulting in delayed 
diagnosis or treatment. 
 
Regular assessment of CRC-related needs and treatment side-effects has recently 
received attention as being important in the ongoing management of patients.[142] 
Assessing and attending to patients’ needs are important steps towards effective 
patient-centred care, with failure to manage these needs appropriately having the 
potential to adversely affect QoL.[143] A standardised screening tool that identifies 
common physical, psychological and social issues could facilitate consultation 
between patients and health professionals to address these needs.[144] 
 
Many instruments assessing the physical and psychosocial side-effects of cancer 
treatment are available, including the Supportive Care Needs Survey,[145] EORTC 
PR29,[101] Supportive Needs Screening Tool[29] and Cancer Survivors’ Unmet Needs 
measure.[143] Some items measured by these questionnaires are relevant to general 
cancer problems, while others are not specific to CRC. Cancer patients’ needs vary 
depending on the type of cancer and the clinical/pathological stage of disease. For 
example, the needs of Stage IV cancer patients differ greatly from those with Stages I 
to III.[3, 143] Moreover, these tools have not been integrated into primary care practice. 
This study reports the development of a patient-administered needs-assessment tool 





The primary aim of Study 1 was to develop a patient-completed needs-screening tool 





The sub-objectives of Study 1 were: 
 to critically evaluate the existing literature to identity problems experienced by 
CRC patients following CRC treatment 
 through a series of validation processes, to generate a list of common problems 
experienced by patients following treatment 
 to pilot the agreed list to test its reliability and ability to identify common 
problems experienced by CRC patients. 
 
3.5 Structural Framework 
 
The structure of the SATp is based on a framework by Pigott et al.[29] and Bonevski et 
al.[145] that suggests that seven criteria should be used to determine the effectiveness 
of needs-screening tools in cancer follow-up care. The SATp has several properties. 
This tool: 
 contains integrated physical, psychological and social aspects to measure 
multiple domains of CRC care; these domains have also been adopted by Jiwa 
et al.[146] in a needs assessment for breast cancer patients 
 uses a self-reporting approach to facilitate direct and comprehensive 
assessment of subjective health needs 
 measures the needs in a defined temporal context—questions relate to needs 
experienced in the previous four weeks; as advocated by the Pigott et al. study, 
the timeframes used should be useful for clinicians to develop a clear 
understanding of patients’ needs 
 demonstrates validity and reliability through expert review, test–retest and pilot 
testing to provide a sound basis for comparison 
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 embraces a user-friendly response framework, such as yes/no responses, to 
simplify the questions for the patient and prompts for the clinician to probe 
further 
 contains only 25 items and is system-friendly by minimising the patient and 
staff time required to complete and review 
 provides an opportunity for clinicians to link patients to services—this tool is 
meant to be a guide during consultations in order to assist a thorough 
exploration of possible issues. 
 
3.6 Methodology 
3.6.1 Study Design 
 
This study used a Delphi methodology to develop a patient self-completed needs-
screening tool to identify potentially unmet physical, psychological and social needs 
among CRC patients. A Delphi study technique solicits the opinions of experts through 
a series of carefully designed questionnaires that are interspersed with information and 
opinion feedback in order to establish a convergence of opinion.[55] 
 
The Delphi method was developed in the 1950s and was originally used to forecast the 
effect of technology on warfare.[147] The method entails a group of experts who 
anonymously reply to a questionnaire and subsequently receive feedback in the form 
of a statistical representation of the ‘group response’, after which the process is 
repeated. The goal is to reduce the range of responses and attain something closer to 
expert consensus. The Delphi method has been widely adopted and is still used 
today.[148] The Delphi methodology offers advantages over other modes of consensus 
building (such as round table discussions)[149] because: 
1. discussions are electronic/internet-based, making it easier for experts to 
participate impartially than during face-to-face discussions 
2. anonymity is preserved, thereby allowing panellists to freely express their 
opinions without feeling pressure to agree with group members[55, 150, 151] 
3. questionnaires are implemented over a period of at least six weeks, thereby 
providing panellists time to carefully consider discussion topics.[149] 
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The Delphi methodology has previously been used in health-related studies to better 
understand the varied symptom presentation in patients who are at different stages of 
their disease trajectory.[152] 
 
3.6.2 Materials 
3.6.2.1 Literature Review 
 
The construction of the SATp was based on a review of CRC survivorship literature 
and subjected to a series of validations. The items focused on long-term issues 
experienced by patients offered treatment with curative intent (Stages I to III). The 
needs of those with Stage IV CRC are entirely different and in most cases are 
palliative;[143] thus, they were not included. 
 
3.6.2.1.1 Item Generation 
 
A systematic search was performed using PubMed/Medline, CINHAL and Cochrane 
Online Library Reviews/Trials databases from 1980 to 2014. Search terms were used 
either singularly or in combination in the index lists of the relevant databases. The 
search terms used were ‘lower bowel cancer’, ‘rectal cancer’, ‘colon cancer’, ‘effects 
of treatment’, ‘effects of adjuvant therapy’, ‘effects of surgery’, ‘follow-up care’, 
‘survivorship care’, ‘quality of life’ and ‘patient unmet needs’. Free text words were 
used to supplement the medical subject heading search terms for Medline. 
 
The search of literature focused on the long-term effects of CRC treatment and their 
prevalence. Titles and abstracts of 650 references were reviewed and 69 studies 
satisfied the following inclusion criteria (Figure 3.1): 
 published in English 
 reported empirical research 
 reported epidemiology of CRC 
 focused on developing a symptoms/needs-assessment questionnaire for 
patients post–cancer treatment—particularly CRC 
 reported the side-effects of CRC treatment 
 focused on patients’ QoL after CRC treatment. 
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From the 69 reviewed papers, 340 possible post–CRC treatment problems were 
extracted. Duplicates were removed, yielding 100 items. These items were assessed 
by a team of three clinicians (medical doctor, public health specialist and nurse). 
Unclear items and those with similar meanings were identified and discussed for 
relevance, which left issues considered common for CRC patients post-treatment. 
Thirty-two problems were grouped into three domains: psychological (n = 6), physical 




Figure 3.1: Flowchart of the Methods Used to Identify Evidence Relevant to 
Study 1 
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3.6.3 Item Reduction 
 
The 32 identified items were further reduced by assessing them against published 
prevalence of CRC treatment side-effects. Any items that had a frequency of 5 or less 
per 100 were removed because this was deemed uncommon by the expert panel. The 
modelling was based on a typical cohort of 100 patients with CRC. 
 
From the reviewed articles, the epidemiology of CRC suggested that approximately 
70% of cases are located in the colon and 30% in the rectum.[153] In addition, 50% of 
patients with colon cancer are likely to be in Stages II or III at diagnosis,[72, 154] while 
rectal cancer cases are evenly spread across all stages.[72] For Stages I to III of CRC, 
nearly all patients (98%) undergo surgery,[72] while treatment with chemotherapy and 
radiotherapy depends on the location (colon or rectum) and stage. For colon cancer, 
the majority (75.5%) of Stage III patients receive chemotherapy,[97] while 
chemotherapy for patients at Stages I and II is less common because there is no general 
agreement on its use for these patients.[111] Approximately 19.6% of patients are 
offered chemotherapy during Stage I[155] and 20 to 24% during Stage II.[155] 
Radiotherapy has a limited role in the treatment of colon cancer; however, for rectal 
cancer patients, it may be offered at all stages: Stage I—19.6%,[155] Stage II—36%[155] 
and Stage III—57%.[97] 
 
Further, the literature suggests that patients may have treatment side-effects or issues 
associated with treatment in the physical, psychological and social domains.[156, 157] 
The prevalence of the published side-effects under these domains are summarised in 
Figure 3.2. Most side-effects in the physical domain relate to bowel issues (7 to 
20%),[1, 2, 4] urinary issues (31 to 38%)[1] and sexual dysfunction (26%).[6] The long-
term psychological issues commonly reported are fear of recurrence (67 to 68%)[1, 8] 
and depression (25%).[7] For social problems, the greatest burden is financial 
difficulties (~50%),[22] followed by activity limitation (15%).[3] Based on these 
statistics, it is anticipated that, in a sample of 100 Stage I to III CRC patients (excluding 
22.5% of Stage IV and 3–5% of un-staged CRC) with typical epidemiology as above, 
53 will have colon cancer and 22 will have rectal cancer. Of these, 75 patients will 
receive surgery, 36 will be offered chemotherapy and 11 will be offered radiotherapy 
(see Appendix 3.1). 
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Further, using modelling to illustrate the frequency of treatment effects in the cohort 
of 100 CRC patients, five to 10 of them will have some form of bowel dysfunction. It 
is anticipated that about seven to nine patients with rectal cancer (a cohort of 23 
patients) who have had surgery and radiotherapy will report urological dysfunction. 
From this cohort, four patients who received chemotherapy will experience some form 
of peripheral neuropathy, and at least one to six patients will experience nausea, 
vomiting and weight loss related to chronic radiation enteritis.[1] Six rectal cancer 
patients will experience some form of sexual dysfunction. 
 
The extent of psychological and social factors experienced by the entire cohort (colon 
and rectal) will be high. Nearly 50 patients will suffer some form of psychosocial 
problem—for example, about 50 patients will have fear of recurrence (details of the 
cohort modelling are shown in Appendix 3.1). Based on the modelling, items with 
fewer than five patients in the cohort were removed from the list; thus, two items 
(fractures and dysuria) were excluded. The results of the cohort modelling identified 
26 items that were subsequently used to formulate the initial SATp questions, which 






Figure 3.2: Process of Item Generation, Reduction and Validation for 
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3.6.4 Content Validity of the SATp 
 
The content was tested using a Delphi method. Initially, a group of health professionals 
involved in the follow-up care of CRC were identified and approached. As informed 
by the literature, questions of the problems experienced by CRC patients were 
formulated and sent to the panel of experts for suggestions and validation. These 
experts were also asked to list other problems CRC patients may present during the 
follow-up appointments. 
 
3.6.4.1 Delphi Method 
 
The primary researcher coordinated the responses of the panel of experts, who were 
selected based on their areas of expertise (seven health professionals—a GP, medical 
oncologist, radiation oncologist, CRC surgeon, CRC nurse specialist, dietician, 
psychologist, occupation therapist and social worker) or were patients who had 
completed treatment for CRC (10 patients). The researcher sent out the draft tool 
containing a list of CRC problems to the consenting experts via email, for them to 
provide their level of agreement of each item using a Likert scale on a questionnaire 
developed for this purpose. Details of this questionnaire are provided in Appendix 3.2. 
The panellists were asked to give a reason for each of their scores. Clear instructions 
were provided, with the expectation that there was to be a two-week turnaround for 
each round of the Delphi. Panellist responses were collated and an average score 
assigned to each item on the second round of the questionnaire to be re-sent to the 
panellists. The panellists were provided with a list of all panellists’ de-identified 
comments. This process was repeated twice until consensus of at least 70% was 
reached for each item. The development and examination of this tool (SATp) by a 
group of experts ensured this tool’s reliability and validity. 
 
The 26 questions were rated on a Likert scale by the panel of health professionals and 
patients, and 90% had total scores > 3 out of a maximum score of five. Scores ≥ 3 were 
regarded by the panel as indicating high relevance. One physical item (constipation) 
and one social need (information need) with scores of two were removed from the list. 
Four other questions were combined into two because they tested the same issue 
(sexual dysfunction for males and females, and frequent bowel movements during 
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night and day). An additional two items suggested by the panel (dietary advice and 
troublesome flatulence) were added to the list. In total, 25 questions were included in 




The SATp was subjected to readability tests, such as the Gunning Frequency of 
Gobbledygook Index, Flesch–Kincaid Grade Level, Simple Measure of 
Gobbledygook (SMOG) Formula, and Flesch Reading Ease (FRE) Scales for functions 
of the number of characters, syllables, words and sentences in a text sample (these tests 
have been used extensively to measure the readability of health information).[158] This 
ensured that the tool could easily be understood by the general population of Australia 
(reading level Year 10, high school). A grade of 4.4 reading level was attained 
(acceptable range are grades four to six) and reading ease was 82.5% (maximum 
reading ease is 100%, with the higher the number, the easier it is for participants to 
read). On average, the SATp takes approximately five minutes to complete. 
 
3.7 Data Analysis 
 
Statistical analysis of SATp was conducted using the Statistical Package for Social 
Sciences (SPSS) Version 19.[159] The kappa coefficient was used to examine test–retest 
reliability at the item level, while Cronbach’s alpha was computed to assess internal 
consistency. The Delphi results of the panellist score were computed and average 
scores calculated. Items with an average score of < 3 out of five for healthcare workers 
and patients were excluded from the list. Descriptive statistics were used to summarise 
the patients’ demographics, clinical characteristics and needs identified by the SATp. 
 
3.8 Study Identification of Participants for the Pilot Study 
 
Participants for the pilot study were recruited from an outpatient cancer centre of 
SCGH—a tertiary referral teaching hospital located in Perth, Western Australia. 
Participants were identified from the outpatient electronic medical register, i.Clinical 
Manager (iCM iSOFT) Version 10,[160] which is commonly used at the SCGH. The 
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ICD-10-AM third edition diagnosis codes relevant to CRC (C18, C19, C20 and 
C21)[161] were used to retrieve all patients with CRC from the outpatient register. A 
sub-criterion was then employed to narrow the results down to patients who had active 
appointments at the time of identification (patients who still had scheduled follow-up 
appointments). Further eligibility criteria and exclusion criteria are shown in Table 3.1. 
 
Table 3.1: Eligibility Criteria for Identifying Possible Study Participants from 




 18 years or over 
 Active CRC follow-up at the SCGH outpatient clinic 
 Diagnosis of primary CRC (ICD-10 AM C18-C20) 
 ACPS, A-C 
 Treated for colorectal surgical intervention with curative intent (ICD-10 
procedures 913, 915, 917, 918, 926, 927, 932, 933, 934, 935 and/or other 





 Recurrent disease 
 Sole non-surgical investigations and procedures, such as colonoscopies, 
biopsies, insertion of catheters and drainage of abscess, hematoma or cysts 
 
 
The researcher telephoned the potential participants identified from the clinic database, 
introduced them to the study, and invited them to participate. Those who verbally 
consented received an information sheet and consent form. The study was approved 
by the human research ethics committees from the participating hospital and university 
(QI3041 and HR 42/2012, respectively). Details of the consent form and participant 









3.9 Piloting and Pre-testing 
 
Piloting of the draft SATp (developed through the Delphi method) was undertaken to 
assess its usefulness in identifying CRC-related problems. Patients involved in the 
Delphi study were excluded from the pilot/pre-testing of the questionnaire to prevent 
contamination. A group of 30 consenting patients agreed to pilot and pre-test the SATp. 
For participants who also consented to participate in Studies 2 and 3 of this project, 
their pilot results were treated as a baseline findings for these studies, and no further 
details were requested from these patients at baseline. 
 
Test–retest reliability was assessed by administering the SATp to a subset of 
participants who agreed to fill it out on two occasions, approximately two weeks apart. 
The SATp was sent to 30 participants and then re-sent 14 days later. The kappa statistic 
(κ) was calculated to assess the test–retest reliability of the instrument. Kappa can 
range between one (perfect agreement) to slightly less than zero (no agreement). A κ 
value of > 0.80 is considered to reflect almost perfect agreement, while 0.61 to 0.80 
indicate substantial agreement, 0.41 to 0.60 indicate moderate agreement, and 0.21 to 
0.40 indicate fair agreement.[162] The question-by-question comparison showed 
substantial agreement with kappa in the range of 0.689 to 1.000 for all questions. 
 
The 25-item SATp achieved moderate to high internal consistency, as demonstrated 
by the Cronbach’s alpha coefficients for the three domains (psychological, social and 
physical) ranging from 0.706 to 0.903. The item-to-total score correlation coefficients 
for all items exceeded 0.595. This showed that questions within each of the three 
domains were assessing different aspects of the same construct. The final set of 
questions in the SATp are shown in Appendix 3.4. 
 
3.9.1 Needs Identified 
 
Participants in Study 1 were 69.2 (SD 9.9) years old on average, and had been 
diagnosed with cancer 26.7 months earlier (range 6–92, median 28). Sixty-five per 
cent had colon cancer, 34.8% had rectal cancer and 81.8% had one or more coexisting 
chronic illness. Of the 30 participants who piloted the SATp, a total of 149 needs were 
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identified by SATp, with an average of 8.1 needs per patient (median 7; IQR [3–
12.25]). Identified needs were in the physical (53, 36%), psychological (53, 36%) and 
social (48, 32%) domains. The most commonly reported physical needs were 
troublesome flatulence (79%) and fatigue (41%). Psychological needs included fear of 
recurrence (53%), insomnia (53%), sexual dysfunction (36%), anxiety (36%) and 
negative body image (23%). Social needs included dietary advice (41%) and 




This study reports the development of a reliable and valid tool (SATp) to assist doctors 
and patients to identify symptoms or problems that may result from CRC treatment. 
The SATp satisfies the prerequisites for assessing the long-term needs of CRC 
survivors because it measures multiple dimensions of CRC-related needs. The items 
included in the SATp were developed via a rigorous literature review and by modelling 
the items using a simulated cohort of CRC patients to derive the most common 
symptoms experienced by this group. Further, the instrument integrates the experience 
of patients in follow-up care with expert input from health professionals involved in 
the care of CRC patients. 
 
The preliminary results indicate that the SATp fulfils the current methodological 
standards for acceptability, internal consistency, and usability. Through an internal 
consistency process, it was possible to demonstrate evidence for a strong, structurally 
reliable SATp with Cronbach’s alpha coefficients exceeding 0.7 in all three domains. 
The test–retest reliability also showed a level of agreement that was not due to chance, 
as evidenced by a kappa of 0.689 to 1.000. 
 
Despite being at least six months post-treatment, each patient was experiencing a 
median of seven unmet needs, all in the three domains (physical, psychological and 
social). These domains have been reported by previous research, suggesting that these 
issues are important aspects for long-term survivors of CRC.[146] The initial results 
confirm that the tool can be self-administered. By examining the needs rated ‘yes’, the 
survey could potentially be used to alert practitioners to refer these patients to 
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secondary care or other appropriate allied health support services. For the SATp to be 
useful, regular use in general practice is required. It is yet to be demonstrated whether 
the SATp facilitates proactive management of related problems in general practice, 
and how GPs might address some of the problems identified, such as fear of 
recurrence. This will be addressed in Study 3 in Chapter 5. 
 
The SATp was unable to test directly for concurrent validity and predictive validity.  
In primary care, there was no Gold Standard identified by literature that SATp would 
be tested against. SATp also failed to test these forms of validity due to the nature of 
the intended outcome. The SATp was to identify CRC related problems and act as a 
prompt sheet to guide a GP consultation, rather than a self-administered diagnostic 
tool. The expected responses were binary in nature (Yes/No) and with a clear intention 
of prompting further examination by the doctor. This examination by the doctor has 
been documented in Chapter 5 of the Thesis. 
 
Despite these limitations, the research outlines some of the practical and operational 
benefits of a specific instrument for CRC patients attending general practice. Further, 
the practicality of the self-administration of this measure obviates the need for follow-
up telephone interviews from health professionals. Thus, the SATp increases the 
practical feasibility and acceptability of assessing patient needs on an ongoing basis as 
a routine part of care. The application of the SATp in general practice may potentially 





Chapter 4: Predicting Study Participants’ Intentions to 
Attend a GP Following CRC Treatment (Study 2) 
 
 
The study detailed in this chapter has been published in the American Journal of 
Health Behavior: 
Ngune I, Jiwa M, McManus A, Hodder R. Predicting general practice 
attendance for follow-up cancer care. American Journal of Health 
Behaviour. 2015; 39(2):167-174. 
doi:http://dx.doi.org/10.5993/AJHB.39.2.2. 
Permission to reproduce this work for education purposes has been granted (see 
Appendix 4.1) 
 
This chapter presents the study examining participants’ intentions to seek CRC-related 
health advice from a GP. It details the factors that may influence patients’ decisions to 
seek health advice. This chapter presents the study design, theoretical framework 
guiding the formulation of the study, methodology and results. 
 
4.1 Study Summary 
 
Objective: This study examined the role of the Theory of Planned Behaviour (TPB) 
in influencing patients’ intentions to seek health advice from a GP. 
 
Methods: A questionnaire was developed based on the TPB to assess CRC patients’ 
intentions to attend follow-up visits with a GP following CRC treatment. 
 
Results: TPB factors accounted for 43.3% of the variance on future follow-up visits. 
Attitude alone explained 23.3% of the variance. Attitude and the presence of 
comorbidities significantly affected future intention to visit a GP (attitude: R2 = 0.233, 
F [1, 65] = 4.345, p < 0.01; comorbidity: R2 = 0.128, F [1, 65] = 3.019, p < 0.05). 
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Conclusion: Patients who believed their GP had the skills and knowledge to detect a 
recurrence and patients with comorbidities were more likely to visit their GP following 
CRC treatment. 
 
4.2 Summary Statement 
4.2.1 What is Known About the Topic 
 
Previous studies have indicated that: 
 there have been difficulties in implementing follow-up care for CRC patients 
in general practice[163] 
 there is limited empirical evidence regarding the factors that influence uptake 
of follow-up care by patients in general practice 
 the factors that influence patients’ decisions to seek health advice from a GP 
about CRC-related problems have not been fully determined. 
 
4.2.2 What this Study Contributes 
 
This study is significant because it contributes the following elements to the literature 
on CRC care. It contributes: 
 a key component of innovation involving the follow-up care of cancer patients 
in primary care, which includes increasing patients’ confidence in the skills 
and knowledge of their GP regarding the current treatment of cancer 
 the finding that it may be more effective to share the follow-up care of CRC 
patients who already attend their GP for other reasons, such as those with 




In Australia, an estimated 105,000 people are CRC survivors, and this number is 
expected to increase by 309 every year.[14] It is likely that the specialist care of patients 
with CRC will need to be reorganised due to the increasing number of survivors.[31] 
Patients who have been treated successfully may benefit from long-term support by a 
GP in addition to specialist care. In Australia, approaches such as GP-led cancer care 
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and shared care for managing patients with breast, colorectal and prostate cancers in 
general practice have been trialled.[35, 41, 49, 164-167] However, to date, conclusive 
evaluations nor have they been conducted on the effectiveness of these approaches, 
nor they have been widely adopted.[38, 122] For breast cancer and other GP-led models 
of cancer care trialled in Australia and the United Kingdom,[168] uptake has been 
slow.[169] 
 
There has been detailed analysis of healthcare system factors that affect the 
implementation of GP-led model, such as: the flow of information from hospitals to 
general practice and vice versa; the training of GPs; and the associated costs.[167] 
However, limited attention has been given to identifying patient factors. Recent efforts 
to report patients’ preferences for cancer care have indicated that a GP-led approach 
in managing cancer care is favourable.[35] However, exploration of these preferences 
has only been in the context of perceived satisfaction with the treatment provided.[36] 
More empirical evidence is required on other factors to be considered for patients to 
attend seek health advice from a GP. 
 
CRC patients are generally older (median age 69 years) compared to other cancer 
patients, and 30 to 60% of those aged 70 years or older with CRC have concomitant 
health conditions.[170] To date, no studies have explored the role of concomitant health 
conditions in influencing patients’ attention to seek health advice from a GP about 
CRC-related problems. Studies have reported patient factors that affect access to 
healthcare, such as ease of travel, area of residence (rural versus urban), cost of 
services, and ease of obtaining an appointment as determinants for attending a GP for 
cancer care.[41, 137] While patient factors are central to determining the uptake of 
programs, the factors affecting people’s choices must also be determined. These 
determinants need to be explored within a behavioural framework that incorporates 
people’s intentions, attitudes, perceived control and barriers, and influences felt from 
other people regarding health-seeking behaviours.[171] 
 
Social and psychological models have an important role in increasing understanding 
of the factors that underlie health-related decisions and behaviours.[172] Many models 
have been applied to predicting the attendance of health programs among cancer 
patients, including the Health Belief Model,[173] Protection Motivation Theory,[174] 
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Health Locus Control[175] and Self-efficacy Theory.[176] However, the TPB has 
attracted growing interest in recent years and continues to dominate behaviour 
research.[172] 
 
The TPB suggests that intention immediately precedes behaviour because it reflects a 
person’s level of motivation and desire to perform a certain action.[172] Intention is 
determined by attitude, subjective norms and perceived behaviour control 
constructs.[177] Perceived behavioural control (PBC) is the perceived opportunities and 
resources available for performing a behaviour, and may directly lead to the behaviour 
if it accurately reflects actual control. Attitude is viewed as the perceived advantages 
and disadvantages of performing the behaviour. Subjective norms are the perceived 
social pressures (such as important people) that influence an individual to perform a 
behaviour or not.[62] A diagrammatic representation of this model is shown in Figure 
4.1. 
 
Among cancer patients, all three factors (attitude, subjective norms and perceived 
behaviour control) have been used to predict behaviours, such as adherence to 
exercise[178] and attendance and re-attendance at screening programmes.[57] Studies 
conducted by Courneya et al. that used the TPB to understand intention and behaviour 
after CRC diagnosis[178, 179] demonstrated that intention is the strongest determinant of 
future behaviour. However, little is known about the role of intention, personal attitude, 
PBC and subjective norms in CRC patients attending follow-up care with a GP, and 
the influence of comorbidities on these factors. The present study seeks to explore the 
role of comorbidities within the TPB framework in predicting intention and behaviour 
in CRC patients who have never attended follow-up cancer care in general practice. 
 
The hypothesis of this study was that personal attitude, PBC and subjective norms 
would be independently associated with intention to seek health advice from a GP 
about CRC-related problems. In addition, the presence of comorbidities would 














The main aim of Study 2 was to assess the factors that influence CRC patients’ 




The sub-objectives were as follows: 
 to assess the influence of TPB constructs (attitude, subjective norms and 
perceived control factors) on patients’ decisions to seek health advice from a 
GP 
















4.4.1 Study Design and Identification of Participants 
 
A cross-sectional study design was used to predict patients’ intentions to seek health 
advice from a GP about their CRC-related problems. The participants were identified 
through a process similar to Study 1, and invited to complete a questionnaire developed 




Participants for Study 2 were recruited from an outpatient cancer centre at SCGH—a 
tertiary referral teaching hospital located in Perth, Western Australia. Participants aged 
18 years or older who had completed CRC treatment (surgery only or surgery and 
adjuvant therapy) and were still undergoing active follow-up at the outpatient cancer 
clinic in SCGH were eligible to participate in this study. 
 
A process similar to that undertaken for Study 1 was followed to identify participants 
for this study. Participants were identified from the outpatient electronic medical 
register, i.Clinical Manager (iCM iSOFT) Version 10,[160] which is commonly used at 
the SCGH. The ICD-10-AM third edition diagnosis codes relevant to CRC (C18, C19, 
C20 and C21)[161] were used to retrieve all patients with CRC from the outpatient 
register. A sub-criterion was then employed to narrow the results down to only patients 
who had active appointments at the time of identification (patients who still had 
scheduled follow-up appointments). Further eligibility criteria and exclusion criteria 











Table 4.1: Eligibility Criteria for Identifying Possible Study Participants from 
the Electronic Medical Records 
 
Eligible Patients 
 18 years or over 
 Active CRC follow-up at the SCGH outpatient clinic 
 Diagnosis of primary CRC (ICD-10 AM C18-C20) 
 ACPS, A-C 
 Treated for colorectal surgical intervention with curative intent (ICD-10 
procedures 913, 915, 917, 918, 926, 927, 932, 933, 934, 935 and/or other organs 
if patient had a synchronous or secondary malignancy) 
 
Ineligible Patients 
 Recurrent disease 
 Sole non-surgical investigations and procedures, such as colonoscopies, biopsies, 
insertion of catheters and drainage of abscess, hematoma or cysts 
 
 
The primary researcher telephoned the potential participants identified from the clinic 
database, introduced them to the study, and invited them to participate. The 
participants who verbally consented received a study information sheet and consent 
form that contained the study details. A protocol of reminder telephone calls and letters 
was followed to enhance participant compliance in the study. The relevant human 
research ethics committees from the hospital (QI3041) and university (HR 42/2012) 




Validated questions for assessing CRC patients’ intentions to attend a GP were 
identified from the literature. Patients responded to questions adapted from a manual 
on constructing questionnaires based on the TPB.[62] Although the individual questions 
had been validated, they were still piloted by a group of five patients to assess for 
readability in an Australian context. Assessment of the internal consistency of the 
various items under each TPB constructs, as well as scoring of these items, were 






4.4.3.1 Demographic and Disease Information 
 
The demographic characteristics included age, marital status, education, previous GP 
visits, employment status, location of cancer, type of treatment offered and existing 
comorbidities. The clinical characteristics were formulated based on patient-
assessment questions identified in the Australian guidelines for cancer follow-up.[37] 
Table 4.3 presents the demographics and clinical characteristics of the participants 
from study 2. 
 
4.4.3.2 Intention to Engage with a GP or a Specialist in the Future 
 
The participants responded to questions adapted from a manual on constructing 
questionnaires based on the TPB.[62] Three questions that assessed this intention were: 
‘In the next six months, I am likely to attend a GP visit’; ‘I’m likely discuss CRC related 
problems with a GP’ and ‘I’m likely to attend a specialist only for CRC-related 
problems’. The responses were coded on a Likert scale ranging from one (unlikely) to 
five (very likely) (see Table 4.2). 
 
4.4.3.3 Personal Attitude about Seeking Health Advice from a GP for CRC-related 
Problems 
 
Attitude was measured using questions requiring responses on five-point Likert scales, 
measuring responses from unlikely to likely, and strongly disagree to strongly agree. 
The three attitudinal items were: ‘Attending a GP about my CRC: (i) is likely to detect 
problems and side-effects early, (ii) is likely to detect problems and side-effects early, 
or (iii) will reassure me’. Internal consistency for this three-item scale was 0.778 








4.4.3.4 Subjective Family and ‘Important Others’ Norms about Engaging with a GP 
 
Subjective norms were measured by three items from Francis[62] on five-point Likert 
scales, which ranged from one (strongly disagree) to five (strongly agree). The three 
items were: ‘Most people who are important—my family, specialist and cancer 
nurse—think I should attend a GP about my CRC’. Internal consistency for this three-
item scale was 0.879 (see Table 4.2). 
 
4.4.3.5 Perceived Behaviour Control Factors and Barriers Influencing GP Visits for 
CRC-related Problems 
 
PBC factors were measured using four items from Francis,[62] also requiring responses 
on five-point Likert scales. Two items used adjectives on a five-point scale, which 
ranged from one (extremely easy) to five (extremely difficult), and one (strongly 
agree) to five (strongly disagree). One item tested the control factors and the other 
tested barriers. The control items were: ‘Making a routine appointment with a GP is 
extremely difficult to extremely easy (1 to 5), and it is easy for me to attend a GP about 
my CRC—strongly agree to strongly disagree’. The internal consistency for this two-
item scale was 0.803. The barrier factors were: ‘It is affordable for me to attend a GP 
about my CRC (strongly agree to strongly disagree)’ and ‘for me to travel to see a GP 
about my CRC is extremely difficult to extremely easy’(1 to 5). The internal 
consistency for this two-item scale was 0.853. 
 
 
4.4.4 Scoring and Statistical Analysis 
 
A five-point Likert scale (described above) was used to score attitude, social norms 
and the perceived behaviour control items identified above. An overall score for each 
construct was calculated by taking an average score of the items under each construct. 
Negatively worded endpoints (‘barriers’) were reverse-scored prior to analysis, so that 
a high score indicated ease of attending a GP, while a low score indicated a reluctance 




Table 4.2: TPB Questions 
Factors Influencing Seeking 
Health Advice from a GP 
Questions Likert Scale Internal 
Consistency 
 
Intention to engage with a GP 
in the future 
‘In the next six months, I am likely to attend a GP visit.’  
1 = unlikely 
5 = very likely 
N/A 
Intention to discuss CRC 
related problems with a GP 
in the future 
“In the next six months, I likely to discuss CRC related 
problems at with a GP 
1 = unlikely 
5 = very likely 
N/A 
Intention to engage a 
specialist only for CRC-
related problems 
‘In the next six months, I am likely to attend a specialist only for 
CRC related problems.’ 
1 = unlikely 
5 = very likely 
N/A 
 
Personal attitude  
‘Attending a GP about my CRC is likely to: (i) detect problems 
and side-effects early, (ii) detect problems and side-effects early or 
(iii) reassure me.’ 
 
 
1 = unlikely 





Subjective family and 
‘important others’ norms 
‘Most people who are important—my family, specialist and cancer 
nurse—think I should attend a GP about my CRC.’ 
1 = strongly agree 
5 = strongly disagree 
0.879 
 
PBC factors and barriers  
 
Control items: 
‘Making a routine appointment with a GP is extremely difficult to 
extremely easy.’ 
‘It is easy for me to attend a GP about my CRC (strongly agree to 
strongly disagree).’ 
 
1 = extremely easy 
5 = extremely difficult 
1 = strongly agree 





‘It is affordable for me to attend a GP about my CRC (strongly 
agree to strongly disagree).’ 
‘For me to travel to see a GP about my CRC is extremely difficult 
to extremely easy.’ 
 
 
1 = strongly agree 
5 = strongly disagree 
1 = extremely easy 




4.5 Questionnaire Readability 
 
The questionnaire was subjected to readability tests, such as Gunning Frequency of 
Gobbledygook Index, Flesch–Kincaid Grade Level, SMOG Formula, and FRE Scales 
for function of the number of characters, syllables, words and sentences in a text 
sample. These tests have been used extensively to measure the readability of health 
information.[180] The Flesch-Kincaid Grade Level and FRE Scale of a grade 4.4 reading 
level was attained (acceptable range are grades four to six), and reading ease was 
82.5%. On average, the questionnaire took 10 minutes to complete. 
 
4.6 Data Analysis 
 
Descriptive statistics were computed using the SPSS Version 19[159] to summarise the 
participants’ personal and clinical characteristics. Pearson’s correlation coefficients 
were used to examine the strength of association between intention to visit a GP in the 
future and attitude, subjective norms and PBC. Multivariate analysis (with 
simultaneous entry) was conducted to examine individual and combined contributions 
of attitude, subjective norms and PBC on future intention to ‘Intentions to attend a 
GP’, ‘Discuss CRC related problems with a GP’, and ‘Intentions to visit a specialist 
only’. Finally, squared semi-partial correlations were computed for each independent 
variable in the regressions to estimate the independent contribution of each variable to 
the model.[181] 
In simultaneous model of regression analysis, all independent variables are entered 
simultaneously and on an equal footing into the model. [159] In this strategy, the analysis 
is dictated in advance by purpose and logic of previous research but does not replicate 
the analytic approach of the guiding studies. In this case, the independent variables are 
entered according to their statistical contribution in explaining the variance in the 
dependent variable. [99]  Such a research strategy is most appropriate when no logical or 
theoretical basis for considering any independent variable to be prior to any other, either 
in terms of a hypothetical causal structure of the data or in terms of its relevance to the 
research goals. [159] In the hierarchical model, all variables are entered cumulatively 
according to some specified hierarchy and it replicates an analytic process of similar 
research. [159] Stepwise regression analysis on the other hand, the investigator has a 
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large pool of potential independent variables and there is very little theory to guide 
selection among them. [159]This may pose a problem as a relatively large number of 
independent variables is used. In stepwise regression analysis, significance test of an 
independent variable contribution to effect size proceeds in ignorance of the large 
number of other such tests being performed at the same time for the other competing 
independent variables, meaning that the analysis capitalises on chance. [99, 207]  
The hierarchical and stepwise regression analysis were considered unsuitable to this 
analysis since the independent variables - ‘Intentions to attend a GP’, ‘Discuss CRC 
related problems with a GP’, and ‘Intentions to visit a specialist only’ were considered 
equivalent before the analysis. Also, because of the nature of the scoring methods, the 
main outcome measures failed tests of Normality.  A simultaneous regression analysis 
is robust to some departure from Normality. The number of participants recruited in 
this study was such that the distribution of the mean scores would be approximately 
Normal. Therefore, the planned correlations and regression models were considered 
appropriate.  The analyses were likely to be conservative in the sense that standard 
deviations may be exaggerated, making any p-values for association higher than they 




4.7.1 Demographic and Clinical Characteristics 
 
Sixty-six of the 88 participants recruited, returned the completed questionnaires. 
Participants were 69.2 (SD 9.9) years on average, with 30.4% single or widowed, and 
71.2% retired. On average, the participants had been diagnosed with cancer 26.7 
months earlier (range 6–92, median 28), while 81.8% had an existing chronic illness, 
65.2% had colon cancer, 31.8% had rectal cancer, and 1.5% had both colon and rectal 






Table 4.3: Participant Demographic and Clinical Characteristics* 
Participant Characteristics (n = 66) Number of Participants 
(%) 
Gender Male 26 (39.1) 
 Female 40 (60.9) 
Age Mean (SD) 69.2 (9.9) 
Age (years) ≤ 60 12 (12.0) 
 61–70 23 (34.8) 
 71–80 21 (31.8) 
 ≥ 81 10 (15.2) 
Marital status Never married 10 (15.2) 
 Widowed 13 (19.7) 
 Married 31 (48.5) 
 Divorced/separated 10 (15.1) 
 De facto partner 1 (1.6) 
Education 
level 
Completed primary school 7 (10.9) 
 Year 10 or equivalent 29 (43.8) 
 Year 12 or equivalent 4 (6.1) 
 Trade certificate/TAFE 12 (18.2) 
 University/College of Advanced 
Education 
14 (21.2) 
Employment Self-employed 4 (6.3) 
 Employed for wages, salary or payment 
in-kind 
10 (10.6) 
 Engaged in home duties 1 (1.5) 
 Unable to work 2 (3.0) 
 Unemployed 1 (1.5) 
 Retired 47 (71.2) 
 Other reasons 4 (6.1) 
Cancer 
location 
Colon 43 (65.2) 
 Rectum 21 (31.8) 
 Colon and rectum 1 (1.5) 
Cancer stage Stage I 17 (25.8) 
 Stage II 30 (45.5) 
 Stage III 19 (28.8) 
Comorbidity Yes 54 (81.8) 
 No 12 (18.2) 
Visited a GP Yes 57 (86.4) 
 No 9 (13.6) 
* Clinical characteristics were formulated based on patient-assessment questions identified in the 
Australian guidelines for cancer follow-up.[182] 
4.7.2 Association between Attitude, Subjective Norms, PBC and Intention to Visit 
a GP 
 
Associations between the components of the TPB model were examined (see Table 
4.4). Only personal attitude and subjective norms were positively correlated with 
future intention to visit a GP for health advice about CRC-related problems, with 
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correlations ranging from 0.43 to 0.59 (medium effects). These two constructs—
personal attitude (r = 0.585, p < 0.01) and subjective norms (r = 0.427, p < 0.05)—
were also positively correlated with intention to discuss CRC side-effects with a GP 
in the future. PBC was not correlated with intention to attend GP follow-up visits and 
discuss CRC side-effects with a GP. 
 
Table 4.4: Correlations between the TPB and Intention to Attend Follow-up 
Visits with a GP 






Intention to engage 
with a GP 
0.585*(p = 0.000) 0.427*(p = 0.000) 0.116(p = 0.352) 0.239(p = 0.053) 
Intention to discuss 
CRC related 
problems with a GP  
0.478*(p = 0.000) 0.280**(p = 0.025) 0.112(p = 0.372) 0.119(p = 0.341) 
Intention to attend a 
specialist only for 
CRC-related 
problems 
0.358**(p = 0.003) -0.176 (p = 0.165) 0.030 (p = 
0.814) 
-0.037(p = 0.771) 
Attitude - 0.696*(p = 0.000) 0.137(p = 0.272] 0.201(p = 0.105) 
Subjective norms  - 0.164(p = 0.195) 0.283*(p = 0.024) 
Perceived barriers - - - 0.815*(p = 0.000) 
Perceived control - - - - 
* Correlation is significant at the 0.01 level (two-tailed). ** Correlation is significant at the 0.05 level 
(two-tailed). 
 
4.7.3 Combined and Specific Contribution of Attitude, Subjective Norms and 
PBC 
 
Table 4.5 shows how the TPB constructs—attitude, PBC and subjective norms—
predict future intention to visit a GP to discuss CRC treatment side-effects. The results 
of the multivariate analysis supported the hypothesis that personal attitude would 
account for significant variance in future intention to attend GP follow-up visits (R2 = 







Table 4.5: Multivariate Analysis Using Attitude, Subjective Norms and PCB to 
Predict Future GP Attendance 







Future intentions to 
engage with a GP 




R2 = 0.433 
Attitude 0.659 4.345 18.881 0.000 0.233* 
Subjective 
norms 
0.220 0.895 1.242 0.219 0.016* 
PBC 0.209 1.512 0.107 0.224 0.024* 
Comorbidity 0.781 3.955 9.113 0.004 0.128 
*  
 
There was a strong effect size for the influence of all the four variables on future 
intention to attend a GP. These factors together accounted for 43.3% of the variance. 
For the unique contribution of the independent variables (attitude, subjective norms, 
PBC and perceived barriers), the analysis indicated that participants’ attitude and 
presence of a comorbidity accounted for 23.3% and 12.8% of the variance in future 
intention to visit a GP for health advice about CRC-related problems respectively. (see 
Table 4.5). 
 
When the social, demographic and clinical variables (age, gender, marital status, 
presence of comorbidity and cancer stage) were entered into the regression model, 
statistically significant associations emerged. Patients with a coexisting chronic illness 
had a more positive attitude towards engaging with general practice than did those who 
did not (p < 0.01). The effect of comorbidity was not seen in the other constructs (PBC 
and subjective norms). Comorbidity alone accounted for 12.8% of the overall variance. 
Comorbidity was also significantly associated with future intention to visit a GP for 
CRC follow-up (R2 = 0.128, F [1, 65] = 9.113, p < 0.01). Neither of the other two 
variables (PBC and subjective norms) significantly affected the relationship between 










This study sheds light on how attitude, subjective norms and PBC influence CRC 
patients’ intentions to engage with a GP. Specifically, it has documented significant 
associations between attitude, the presence of a chronic illness, and future use of GP 
services for care. The regression analysis also suggested that the combined effect of 
these factors had a strong influence (43.3%) on future intentions to seek health advice 
from a GP about CRC-related problems. Attitude and the presence of a chronic illness 
were responsible for 23.3% and 12.8% of this variance, respectively. 
 
Analysis of the regression models provided a different picture regarding the other TPB 
constructs. Although personal attitude was strongly associated with patients’ intention 
to visit a GP, PBC and subjective norms did not account for significant variance on 
future use of general practice services for CRC care. This finding is in contrast to 
research among CRC patients attending physical exercise sessions, which suggested 
that PBC has a significant influence on intentions.[179] PBC factors such as 
affordability, travel and ease of booking an appointment with a GP had limited 
influence on patients’ intentions. As the mean age of participants was 69.2 (SD 9.9) 
years, PBC may not have had as strong an influence on this age category in Australia 
due to government-subsidised GP consultations and travel concessions. 
 
Other studies show that CRC patients living alone have a more positive attitude 
towards seeking health advice from a GP about their CRC-related problems than do 
people who are married or living with a sibling or friend.[183] However, this study found 
that socio-demographic characteristics, such as age and marital status, had no effect 
on patients’ attitude towards visiting a GP for health advice. The only statistically 
significant association with socio-demographic and clinical characteristics was that 
patients with a coexisting chronic illness had a more positive attitude towards attending 
a GP for CRC-related health advice (p < 0.05). This may be expected as 30 to 60% of 
CRC survivors aged 70 years or older have a coexisting chronic illness[170] and are 






In summary, this study examined whether the TPB constructs influenced patients’ 
intentions to attend follow-up visits with a GP post–CRC treatment. The results 
suggest that patients’ attitude can predict intention to visit a GP, and patients with an 
existing chronic illness are more likely to attend a future follow-up visit with a GP. 
Socio-demographic variables, such as age, marital status and employment status, do 
not appear to have a significant influence. 
 
This information is valuable because it informs interventions implemented for follow-
up care in general practice. Educating patients about how GPs can help them with their 
CRC-related issues may increase their confidence in seeking medical advice for issues 
that continue to affect their QoL. In addition, by identifying patients with a coexisting 
chronic illness, it is possible to target those who would benefit from follow-up through 
general practice. 
 
4.9.1 Clinical Implications 
 
The findings of this study will inform intervention efforts aimed at supporting CRC 
survivors. Intervention efforts are likely to be most effective by tailoring programs to 




The results of Study 2 should be interpreted with caution for the following reasons. 
These findings may only be applicable to comparable patients with CRC. Also, the 
intention to attend a GP visit may not necessary result in patients reporting CRC related 
problems with a doctor.  The sample size was relatively small and homogenous in 
terms of age. Future research may benefit from a larger sample with younger 
participants. Additionally, PBC may influence the intention of younger participants, 
who may perceive greater barriers to attending consultations with a GP. The data from 




Chapter 5: A trial of the Self-assessment Tool (SATp 
Intervention) (Study 3) 
 
 
This chapter describes the trialling of the SATp developed in Chapter 3. It discusses 
the study design, the theoretical framework guiding the development of the study, the 




Background: Patients treated for CRC experience considerable physical, social and 
psychological morbidity. 
 
Methods: A total of 66 participants with localised (Stages I to III) CRC were enrolled 
in a prospective study. Following collection of baseline data, participants completed 
the SATp each month over a five-month period. They were encouraged to visit a GP 
with a copy of their SATp to assist in the management of any problems associated with 
their CRC treatment. The GPs’ notes were reviewed for management actions over the 
five-month period. 
 
Results: Of the 66 participants who completed the study, 86% visited a GP over the 
five-month study period. A total of 547 problems were identified (median 7; IQR [3–
12.25]). Participants with physical problems were more likely to consult their GP (p = 
0.05) than were those with social or psychological problems. This trend was 
demonstrated in participants with diarrhoea (OR 1.84, 95% CI 1.05–3.21, p = 0.03). 
The number of problems experienced by participants did not appear to have any 
influence on the decision to visit a GP. Self-reported psychological problems (p < 0.01) 
significantly reduced over the five-month period. There were no statistically 
significant reductions in the number of physical or social problems, but SATp helped 
identify these problems during GP consultations. GP consultations (n = 117) resulted 
in a total of 78 management actions. Of these, 25 of 78 (32%) were prescriptions, 17 
of 78 (22%) were investigations and nine of 78 (11.5%) were referrals. Prescriptions 
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were mostly for antidepressants (nine of 25, 36%), sedatives (six of 25, 24%) and 
analgesics (three of 25, 12%). 
 
Conclusion: This pilot study found that regular use of the SATp facilitates the 
identification of CRC treatment–related problems. Some of these problems could be 
addressed in primary care. The SATp should now be evaluated in a randomised control 




Patients with CRC experience physical and psychological morbidity.[3] Treatment for 
CRC includes surgery and, in some cases, chemotherapy and/or radiotherapy. This 
may result in long-term physical problems, such as bowel dysfunction, urinary 
problems and neurological deficits.[1, 18] Psychological effects (such as anxiety,[7, 19] 
depression[7, 19] and fear of recurrence[1, 20, 21]) and social problems (such as financial 
difficulties[22] and activity limitation[1, 23]) may also affect patients for many years 
following treatment. 
 
Interventions for CRC patients, such as telephone support, have been effective in 
addressing problems following treatment.[52] Support is usually provided to patients 
immediately after discharge from hospital. However, there is evidence that some 
treatment-related side-effects may present or worsen many months after treatment.[1] 
Other side-effects and problems may persist even longer than this.[1] Further, some 
treatment side-effects or problems such as sexual dysfunction, anxiety and depression 
may manifest some time after treatment.[1] 
 
Most people with CRC are now living beyond five years post-treatment and have other 
comorbidities for which they regularly visit their GPs.[32] Between 30 and 60% of CRC 
survivors aged 70 years or older have at least one other health condition.[117] The 
overall five-year survival rate for people treated for CRC in Australia is 89%.[14] As 
the survival of patients with CRC improves, GPs may find that they occupy a larger 
proportion of their practices, and supporting these people may contribute a significant 
burden to GPs’ workload. 
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In Australia, it is estimated that a GP encounters 200 cancer patients each year.[184] As 
GP services are the first point of contact in the Australian health system, there is 
potential for GPs to support cancer patients, despite ongoing specialist care. Moreover, 
there is evidence that cancer patients present to a GP with cancer-related side-effects 
or symptoms of recurrence, even when receiving ongoing management by their 
specialist.[35] 
 
Thus far, only limited approaches to support CRC patients beyond the acute treatment 
phase have been trialled in general practice. The few studies that have trialled GP-led 
interventions focused on the organisation of patient care and flow of information 
between hospital and primary care.[123-125, 169] Although these studies make 
recommendations regarding communication between the GP and hospital, data on 
which patients’ problems were addressed during visits with the GP are limited. 
 
Therefore, the current study provided patients treated for CRC with a self-completed 
needs-assessment measure (SATp) to monitor their treatment-related side-effects. 
Participants were encouraged to take their completed SATp to any future GP visits. 
This intervention was offered alongside routine hospital follow-up visits. A pilot study 
was conducted to assess the feasibility and effect of the intervention on identifying the 
participants’ problems associated with CRC treatment. 
 
5.3 Primary Hypotheses 
 
The main aim of Study 3 was to test whether the SATp developed in Study 1 would 
identify physical, psychological and social problems related to CRC treatment, and 
whether the problems identified by patients in the SATp would be addressed during 
GP consultations. The following hypotheses were tested: 
1. whether the SATp intervention identified the physical, psychological and 
social problems of CRC patients following treatment 
2. whether these physical, psychological and social problems were addressed 




5.4.1 Study Design 
 
A prospective pre-post study was undertaken in Western Australia with people at 
Stages I to III CRC. The basic premise behind the use of this design involves obtaining 
a pre-test measure of the outcome of interest prior to administering some treatment, 
followed by a post-test on the same measure after the intervention. Administering a 
test at baseline can determine whether the prerequisites have been met. [152]   Also, 
knowledge of the group at the beginning provides guidance for future activities as well 
basis for comparison of the results. The advantage of this design is ability to show 
methodological rigour without use of a control.[152]  
 
This design was adopted for ethical reasons. The intervention was considered 
beneficial to all patients on follow-up care for CRC in this study site and would have 
otherwise disadvantaged some patients if a control was introduced. Participants from 
Study 2 were invited to participate in the trial of the SATp. They completed a SATp 
(developed in Chapter 3, Study 1) monthly, and were asked to take the SATp with 
them whenever they consulted their GP. With participant’s permission their GPs were 
surveyed concerning the issues they presented with, and were asked to describe how 
the problems were addressed. 
 
5.4.2 Recruitment and Ethical Approval 
 
The participants were selected from a convenience sample of patients (n = 250) 
attending an outpatient CRC clinic of a tertiary referral hospital in Perth, WA. Those 
aged 18 years or over who had completed CRC treatment with curative intent (Stages 
I to III) were invited to take part in Study 2. Patients with Stage IV CRC were excluded 
from the study because their problems were likely to be palliative.[185] In addition, 
treatment side-effects are most likely to persist beyond 12 months post-treatment.[1] 




The potential participants were telephoned by the primary researcher and invited to 
participate in the study. The participants who consented to take part received a study 
information sheet and consent form. The participants were asked to nominate their 
regular GP, who was then contacted and advised that the patient was participating in 
the study, and that the researcher had consent to access their records. The baseline 
demographic and clinical information of the study participants was ascertained. Data 
were collected from participants who declined to participate, but consented to provide 
demographic and clinical data from their hospital. The relevant human research ethics 
committees from the hospital (QI3041) and university (HR 42/2012) approved the 




Figure 5.1: Study Flow Diagram 
 
Total patients attending 
outpatient CRC care  
(n = 250) 
Eligible from records, and 
contacted (n = 96) 
Ineligible from records (n = 154) 
 
- Follow-up < 6 months (n = 
115) 
- Stage IV cancer (n = 39) 
 
Eligible after contact, and 
consented (n = 88) 
Ineligible after contact (n = 8) 
 
- Non-English-speaking (n = 
2) 
- Unable to consent—other 
serious comorbidities (n = 
2); aged care facilities (n = 
4) 
Declined study (n = 20) 
- No reason provided (n = 
20) 
 
Consented to participate 
(n = 68) 
Lost to follow-up—non-contactable 
after consent (n = 2) 
 
 
Completed study (n = 66) 
Included in the analysis  
(n = 66) 
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5.4.3 Principles Underpinning Trialling of the SATp 
 
This study used the Glasziou and Haynes model of evidence-based medicine that 
outlines the path from research to improved health outcomes.[54] According to Glasziou 
and Haynes, there are substantial gaps between evidence and the management patients 
receive. To achieve better clinical outcomes for patients, clinicians must: (i) be aware 
of, (ii) agree with, (iii) adopt and (iv) act on evidence. The model further states that, 
even with high rates of compliance at each stage of the model, there may be little effect 
on patient outcomes. Hence, there must be strategies to assist GPs to progress through 
each stage of the model. To improve GPs’ awareness of the CRC problems patients 
experience following treatment, participants of this study presented a CRC-specific 
validated problems checklist (SATp) to their GP. The SATp is a self-completed 
assessment tool to assist patients to identify problems post–CRC treatment, and then 
raise them with their GP. 
 
Glasziou and Haynes further indicated that, even when clinicians know and accept the 
evidence, they often fail to action it. This is particularly the case for non-acute and 
preventive issues because they may not be the focus of a consultation. A simple 
reminder may be sufficient to prevent such omissions. This study incorporates a 
‘reminder’ approach by using the SATp to aid consultation between CRC patients and 
their GPs. By participants presenting their SATp during a consultation, the GP 
becomes aware of CRC-related issues that may otherwise go unnoticed during a 
routine doctor–patient visit. Strategies such as using a pre-defined list of possible 
issues to prompt patients and/or their clinicians can improve communication and direct 
discussion during consultations.[186] 
 
The intervention involved: 
1. providing a booklet with copies of the SATp for participants to keep monthly 
records of problems they experience related to their CRC treatment 
2. participants bringing problems identified to the attention of their GP during 
consultations using the SATp as a guide. 
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5.4.4 Development and Piloting of the SATp 
 
The predetermined list of possible CRC related issues included in the SATp were 
identified from a review of the most common problems experienced by patients post–
CRC treatment in published studies. The top 25 common problems were included on 
the draft SATp. The issues included in the SATp were then validated with two panels 
of patients and health professionals (via Delphi technique). The SATp was then pre-
tested with a group of patients who satisfied the study’s eligibility criteria. Detailed 
procedures for the development and validation of the SATp were described in Chapter 
3 of this thesis—Study 1.[33] 
 
5.4.5 Procedure and Measures 
 
The intervention consisted of a baseline assessment followed by monthly follow-ups 
for five months. Participants may have had one or more consultations with a GP during 
the study period. The baseline assessment consisted of demographics, clinical 
characteristics and a baseline SATp. Demographic questions were derived from the 
Australian National Census Survey[187] and clinical characteristics included 
comorbidities, the cancer location, the pathological stage of the cancer, the type of 
surgery offered, the presence or absence of stoma, and whether neo-adjuvant therapy 
was offered. Follow-up consisted of questions about participants’ physical, 
psychological and social problem related to their CRC treatment 
 
5.4.6 Data Collection 
 
The consenting participants were follow-up for five-month post baseline. They were 
provided a booklet of SATp questionnaires (developed in Study 1), which they 
completed at six time points (at baseline and monthly for five months). They were also 
invited to take their SATp booklet whenever they consulted their GP. At the start of 
the study, a baseline assessment of the patients’ demographics and clinical 
characteristics, as well as the SATp, was completed. Thereafter, SATp was completed 
in triplicate carbon copies (participant’s, researcher’s and GP copies). Pre-paid 
envelopes were posted to the participants monthly so they could send back a copy of 
the completed SATp questionnaire. Posting of these envelopes was followed by a 
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courtesy telephone call five days later to confirm that the participants had received the 
envelope. A further telephone call was made two weeks later to participants whose 
SATp questionnaire had not been received by the researcher. 
 
5.4.6.1 Outcome Measures 
5.4.6.1.1 SATp Questionnaire 
 
If participants made an appointment to visit their GP, they were encouraged to present 
their most recent SATp questionnaire. The primary outcome of the study was the 
number of problems experienced by each participant, while the secondary outcomes 
were the number of GP consultations and the management actions taken by the GPs 
during the visits. 
 
The SATp recorded problems in three domains: physical, psychological and social. 
Management actions were categorised into referrals, prescriptions, investigations 
(laboratory and radiological tests) and health advice. CRC-related GP consultations 
were reported by the participants each month. The reliability of self-reported GP visits 
was ascertained from the GP notes at the end of the study. To assess the management 
actions taken by the GPs, they were sent a survey post-intervention to record whether 
any new prescriptions, tests or referrals were offered to participants during the study 
period. Details of these management actions were also collected by the researcher from 
the clinical notes at the end of the study (see below). 
 
5.4.6.1.2 Review of Clinical Notes 
 
A review of the clinical notes (integrated notes) was completed at the end of the study 
follow-up period (at five months). The researcher requested GPs to fax the clinical 
notes to a secure university fax line or (in cases where that was not possible) collected 
them personally. This was done to maintain patient confidentiality. The primary 
researcher independently reviewed the paper-based clinical records and abstracted data 
using a data collection form (see Appendix 5.1). Another trained researcher/GP 
reviewed the clinical notes and the primary researcher abstracted data in order to 
confirm the data. Any discrepancies noted were discussed with a third researcher who 
was also a GP, and consensus was achieved. 
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For each of the clinical records, the following information was recorded: 
1. name of the patient 
2. date of contact with the GP (whether at the practice or a home visit) 
3. type of CRC-related management offered to the patient 
 referral for further management (to specialist or allied health worker) 
 investigations undertaken: 
- laboratory tests 
- radiological tests 
 prescription (type of medication offered) 
4. CRC-related health advice offered. 
 
Assessment of GP approaches to treating cancer-related side-effects using the domains 
of referral, investigation, prescription and health advice (used for the clinical data 
extraction form in this study) has been widely employed by other studies assessing the 
role of GPs in the follow-up of cancer patients.[48, 188-191] These domains (refer, 
investigate, prescribe and offer health advice) were also identified by the panellists in 
Study 4 (see chapter 6). 
 
5.4.7 Sample Size 
 
This study was conducted to determine whether the SATp helped participant to 
identify problems, and which participant-reported problems would result in GP 
management actions. This study also assessed the feasibility of the intervention 
(participant attendance to GPs visits, and acceptability of SATp). A sample size of 
approximately 60 participants gave 360 completed SATp records on which the 
analysis was based. This number was adequate to estimate the proportion of occasions 
on which at least one problem was identified for each participant, with reasonable 
precision (approximately ± 10%).[192] In total 66, participants were recruited for this 
study, allowing for a 10% attrition.[192] 
 
A regression model was used to identify factors associated with GP actions in response 
to the problems. Presuming that each participant attends their GP twice (on average) 
during the five-month follow-up period, a sample of 60 people was adequate for the 
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regression model to identify independent variables showing a moderate effect size on 
the number of problems identified. The analysis took into account multiple CRC 
problems belonging to the same person (using a random effects regression model). As 
this was a pilot study, the data analyses provided information on the primary outcomes, 
as well as the correlations between observations from one month to another throughout 
the study. 
 
5.4.8 Statistical Methods 
5.4.8.1 Demographics and Clinical Characteristics 
 
Descriptive statistics were computed using the SPSS Version 19 for Windows[159] to 
summarise participants’ personal demographics and clinical characteristics. The 
characteristics of the participants who completed the study were compared with those 
who were invited to participate but declined the offer to assess any significant 
differences in their demographics. 
 
5.4.8.2 SATp Assessment 
 
The total number of problems identified by participants using the SATp in each 
domain (physical, psychological and social) for each time point (monthly) were 
calculated. The SATp recorded the presence or absence of common problems 
associated with CRC post treatment. The maximum number of problems recorded by 
a participant was 25 (the total number of problems identifiable using the SATp). A 
random effects regression model was used to identify factors associated with the scores 
(total and within domains) over time. This model took into account the correlation 
between responses from the same individual. The general estimating equation (GEE) 
model was used to identify factors associated with visiting the GP. Again, correlations 
within the data due to the multiple responses from each participant were taken into 
account in this model. This models was able to explicitly identify any trends over time 






5.4.8.3 GP Visits: Intervention Adherence and General Practice Use 
 
This study calculated the number of GP consultations for each participant where the 
SATp was presented. It also calculated the number of times each participant visited a 
GP and the proportion of participants who visited a GP for various problems. 
 
5.4.8.4 Actions Taken by the GP 
 
GP actions in response to SATp-identified problems were summarised, and 
relationships between these actions and the type of problems identified were analysed 
using the GEE model. A p-value of < 0.05 was considered significant in all tests. 
 
5.5 Results 
5.5.1 Participant Profile 
 
Of the 250 CRC patients attending the target outpatient services, 88 were eligible for 
this study. Patients with Stage IV cancer (n = 39), patients unable to consent because 
they were hospitalised, non-English-speaking patients, patients in aged-care facilities 
(n = 8) and patients within six months of treatment (n = 115) were excluded. Of the 88 
eligible participants, 66 consented and returned the completed questionnaires. 
 
The average age of participants was 69.2 (SD 9.9) years, and had been diagnosed with 
cancer 26.7 months earlier on average (range 6–92, median 28). Of the participants, 
65.2% (n = 41) had colon cancer, 34.8% (n = 23) had rectal cancer and 81.8% (n = 54) 
had one or more coexisting chronic illnesses. The characteristics of the study 
participants are provided in Table 5.1. The characteristics of the participants who 
declined to participate in the study were comparable, with the exception that males 
were significantly less likely to participate (χ2 = 5.779, df = 1, p = 0.02). Completion 
of the SATp at each scheduled time point was high, with a range of 98% at baseline 





Table 5.1: Participants’ Demographic and Clinical Characteristics* 
Participant Characteristics (n = 66) Number of Participants 
(%) 
Gender Male 26 (39.1) 
 Female 40 (60.9) 
Age Mean (SD) 69.2 (9.9) 
Age (years) ≤ 60 12 (12) 
 61–70 23 (34.8) 
 71–80 21 (31.8) 
 ≥ 81 10 (15.2) 
Marital status Never married 10 (15.2) 
 Widowed 13 (19.7) 
 Married 31 (48.5) 
 Divorced/separated 10 (15.1) 
 De facto partner 1 (1.6) 
Education 
level 
Completed primary school 7 (10.9) 
 Year 10 or equivalent 29 (43.8) 
 Year 12 or equivalent 4 (6.1) 
 Trade certificate/TAFE 12 (18.2) 
 University/college 14 (21.2) 
Employment Self-employed 4 (6.3) 
 Employed for wages 10 (10.6) 
 Engaged in home duties 1 (1.5) 
 Unable to work 2 (3.0) 
 Unemployed 1 (1.5) 
 Retired 47 (71.2) 
 Other reasons 4 (6.1) 
Cancer 
location 
Colon 43 (65.2) 
 Rectum 23 (34.8) 
Cancer stage Stage I 17 (25.8) 
 Stage II 30 (45.5) 
 Stage III 19 (28.8) 
Comorbidity Yes 54 (81.8) 
 No 12 (18.2) 
Visited a GP Yes 57 (86.4) 
 No 9 (13.6) 
* Clinical characteristics were formulated based on patient-assessment questions identified in the 
Australian guidelines for cancer follow-up.[182] 
 
5.5.2 Intervention Adherence and General Practice Service Use 
 
All participants completed the SATp each month during the five-month study period. 
In total, 88% (n = 57) attended a GP visit at least twice during the study. A higher 
number of GP–participant contacts were recorded in the second (33 of 66, 50.0%) and 
third (35 of 66, 53.0%) months, than in subsequent months (15 of 66, 22.7%). The 
number of participants who visited a GP during the five month follow-up period 
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decreased over the study period, with a significant reduction observed at four and five 
months (n = 15 of 66, p = 0.002 and n = 11 of 66, p = 0.001, respectively) (see Table 
5.2). 
 
Participants with physical problems visited their GP more often (p = 0.05) than those 
with social or psychological problems. In particular, participants who reported 
diarrhoea were significantly more likely to visit their GP than those without this 
symptom (OR 1.84, CI 1.05–3.21, p = 0.03) (see Table 5.2). The number of problems 
experienced by participants did not have any influence on their attendance to a GP. 
 
Table 5.2: Results of a Regression Model in which the Dependent Variable is the 
Patient Attending Their GP 
Variable Number (%) Who 
Attended a GP 
OR 95% CI for 
OR 
p-value 
Month 1 33/66 (50.0%) 1 (reference)   
Month 2 23/66 (34.9%) 0.52 0.26 to 1.05 0.0701 
Month 3 35/66 (53.0%) 1.12 0.56 to 2.26 0.7498 
Month 4 15/66 (22.7%) 0.29 0.13 to 0.65 0.0028 
















1 Endpoint: Study participant went to a GP during the month. The symptom was reported at the 
commencement of the month (prior to the possible GP visit). 
 
5.5.3 Identified Problems 
 
Fifty-eight participants who completed the SATp and also visited a GP reported at 
least one problem related to treatment, with 96% of these participants reporting more 
than one such problem (range 3-12 problems). Over the 396 observations (66 
participants over five observations), a total of 547 problems were identified on the 
SATp, with an average of 8.1 problems per participant (median 7, IQR [3–12.25]). 
Problems were in the physical (175, 32%), psychological (175, 32%) and social (197, 
36%) domains. The most commonly reported physical problems were troublesome 
flatulence (79%, n = 52 of 66), need for dietary advice (41%, n = 27 of 66) and fatigue 
(41%, n = 27 of 66). Psychological problems included fear of recurrence (53%, n = 38 
of 66), insomnia (53%, n = 38 of 66), sexual dysfunction (36%, n = 24 of 66), anxiety 
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(36%, n = 24 of 66) and negative body image (23%, n = 15 of 66). Social problems 






Key: BA = bowel action; Abd = abdominal; Neg = negative 
 



































A high proportion of participants who reported a physical or psychological problem 
were in Stage II (93.3 and 86.7%, respectively) and Stage III (94.7 and 86.2%, 
respectively) compared to Stage I (76.1 and 70.1%, respectively). However, this 
difference was not statistically significant (Table 5.3). There was a gender difference 
with respect to the type of problem reported by participants, with men reporting more 
social problems (p = 0.03) than women. The SATp scores varied across domains over 
time, with a major decrease evident in the second month for the psychological domain. 
Physical and social problems remained similar throughout the study period. This trend 
is shown in Figure 5.3. The greatest improvement was observed in psychological 
problems, with a statistically significant reduction in the number of problems reported 
by participants in all time periods (p < 0.01) compared to the baseline (Table 5.4). 
  
Figure 5.3: Proportion of Participants Reporting the Various Types of Problems 
 

































Table 5.3: Comparison of Symptoms or Problems by Gender, Cancer Location and Cancer Stage 
  Gender (n = 66) Cancer Location (n = 66) Cancer Stage (n = 66) 
Problem Response Male Female p-value* Colon Rectum p-value* Stage I Stage II Stage III p-value* 
Physical (%) Yes 24 (92.3) 35 (87.5) p = 0.535 37 (86.1) 21 (100) p = 0.072 13 (76.4) 28 (93.3) 18 (94.7) p = 0.131 
No 2 (7.7) 5 (12.5)  8 (13.9) 0 (0)  4 (23.5) 2 (6.67) 1 (5.26)  
Psychological 
(%) 
Yes 22 (84.2) 32 (80.0) p = 0.635 34 (79.1) 19 (90.5) p = 0.256 12 (70.1) 26 (86.7) 16 (84.2) p = 0.370 
No 4 (15.4) 8 (20.0)  9 (20.9) 2 (9.5)  5 (29.4) 4 (13.3) 3 (15.8)  
Social (%) Yes 23 (88.5) 26 (65.0) p = 0.033 31 (72.1) 17 (80.9) p = 0.442 12 (70.6) 21 (70) 16 (84.2) p = 0.499 
No 14 (35.0) 26 (65.0)  12 (27.9) 4 (19.0)  12 (29.4) 9 (30) 3 (15.8)  
* Fisher’s exact test. 
 
Table 5.4: Type of SATp Needs Reported by Time 
















































































5.5.4 Actions Taken by the GP 
 
Participant self-reported GP consultations were validated through GP clinical notes for 
45 of 57 participants (79%), with a 100% agreement between patient report and GP 
notes. In total, there were 117 GP consultations during which the SATp was presented, 
and a total of 78 GP actions recorded. Of these, 52 of 78 (44%) were prescriptions, 11 
of 78 (14.5%) were investigations and six of 78 (7.7%) were referrals. Nearly all (n=76 
of 78, 98%) participants were offered advice relating to the problems identified. 
Prescriptions (n=25) were mostly for antidepressants (nine of 25, 36%), sedatives (six 
of 25, 24%), analgesics (three of 25, 12%) and erectile dysfunction (two of 25, 8%). 
For those who visited a GP, the odds of receiving a prescription were similar for those 
reporting physical (OR 0.01, CI -1.14–1.14, p = 0.90) or psychological problems (OR 




This study evaluated the feasibility and effect of a problem-identification intervention 
for participants with CRC. The various ways in which GPs addressed participants’ 
problems across the five-month time frame were recorded. The success of the SATp 
intervention was assessed by the number of physical, psychological and social 
problems identified, changes in participants’ number of problems and the number of 
problems addressed by the GPs. In this pilot study, all participants were able to 
complete the SATp throughout the study period, thereby demonstrating that the 
intervention was acceptable. The SATp was also able to identify patient problems, 
with 96% of participants reporting at least two problems, with a median of seven 
problems per patient. 
 
There was a non-significant trend for reduction of physical and social problems, while 
psychological problems were significantly reduced (p < 0.01). The non-significant 
effect on physical outcomes may be partially explained by the relatively short study 
follow-up period. Some physical problems may have required radiological and 
laboratory investigations before a GP could provide treatment advice; thus, symptoms 
may have continued to be reported in the subsequent months. Similarly, social 
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problems, such as financial difficulties, require the involvement of other services and 
may take time to resolve, or may have been present prior to the cancer diagnosis. These 
factors may have contributed to the finding that the intervention appeared to have no 
statistically significant influence on these outcomes over the five-month timeframe. 
 
Participants with physical problems tended to visit their GP more frequently (p = 0.05). 
This was confirmed particularly for participants with diarrhoea (p = 0.03). Other 
studies have reported similar findings that cancer patients are more likely to consult 
their GP more for physical symptoms than for other symptoms.[119] Although 
participants with physical problems used GP services more often than did those with 
psychological and social issues, most (17 of 25, 68%) prescriptions offered to 
participants were related to psychological problems, such as anxiety and depression. 
It is possible that some of the physical symptoms were manifestations of the 
underlying psychological distress that may be more evident during a doctor–patient 
consultation. [134] These results resonate with the results reported by Roorda et al. that, 
although patients with physical problems may be more likely to present in general 
practice, many also have psychological problems that are only identified during a 
consultation.[134] 
 
Overall, there was a significant reduction in the number of participants who presented 
to a GP over the five months of the study. It is possible that the problems of these 
participants were addressed by the GP during the previous visits, or that participants 
whose problems were not being addressed ceased attending. Alternatively, the 
problems may have resolved on their own accord and patients became tolerant of the 
problem. 
 
This study had the advantage of being prospective, with a participation rate of 75% 
(66 of 88). The characteristics of those who declined the study were similar to the 
participants, indicating that the results may be generalisable to other similar groups of 
participants. Moreover, this study was able to confirm that the patients continued to 
experience significant symptoms in the physical and psychosocial domains even years 
after completing treatment. Research has shown that a structured symptom checklist 
and screening tools are effective in eliciting the full range of problems for patients with 
other cancers.[193, 194] Although the SATp was structured, the response format was 
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meant to be a prompt to consultation to assist in a thorough exploration of possible 
problems. 
 
A number of factors may have limited the influence of the intervention. The eligibility 
criteria may have excluded a group of participants with potentially higher or lower 
problems than those included. In addition, this study’s measure was presented only in 
English, which meant that participants who were not fluent in English or unable to 
provide consent did not participate. Finally, this study was unable to assess whether 
participants not using the SATp intervention would have experienced similar 




This study showed that the SATp may be useful in primary care to facilitate 
identification of problems post–cancer treatment. In addition, it illustrates the 
possibilities of monitoring the long-term problems of CRC patients on a regular basis. 
This has value in general practice, where the majority of patients continue to receive 





Chapter 6: Supporting Patients Treated for CRC—A Video 





Background: Although under specialist care, patients who have been treated for CRC 
in Australia can consult their GP for advice about symptoms or side-effects at any time 
following treatment. However, there is no evidence that such patients are consistently 
advised by GPs, and patients experience substantial unmet needs for reassurance and 
advice. 
 
Objective: This study sought to explore the influence of a variety of clinical and 
respondent characteristics on GPs’ decisions to treat patients with treatment side-
effects or symptoms of recurrence of CRC. 
 
Methods: This was an email-based survey. Participants (GPs) viewed six video 
vignettes of actor-patients representing people who had been treated for CRC. The 
actor-patients presented problems that were a result of CRC treatment. The participants 
indicated their diagnosis and stated whether they would prescribe, refer or order tests 
based on that diagnosis. These responses were rated against the management decisions 
for those vignettes, as recommended by a team of experts in CRC. 
 
Results: In total, 52 GPs consented and 40 (77%) completed the study. Most GPs 
completed diagnoses of CRC treatment side-effects or symptoms of recurrence that 
were consistent with the expert opinion. However, correct diagnosis was dependent on 
the type of case viewed. Compared to radiation proctitis, GPs were more likely to 
recognise peripheral neuropathy (OR 12.55, 95% CI 1.38–2.74) and erectile 
dysfunction (OR 21.98, 95% CI 2.24–36.84) and less likely to identify fatigue (OR 
0.02, 95% CI 0.09–0.46). GPs who had worked more hours of direct patient care (OR 
8.67, 95% CI 1.23–70.70, p = 0.03) and were more experienced (OR 9.78, 95% CI 





Conclusion: In this pilot study, years of experience and direct patient contact hours 
had a significant and positive effect on the successful management of patients. This 
study also showed promising results that management of the common side-effects of 
CRC treatment could be delegated to GPs. Such an intervention could support the 
application of shared care models of healthcare. However, a larger study that includes 





CRC is the second most commonly diagnosed adult cancer in Australia,[14] with one in 
12 people in Australia developing CRC in their lifetime.[153] Most people with CRC 
survive more than five years and die of unrelated causes.[139] The treatment of CRC 
may include surgery, radiotherapy and chemotherapy. In the months and years 
following treatment, people may experience a number of troublesome side-effects, or 
symptoms and signs related to cancer recurrence. Many patients may experience bowel 
dysfunction, sexual dysfunction, urinary dysfunction and fatigue,[1] among other 
problems. 
 
Post-treatment follow-up is provided in a secondary setting in some instances; 
however, this follow-up may only be for a short period for some patients, after which 
they are encouraged to see their GP about any ongoing problems.[31] Previous studies 
have demonstrated that cancer patients consult a GP routinely in the months and years 
after treatment for CRC, even for those with scheduled follow-up visits at the 
hospital.[35] CRC patients may contact their GP for a range of symptoms, such as 
radiation proctitis, urinary incontinence/urgency, fatigue, erectile dysfunction and 
symptoms of recurrence.[168] In order to address the needs of patients treated for CRC, 
GPs must be knowledgeable about the recommended treatment for the side-effects of 
CRC treatment, as well as the signs and symptoms that merit referral for further 
specialist treatment. This pilot video vignette study sought to explore the effect of a 
variety of clinical and respondent characteristics on GPs’ decisions to treat patients 




6.3 Study Design and Participants 
 
This video vignette study was developed to assess GP approaches to the management 
of CRC-related treatment side-effects or symptoms of recurrence. The videos were 
developed using scenarios of standardised patients (professional actors).[195] Using 
video vignettes as a method of data collection has been employed in health-related 
studies and to instruct students in schools of medicine.[196, 197] The usefulness of 
vignettes has resulted in their extensive use in medical school education,[198, 199] as well 
as in various studies that explicitly evaluate the quality of clinical practice in real-life 
settings and for comparative analysis among national healthcare systems.[195, 197, 200, 
201] Video vignettes are suitable for cases in which ethical issues preclude recording 
patients’ consultations or viewing patients’ records,[202, 203] as in this study. They are 
also ideal for evaluations that require holding patient variation constant,[204, 205] so that 
participants are exposed to a similar stimuli, or for manipulating patient-level 
variables.[205, 206] 
 
Participants were recruited from a convenience sample of 100 GPs across Australia 
who were members of the Curtin University Health Innovation Research Network. 
This is a free network formed to provide a safe and convenient venue for networking 
and exchanging information between primary healthcare practitioners (GPs, nurses, 
pharmacists, physiotherapists, dieticians, occupational therapists, podiatrists, 
psychologists, social workers, diabetes educators and so forth) and researchers with 
the common objective of improving primary healthcare. GPs were emailed invitations, 
and the original form of emails was supplemented with follow-up personal invitations 
to the invitees who did not initially respond. Participants were remunerated with 
AUD$50 for their contribution. Ethics approval was sought from the Curtin University 





6.3.1 Development of the Survey: Delphi Process 
 
Six video vignettes were developed to present potential side-effects related to 
treatment for CRC or the features of cancer recurrence (see multimedia Appendix 6.1 
for an exemplar). The range of scenarios was based on the most common side-effects 
reported by CRC patients. The identification and validation of these side-effects is 
reported in a different phase of this project (see chapter 3).[33] Each vignette depicted 
a patient with clear indications for specific management, including referral, 
prescription, reassurance and/or investigation. The vignettes were developed by four 
GPs, a radiation therapist, a medical oncologist and a surgeon. The expert panel also 
suggested the management of each case with details of prescription, referral for 
specialist treatment and laboratory investigation (see Table 6.1). Management 
suggestions were gathered using a Delphi technique discussed in chapter three of this 
thesis. The primary researcher coordinated the responses of the panel of experts, who 
were selected based on their areas of expertise (Medical oncologist, Colorectal Cancer 
Surgeon, General Practitioners, and Radiation therapist). The panellists were asked to 
give a reason for each of their responses. The responses were then assessed against the 
existing Australian guidelines for management of colorectal patients by a team of three 
researchers.[37] Where marked deviations from the guidelines were noted, experts were 
asked to provide reasons for their responses until a consensus was reached. 
These categories for patient management were identified by the panellists and have 
also been used in several other studies to assess the role of GPs in the follow-up of 
cancer patients.[48, 188-191] 
 
The vignettes were then prepared as a short video monologue by an actor-patient. The 
videos included an off-camera commentary by an actor-doctor describing relevant 
signs to be found during clinical examination. Participation in the study was via the 
internet. Information about the actor-patients’ medical history, family history, 
medication history and physical assessment were offered at the onset of each video. 
The participants were then asked four questions after watching each video vignette: 
1. What is your diagnosis? 
2. Would you prescribe something? If so, what would you prescribe? 
3. Would you refer the patient? If so, to whom? 




The survey was administered via web-based software (https://www.qualtrics.com/) 
approved by Curtin University. The six video vignettes were presented to each 
participant. Randomisation was not undertaken because each participating GP was 
expected to view the six scenarios. The survey was pilot tested on the four GPs who 
were involved in developing the scenarios to test for the participants’ ease of access to 
web link to the survey, the functionality of the videos, the estimated time of completion 
and the data recording. Details of the administered survey are presented in Appendix 
6.2. 
 
Table 6.1: Specific Recommendations for the Management of Specific CRC 
Side-effects and Recurrence 
Symptom Action to be Taken by GP 
Case 1: Peripheral 
neuropathy 
Prescribe: Amitriptyline or low dose of carbamazepine. 
Health advice: Inform patient that there is potential that this may not 
improve or may improve slowly over time. If fingers are still numb at 12 
to 18 months post-chemotherapy, there is a likelihood that it will be 
permanent. 
Refer back to oncologist for consideration of pregabalin. 
 
Case 2: Erectile 
dysfunction secondary to 
lower anterior resection 
(LAR) 
Prescribe: First-line therapy. The use of phosphodiesterase inhibitors is 
recommended. 
Refer: Refer the patient back to the hospital for further management, 
such as second-line therapy, such as penile self-injectable drugs, 
intraurethral alprostadil and vacuum devices. 
Link patient to support services. 
 
Case 3: Urinary 
dysfunction secondary to 
LAR/radiation 
Order tests: Do this to rule out cardiovascular causes. 
Refer: Refer patient to physiotherapist for physical exercise. 
Refer to the specialist for further neurogenic examination. 
 
Case 4: Tumour 
recurrence 
Order tests: Computed tomography (CT), magnetic resonance imaging 
(MRI) or positron emission tomography (PET) scans. Scanning and 
endo-rectal ultrasound (ERUS). Repeat PET scan, and undertake full 
blood examination and blood film, liver function test, and urea 
electrolytes and creatinine (UEC) test. 
Refer: Refer back to the oncologist for further management. 
 
Case 5: Fatigue Order tests: Assess for causes because management of cancer-related 
fatigue involves specific treatment for potentially reversible causes 
(such as treating anaemia or metabolic or endocrine abnormalities, as 
well as managing pain, insomnia, depression or anxiety). Take 
symptomatic measures when no obvious aetiology or reversible cause 
can be identified. 
Prescribe: Psychostimulants. For patients with severe fatigue for whom 
non-pharmacologic methods do not resolve fatigue, and anaemia and 
other medical conditions and symptoms causing fatigue are controlled, a 
therapeutic trial of a psychostimulant (methylphenidate or modafinil) is 




Symptom Action to be Taken by GP 
Case 6: Chronic radiation 
proctitis 
Order tests: Attend visual inspection of lower bowel by proctoscopy, 
sigmoidoscopy and/or colonoscopy, and test for anaemia, full blood 
count and stool culture to rule out comorbidities. 
Prescribe: If true diarrhoea is established, use an antidiarrheal agent 
(often combined with stool bulking). 
Health advice: Anorectal dysfunction has its origin in nerve and muscle 
fibrosis, and may be ameliorated by pelvic floor exercises and bowel 
‘re-training’. 
Refer: If (significant) bleeding develops or is confirmed, refer patient for 
endoscopic therapies, such as thermal coagulation therapy or surgical 




6.4 Sample Size and Statistical Analysis 
 
The main aim of this study was to evaluate the treatment GPs offer to standardised 
patients presenting with side-effects from CRC treatment or symptoms of recurrence. 
Each GP reviewed the same set of six video vignettes and responded to the four binary 
(yes/no) questions above regarding diagnosis, prescribing, referral and tests. Each of 
these four questions were analysed in a separate GEE model, with the binary response 
as the dependent variable, and the subject named as the random effect. The GEE model 
is appropriate for this design because it considers the correlation between responses 
from the same GP (across the six vignettes). 
 
It was difficult to determine the estimated sample size required to give adequate power 
to detect associations with the independent variables, but it depends on the expected 
response proportions (such as the proportions of positive responses), and the 
correlations between responses belonging to the same respondent. In the absence of 
pilot data on which these quantities may have been estimated, a sample of 40 GPs was 
sought (who would provide 240 observations in total). This projected number cannot 
be mathematically justified in the absence of pilot data. However, in a standard 
regression model, a sample of 120 uncorrelated measurements should be adequate to 
identify an independent variable exhibiting a moderate effect size with 80% power.[207] 
It was assumed that doubling the number of observations would be adequate to 
compensate for the internal correlations in the dataset. 
 
Each of the GEE models initially included the following independent variables: age, 
years of GP experience, recognised speciality qualification with the Fellows of the 
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Royal Australian College of General Practitioners (FRACGP), number of patient 
consultations per week, and patient consultation hours per week. A backwards 
elimination method was used to arrive at the final model. This method involved 
dropping the least significant variable, one at a time, until all variables remaining in 
the model were significantly associated with the outcome. The SPSS Version 21 
software was used to perform the analysis and, following convention, a p-value < 0.05 





In total, 52 GPs consented to participate in the project and 40 completed the study. 
Those who participated in the study were younger than general Australian GPs (mean 
age of 36.9 years v. 50.5 years) and a greater proportion were females (58.0% v. 
39.1%) and registrars (32.7% v. 3.8%). The demographic details of the respondents 
are shown in Table 6.2. 
Table 6.2: Participants’ Demographic Information 
Characteristics (N = 52) Study Sample National Population a 
Mean % 
Demographics 
Age (years)—mean (SD) 36.9 (10.5) 50.5 
Years of GP experience—mean (SD) 7.0 (9.7)  
Sex—n (%)   
Male 22 (42.0) 60.9 
Female 30 (58.0) 39.1 
Registrars (GPs in training)—n (%) 17(32.7) 3.8 
Fellows of the Royal Australian College of GPs—n 
(%) 
28 (53.8) 56.8 
Practice demographics 
Practice accredited—n (%) 52(100%) 88.6 
Clinic remoteness—n (%)   
Major city 36 (69.2) 71.1 
Non-major city 16 (30.8) 28.9 
Clinic location—n (%)b   
Capital 27 (51.9)  
Other metropolitan 14 (26.9)  
Large rural 6 (11.5)  
Small rural 4 (7.7)  
Remote centre 1(1.9)  
GP position in the practice—n (%)   
Principal 8 (15.4)  
Non-principal 35 (67.3)  
Others 9 (17.3)  
Patient consultations 
Patient consultations per week—n (%)   
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Characteristics (N = 52) Study Sample National Population a 
Mean % 
< 100 22 (42.3)  
100–149 21(40.4)  
≥ 150 9 (17.3)  
Patient consultations hours per week—n (%)   
< 11 10 (19.2) 1.2 
11–20 4 (7.7) 12.2 
21–40 24 (46.2) 53.0 
41–60 14 (26.9) 33.5 
Non-English consultations—n (%)   
No 45(86.5)  
Yes 7 (13.5) 24.5 
a Sourced from national data when available.[208] b Classification based on rural, remote and metropolitan 
area (RRMA) classification.[209] 
 
6.5.2 Diagnosis Consistent with Expert Opinion 
 
The colorectal cancer video vignettes were presented 240 times in the study (40 GPs 
x 6 vignettes). Of the 240 diagnoses made by the GPs, an average of 168/240, 70% 
(range 35–95%) were consistent with the expert diagnosis. This consistency was 
observed more for erectile dysfunction (38/40, 95%), peripheral neuropathy (36/40, 
90%) and tumour recurrence (31/40, 76%), compared to urinary dysfunction (23/40, 
58%) and cancer-related fatigue (14/40, 35%). A higher proportion of correct 
diagnoses were made by GPs who worked more than 60 patient care hours per week 
(15/18, 83%), those who held a GP fellowship (101/138, 73%), and those who had less 
than 10 years of experience (1–2 years 71/96, 74%; 3–10 years 53/72, 74%). 
 
A multivariate GEE analysis was carried out to determine whether a correct diagnosis 
depended on the case itself, or characteristics of the GP. There were some statistically 
significant differences in the diagnosis of the cases. Compared to radiation proctitis, 
GPs were more likely to identify cases with chemotherapy-induced peripheral 
neuropathy [OR 4.43, 95% CI 1.41–13.96, p=0.01] or erectile dysfunction [OR 9.70, 
95% CI 2.48–38.03, p=0.001], but were less likely to recognise chemotherapy-induced 
fatigue [OR 0.19, 95% CI 0.08–0.44, p=0001]. Also, younger GPs (<30 years of age) 
[OR 2.64, 95% CI 1.12–6.22, p=0.03] and those who held a GP fellowship [OR 3.26, 
95% CI 1.62–6.62, p=0.000] were more likely to identify cases consistent with the 
expert opinion. The demographic characteristics of the GP did not have any significant 
influence on their ability to recognise colorectal cancer treatment side effects or 
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symptoms of recurrence. Details of the factors associated with correct diagnosis are 




Table 6.3: Factors Associated with a Diagnosis Consistent with Expert Opinion 
 
Outcome Variable n/N (%) Odds ratio 95% CI p-value 
Diagnosis 
Age     





30 or younger 67/84 (80) 2.64 1.12–6.22 0.0262 






5 or more 69/108 (64) 0.42 0.20–0.87 0.0189 








3.26 1.62–6.54 0.0009 
Case vignette 

















23/40 (58) 0.54 0.20–1.46 0.2227 
4: Tumour recurrence 31/40 (78) 1.55 0.48–5.06 0.4663 
5: Cancer-related 
fatigue 
14/40 (35) 0.19 0.08–0.44 0.0001 





*p-value for the variable as a whole. 
Note: the dependent variable was a correct response. For example, in the first analysis, 
respondents who were aged 30 or younger were significantly more likely (OR 2.64) to 
give a correct diagnosis than the older participants. The numbers in the third column 
 
 
6.5.3 Management Consistent with Expert Opinion 
 
The GP management of the cases according to expert opinion was categorised into 




Of the 200 observations made by the GPs to correctly refer cases, only 43% (range 
18–60%) were consistent with expert opinion. Most referrals were inconsistent with 
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the expert opinion. This inconsistency was greater for erectile dysfunction, radiation 
and peripheral neuropathy, with only 18% (7 of 40), 36% (15 of 40) and 43% (17 of 
40) correctly referred, respectively. Similarly, only 38% (15 of 40) of referrals made 
by GPs who worked more than 60 patient care hours per week, and 33% (26 of 80) of 
those made by GPs who had one to two years of experience, were consistent with 
expert opinion. 
 
The results of a regression analysis revealed that only the number of patient care hours 
worked by a GP per week influenced GPs’ decisions to refer. Compared to GPs who 
worked more than 60 hours, GPs who worked 21 to 40 hours were more likely (OR 
8.67, 95% CI 1.23–70.70, p = 0.03) to make referrals that were consistent with the 
expert opinion. The type of case viewed did not have any significant effect on a GP’s 
decision to refer. Details of the factors associated with correct referrals are displayed 




Of the 160 observations made by the GPs to correctly prescribe, only 39% (range 29–
70%) of the prescriptions were consistent with the expert opinion. The only cases with 
a higher proportion of GPs who gave prescriptions that were consistent with expert 
opinion were erectile dysfunction (28 of 40, 70%) and radiation proctitis (26 of 40, 
65%). 
 
The results of the regression showed that GPs with more years of experience were 
more likely to offer a prescription that was consistent with the experts. Compared to 
doctors with three to 10 years of experience, doctors with more than 11 years were 
seven times more likely to give a prescription consistent with the expert opinion (OR 
7.11, 95% CI 2.08–24.38, p = 0.001). Similar results were observed for GPs with a 
higher patient load per week. Compared to GPs who attended less than 100 patients 
per week, GPs who attended more than 150 patients had a 32% chance to offer 
prescriptions that were consistent with expert opinion (OR 0.32, 95% CI 0.12–0.84, p 
= 0.021). In addition, GPs had 16% chance to prescribe correctly for cases of 
peripheral neuropathy (OR 0.16, 95% CI 0.06–0.45, p = 0.000) than for radiation 
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proctitis. Details of the factors associated with correct prescription are displayed in 
Table 6.4. 
 
6.5.3.3 Ordering Tests 
 
Of the 160 observations made by the GPs to order tests, most were consistent with the 
expert opinion. At least 50% of the observations were consistent (average 36%, range 
10–85%). This consistency was observed more for fatigue (33 of 40, 83%) and tumour 
recurrence (32 of 40, 80%) than for radiation proctitis (4 of 40, 10%) and urinary 
dysfunction (16 of 40, 40%). Fifty per cent (6 of 12) of tests ordered by GPs who 
worked more than 60 patient care hours per week, 64% (23 of 36) of those who worked 
in practices that had more than 150 consultations per week, and 58% (28 of 48) who 
had more than 11 years of experience were consistent with the expert opinion. 
 
The regression analysis results showed that, compared to radiation proctitis, GPs were 
more likely to order tests for urinary dysfunction (OR 13.6, 95% CI 1.63–32.1, p = 
0.01), tumour recurrence (OR 188.7, 95% CI 11.8–224.8, p < 0.001) and fatigue (OR 
149.0, 95% CI 12.2–305.8, p < 0.001). Several demographics also influenced GPs’ 
decisions to order tests. GPs with one to two years (OR 13.2, 95% CI 1.42–12.98, p = 
0.01) and more than 11 years (OR 9.78, 95% CI 1.18–8.84, p = 0.02) of experience 
were more likely to order correct tests than were GPs with three to 10 years of 
experience. In addition, GPs with 21 to 40 hours (OR 0.12, 95% CI 0.10–0.93, p = 
0.04] and 41 to 60 hours (OR 0.07, 95% CI 0.10–0.69, p = 0.01) of direct patient care 
were less likely to order tests that were consistent with the expert GPs than were GPs 
with more than 60 hours. Details of the factors associated with the correct ordering of 
tests by GPs are displayed in Table 6.4. 
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Table 6.4: Factors Associated with Management Consistent with Expert Opinion 
 Referral Prescription Tests 
 Correct OR (95% CI), p-value Correct OR (95% CI), p-value Correct OR (95% CI), p-value 
 N %  N %  N %  
GP years of practice          
1–2 years 26/80 33 0.16 (0.09-1.08), 0.06 29/64 45 2.15 (0.62-7.49), 0.23 35/64 55 13.2 (1.42-12.98), 0.01 
3–10 years 30/60 50 1 (Reference) 14/48 29 1 (Reference) 22/48 46 1 (Reference) 
11+ years 30/60 50 0.54 (0.16-2.56), 0.54 22/48 46 7.11 (2.08-24.38), 
0.001 
28/48 58 9.78 (1.18-8.84), 0.02 
Total  86/200 43  65/160 39  85/160 36  
GP holds a fellowship          
No 30/85 35 1.75 (0.53-3.11), 0.57 33/68 49 0.53 (0.19-1.49), 0.23 35/68 51 5.42 (0.89-5.26), 0.09 
Yes 56/115 49  32/92 35  50/92 54  
Total  86/200 43  65/160 39  85/160 36  
Number of patients seen in the practice/week        
Less than 100 38/75 51 1 (Reference) 27/60 45 1 (Reference) 30/60 50 1 (Reference) 
100–149 35/80 44 0.51 (0.17-1.77), 0.50 25/64 39 0.48 (0.17-1.41), 0.18 32/64 50 1.27 (0.44-2.85), 0.81 
150–199 13/45 29 0.4 (0.21-1.74), 0.35 13/36 36 0.32 (0.12-0.84), 0.021 23/36 64 5.58 (0.87-8.14), 0.08 
Total  86/200 43  65/160 39  85/160 36  
GP direct patient care hours/week        
Less than 11 24/50 48 5.10 (0.69-55.6), 0.22 17/40 43 0.18 (0.04-0.82), 0.02 22/40 55 0.46 (0.21-1.94), 0.43 
21–40 45/95 47 8.67 (1.23-70.7) 0.03 31/76 41 0.17 (0.04-0.70), 0.01 38/76 50 0.12 (0.10-0.93), 0.04 
41–60 15/40 38 3.42 (0.47-27.6), 0.22 11/32 34 0.21 (0.05-0.92), 0.04 17/32 53 0.07 (0.10-0.69), 0.01 
More than 60 2/15 13 1 (Reference) 6/12 50 1 (Reference) 8/12 67 1 (Reference) 
Total 86/200 43  65/160 39  85/160 36  





Cases          
Case 1: Peripheral 
neuropathy 
17/40 43 1.78 (0.57-2.8), 0.56 11/40 28 0.16 (0.06-0.45), 0.000 n/a n/a n/a 
Case 2: Erectile dysfunction 7/40 18 0.15 (0.98-1.03), 0.06 28/40 70 1.30 (0.43-3.90), 0.64 n/a n/a n/a 
Case 3: Urinary dysfunction 23/40 58 6.17 (0.93-6.78), 0.07 n/a n/a n/a 16/40 40 13.60 (1.63-32.14), 0.01 
Case 4: Tumour recurrence 24/40 60 7.17 (0.97-8.16), 0.06 n/a n/a n/a 32/40 80 188.67 (11.77-224.80), 
< 0.0001 




 Referral Prescription Tests 
 Correct OR (95% CI), p-value Correct OR (95% CI), p-value Correct OR (95% CI), p-value 
 N %  N %  N %  
Case 6: Radiation proctitis 15/40 36 1 (Reference) 26/40 65 1 (Reference) 4/40 10 1 (Reference) 
Total  86/200 43  65/160 39  85/160 36  







This study explored the effect of a variety of clinical and respondent characteristics on 
GPs’ decisions to treat patients with treatment side-effects or symptoms of recurrence 
of CRC. Peripheral neuropathy, fatigue, bowel dysfunction, urinary dysfunction, 
tumour recurrence and sexual dysfunction are common presentations of patients with 
CRC in general practice.[50] This study’s data indicate that the GPs correctly diagnosed 
most of these conditions, with the exception of fatigue. Compared to radiation proctitis, 
the GPs were less likely to recognise fatigue. This could be expected because, in most 
cases, fatigue presents as a manifestation of other underlying conditions and is difficult 
to diagnose.[210] The results of the regression analysis alluded to this scenario. 
Although almost three quarters the participating GPs did not recognise cancer related 
fatigue, the regression results showed that they ordered tests to explore underlying 
conditions, which was consistent with the expert suggestions. 
 
However, suggestions for management plans for these conditions were not consistent 
with expert opinion in all the applicable categories of management (referrals, 
prescribing and ordering tests) for the specific cases. The regression analysis led to the 
conclusion that, compared to radiation proctitis, tumour recurrence, fatigue and urinary 
dysfunction were more likely to be managed as per the experts. There were marked 
deviations from the experts’ suggestions for erectile dysfunction and peripheral 
neuropathy. For example, for erectile dysfunction, GPs were less likely to refer this 
case back to the specialist, but did offer appropriate medication. There were similar 
deviations from expert management for peripheral neuropathy and urinary dysfunction. 
Such deviations from expert opinion have been reported previously in similar studies 
with prostate cancer patients.[48] The differences in management between the 
participants and expert panel were less marked for the management of tumour 
recurrence. This could be expected because most patients present to a GP before cancer 
diagnosis[184] or present with symptoms of recurrence even when receiving ongoing 
management by their specialist.[35] Thus, it is plausible that the GPs were well 





The regression analysis also suggested that there were other influential variables 
affecting the management of these conditions. The results indicated influence from 
some of the demographic characteristics of the participants—specifically, the number 
of patient contact hours and years of experience. GPs with one to two years and more 
than 11 years of experience were more likely to manage patients according to expert 
opinion. This was not unexpected for patients treated for CRC because many of these 
problems are likely to present infrequently when patients are still receiving follow-up 
from their specialist, and some doctors may not have encountered them previously. 
However, it was surprising that less experienced GPs (one to two years of experience) 
were indicated. In this case, it is plausible that their patient contact hours were more 
than their counterparts, hence they more likely to have encountered similar cases. Also 
the currency of training may have contributed to their level of awareness of CRC 
treatment related problems and their management. 
 
A number of approaches have been reported in the literature to promote the consistent 
and reliable management of chronic conditions in primary care.[211, 212] A few of these 
have focused specifically on the knowledge of GPs,[48] while others have reported that 
attitudes and beliefs are important in the context of a cancer diagnosis.[213] These issues 
were not evaluated in this study. For example, this study was unable to report the 
participants’ attitudes towards the management of patients following treatment, and 
whether they felt this role extended to investigating and treating conditions that may 
have resulted from specialist treatment. In addition, this study could not identify any 
practitioners with specialist training in CRC. However, all participants were working 
as GPs when they participated in this study, and it is reasonable to assume that there 
were a negligible number with specialist training in a specific cancer. 
 
This pilot study had a modest sample size of 240 observations—a number that was 
assumed to be adequate to estimate the proportion of occasions on which at least one 
problem was correctly identified or managed with reasonable precision (approximately 
± 10%). This was not true of all management modalities. In some cases, the number 
of observations was very low, as evidenced by the wide confidence limits shown in 
Table 6.3. Therefore, a much larger and randomised study is required to robustly test 






In this pilot study, direct patient contact hours had a significant and positive effect on 
the successful management of patients. In addition, this study showed promising 
results that management of the common side-effects of CRC treatment could be 
delegated to GPs. Such an intervention could support the application of shared care 
models of healthcare. However, a larger study that includes management of the side-






Chapter 7: Discussion and Conclusions 
 
 
7.1 Overview of the Chapter 
 
This chapter provides a summary of the key findings, as reported in Chapters 3 to 6. It 
also includes an exploration of how the research questions and intentions were 
addressed via these studies. The overall intention of this thesis was to assess whether 
patients treated for CRC would benefit from GP support, even with ongoing specialist 
care. To address this intention, a series of studies were undertaken. 
 
1. First was the development of a patient-completed self-assessment tool (SATp) that 
included the most common problems reported by CRC patients (Study 1 in Chapter 
3). This study identified from the literature the most commonly reported problems 
encountered by CRC patients following treatment. Through a Delphi method, these 
problems were validated by two expert panels, including a group of CRC patients 
who had completed treatment, and experienced CRC healthcare professionals. 
Test–retest reliability was assessed by administering SATp to a subset of 
participants who agreed to fill it out on two occasions, approximately two weeks 
apart. The SATp was then subjected to readability testing. The final items were 
structured into physical, social and psychological problems based on a framework 
reported by Pigott et al.[29] and Bonevski et al.[145] The SATp was employed by the 
CRC patients to aid GP consultation. 
 
2. The second study explored the factors that may influence CRC patients’ intentions 
to seek health advice from a GP (Chapter 4). In this study, participants completed 
a questionnaire that was developed based on the TPB, and CRC patients’ intentions 
to attend a GP for care. The influence of a variety of TPB constructs (attitude, 
influence of important others, perceived control and barriers) and respondent 
characteristics on patients’ decisions to seek help from a GP were reported. The 
results of this study were presented as barriers to and facilitators for seeking health 




3. Third was an evaluation of the feasibility and effect of a problem-identification 
intervention for participants with CRC (Chapter 5). In this prospective study, a trial 
of SATp (developed in Study 1) was undertaken. Participants were provided with 
a booklet including the SATp for them to keep a monthly record of problems they 
experienced, and to aid GP consultation. A baseline assessment was done, followed 
by monthly evaluations for five subsequent months. The Glasziou and Haynes 
model of evidence-based medicine that outlines the path from research to improved 
health outcomes[54] was used as the theoretical framework to guide deployment of 
the intervention. The success of the SATp intervention was assessed via the 
number of physical, psychological and social problems identified, changes in the 
participants’ number of problems, and the number of problems addressed by the 
GPs. 
 
4. Finally, this project explored the effect of a variety of clinical and respondent 
characteristics on GPs’ decisions to treat patients with treatment side-effects or 
symptoms of recurrence of CRC (Chapter 6). This was an email-based survey. 
Participants viewed video vignettes of actor-patients representing people who had 
been treated for CRC. The actor-patients presented problems that were resultant 
from CRC treatment. The participants indicated their diagnosis and stated how they 
would treat the problem. These responses were then rated against the management 
decisions for those vignettes recommended by a team of experts in CRC. 
 
7.2 Principal Findings of the Thesis and How They Answered the 
Research Questions 
 
Figure 7.1 provides a schematic representation of the relationship between the various 









Figure 7.1: Relationship between the Various Studies and Research Questions and Intentions 
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7.2.1 Study 1: Development of the SATp to Assess Problems that Patients may 
Experience Following Treatment for CRC 
 
This study answered Research Questions 3 and 4: 
 
RQ 3. Could a user-friendly, patient completed data collection tool (SATp) 
be developed to assess problems that patients may experience following 
treatment for CRC? 
 
RQ 4. Is the SATp a reliable and valid data collection tool for assisting 
patients to discuss issues associated with their CRC treatment with their GP? 
 
According to the seven criteria for needs-assessment tools outlined in Chapter 3, a tool 
is effective if it: 
1. contains physical, psychological and social aspects to measure multiple 
domains of CRC care[142, 146] 
2. uses a self-reporting approach to facilitate direct and comprehensive 
assessment of subjective health needs[142] 
3. measures the needs in a defined temporal context[29] 
4. demonstrates validity and reliability through expert review, test–retest and pilot 
testing to provide a sound basis for comparison[145] 
5. embraces a user-friendly response framework[145] 
6. is ‘system-friendly’ by minimising the patient and staff time required to 
complete and review[142] 
7. provides an opportunity for clinicians to link patients to services.[29] 
The SATp fulfilled all the criteria outlined by these studies. The SATp 
comprehensively evaluated a wide range of problems specific to CRC patients. This 
tool integrated physical, psychological and social aspects to measure multiple domains 
of CRC care. Similar studies done among breast cancer patients have emphasised the 
use of such domains to assess patients’ problems following cancer treatment.[146] The 
participants were asked to report issues they may have experienced during the previous 





The results of this study indicated that the SATp fulfils the current scientific criteria 
for acceptability, internal consistency, validity and usability. Through an internal 
consistency process, it was possible to demonstrate evidence for a strong, structurally 
reliable SATp tool as reported in chapter 3.  
 
Throughout the developmental phases, opinions from the expert team and from 
patients were incorporated to balance the two perspectives that might be discordant. 
The findings from consultation with experts and patients suggested similarity in 
ranking for most of the items. However, higher rankings were reported for physical 
symptoms by experts and for social needs by patients. These findings are consistent 
with other studies showing an emphasis by experts on symptom management and by 
patients on other type of needs.[27, 142] 
 
In terms of need prevalence, this study’s results seem to suggest the universal nature 
of need experiences. The pattern of need prevalence in the current study seems 
substantially similar to those reported by previous studies. Consistent with studies 
indicating psychosocial problems as the most prevalent needs, three—fear of 
recurrence (53%), insomnia (53%) and housework difficulties (45%)—of the top five 
needs were found in the psychological and social domains.[143, 214] According to 
Hodgkinson et al.,[143] psychological comorbidity results in a fourfold increase in 
unmet needs among cancer patients. 
 
7.2.2 Study 2: Predicting Study Participants’ Intentions to Attend a GP Following 
CRC Treatment  
 
This study answered Research Questions 5 and 6: 
 
RQ 5. Are personal attitude, perceived control/barriers, and the influence of 
other people independently associated with CRC patients’ intentions to 
attend a GP for future health advice about their CRC problems? 
 
RQ 6. Do patients’ demographics and clinical characteristics, such as the 
presence of an existing chronic illness, influence their intentions to visit a GP 




This study used the TPB to explore factors that may influence CRC patients to seek 
health advice from a GP about their CRC-related problems. The TPB suggests that 
intention immediately precedes behaviour because it reflects the person’s level of 
motivation and desire to perform a certain action. Intention is determined by attitudes, 
subjective norms and perceived behaviour control constructs.[177] PBC is the perceived 
opportunities and resources available for performing the behaviour, and may directly 
lead to the behaviour if it accurately reflects actual control. Attitude is viewed as the 
perceived advantages and disadvantages of performing the behaviour. Subjective 
norms are the perceived social pressures (such as important people) that influence an 
individual to perform the behaviour or not.[62] 
 
This study sheds light on how attitude, subjective norms and PBC influence CRC 
patients’ intentions to engage with a GP following cancer treatment. Specifically, 
significant associations between attitude, subjective norms, the presence of a chronic 
illness, and future use of GP services by participants were documented. This study also 
assessed attitude factors, such as ‘attending a GP about CRC is likely to: (i) detect 
problems and side-effects early and (ii) reassure me’, and subjective norms factors, 
such as the influence of family, specialists and cancer nurses on attendance. 
 
Although this study recruited participants via hospital cancer clinics, previous studies 
have reported that prediction of intentions by attitudes and subjective norms can be 
strongest in studies that recruit via GP practices.[57] The large attitude–intention 
relationship for seeking health advice from a GP suggests that individuals may value 
visits to their GP more than visits to settings such as hospitals. The subjective norm–
intention association for GP settings may be a reflection of participants having family 
who attend the same practice and/or having a good relationship with the GPs at their 
local practice. However, this finding regarding subjective norm emerging as a 
significant predictor of intention contrasts to other studies predicting CRC patients’ 
intentions to attend screening programs.[215] It is possible that this might be related to 
the way in which the subjective norm was measured. A more reliable, multi-item scale 




The regression analysis also suggested that the combined effect of these factors 
accounted for a strong influence (43.3%) on future intention to attend follow-up visits. 
Attitude and the presence of a chronic illness were responsible for 23.3% and 12.8% 
of this variance, respectively. Analysis of the regression models provided a different 
picture regarding the PBC construct. Although personal attitude was strongly 
associated with patients’ intentions to seek health advice from a GP, PBC did not 
account for significant variance on future use of primary care services for CRC follow-
up care. This finding contrasts research among CRC patients attending physical 
exercise sessions, which suggests that PBC has a significant influence on intention.[60, 
179] 
 
PBC factors such as affordability, travel and ease of booking an appointment with a 
GP had limited influence on patients’ intentions, which was not anticipated with this 
group as the majority were retired 47/66 (71.2%). Noting that the mean age of 
participants was 69.2 (SD 9.9) years, PBC may not have had an influence because 
patients in this age category in Australia receive government-subsidised GP 
consultations and travel concessions. However, other studies on attendance to 
screening programs align with this study’s findings that perceive behaviour control as 
a relatively unimportant predictor of attendance.[57] 
 
Other studies show that CRC patients living alone have a more positive attitude 
towards follow-up care than do those who are married or living with a sibling or 
friend.[183] However, this study showed that socio-demographic characteristics, such 
as age and marital status, had no effect on patients’ attitudes towards visiting a GP for 
health advice about their CRC-related problems. The only statistically significant 
association with socio-demographic and clinical characteristics was that patients with 
a coexisting chronic illness had a more positive attitude towards attending a GP (p < 
0.05). This may be expected because 30 to 60% of CRC survivors aged 70 years or 
older have a coexisting chronic illness[117] and are more likely to attend primary care 







7.2.3 Study 3: A trial of the Self-Assessment Tool (SATp Intervention) 
 
This study answered Research Questions 7 and 8: 
 
RQ 7. Can the SATp help identify physical, psychological and social 
problems related to CRC treatment? 
 
RQ 8. If patients present the SATp to their GP, would this facilitate 
discussions about any physical, psychological and social problems associated 
with their CRC treatment? 
 
This study evaluated the feasibility and influence of a problem-identification 
intervention for participants with CRC. Various ways in which GPs addressed 
participants’ problems during the study period were recorded. The number of physical, 
psychological and social problems was recorded, and changes in the participants’ 
number of problems over the five-month period were documented. The results of this 
study showed that the SATp tool was able to identify patient problems, with 96% of 
participants reporting at least two problems (a median of seven problems per patient). 
Research has shown that a structured symptom checklist and screening tools are 
effective in eliciting the full range of problems for patients with other cancers.[193, 194] 
Although the SATp was structured, the response format was meant to be a prompt to 
consultation in order to assist in a thorough exploration of possible problems. 
 
There was a non-significant trend in reducing physical and social problems, while 
psychological problems were significantly reduced (p < 0.01). The lack of effect on 
physical outcomes may be partially explained by the relatively short study follow-up 
period. Some physical problems may have required radiological and laboratory 
investigations before a GP could provide treatment advice; thus, symptoms may have 
continued to be reported throughout the study period. These factors may have 
contributed to the finding that the intervention appeared to have no influence on these 
outcomes over the five-month timeframe. 
 
Participants with physical problems visited their GP more frequently (p = 0.05) 
compared to those with social or psychological problems. Other studies have reported 
 
123 
similar findings that cancer patients are more likely to consult their GP more often for 
physical symptoms than for other symptoms.[119, 216] It is also possible that patients felt 
less compelled to seek health advice regarding psychological and social problems, 
rather than physical problems. Heins et al. reported that direct fear of cancer recurrence 
was rarely recorded as reason for a GP visit, even though participants had significant 
psychological morbidity.[216] Similarly, Mikkelsen et al. conducted a survey among 
cancer survivors and found that, although many experienced psychosocial problems—
such as fear of recurrence of cancer or problems within the family—these problems 
were rarely discussed with the GP or other medical care providers.[217] However, Heins 
et al. stated that, when a clinician suspects psychosocial issues in a patient, they must 
take a proactive approach to discussing these problems. 
 
This study was able to confirm that patients continue to experience significant 
symptoms in the physical and psychosocial domains even years after completing 
treatment. Although the sample size was modest and the prevalence of the reported 
symptoms may have been higher than for other CRC survivors in general, these results 
reaffirm the findings of several other studies of CRC survivors.[1, 21, 142, 218, 219] 
 
7.2.4 Study 4: Approach to Managing CRC Treatment–related Side-effects and 
Symptoms of Recurrence: A Video Vignette Study in General Practice 
 
This study answered Research Questions 9 and 10: 
 
RQ 9. Can GPs recognise the side-effects of CRC treatment or recurrence of 
CRC? 
 
RQ 10. Can GPs manage the side-effects of CRC treatment or recurrence of 
CRC, in accordance with experts’ opinion? 
 
This study explored the effect of a variety of clinical and respondent characteristics on 
GPs’ decisions to treat patients displaying treatment side-effects or symptoms of 
recurrence of CRC. Six video scenarios were viewed by GPs, involving peripheral 
neuropathy, erectile dysfunction, urinary dysfunction, tumour recurrence, cancer-
related fatigue and radiation proctitis. The GPs were asked to provide a diagnosis and 
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management plan based on the experts’ opinion. This study indicated that GPs can 
recognise most of the conditions that were presented. However, GPs’ suggestions for 
management plans for these conditions were not consistent with expert opinion in all 
the applicable categories of management (refer, test and prescribe). Such deviations 
from expert opinion have been reported previously in similar studies with prostate 
cancer patients.[220] The differences in management between the participants and 
expert panel were less marked for the management of tumour recurrence. This may be 
expected because most patients present to a GP before the cancer diagnosis,[184] or with 
symptoms of recurrence, even when receiving ongoing management from their 
specialist.[35] Thus, it is plausible that the GPs were well experienced in recognising 
and making appropriate decisions related to tumour recurrence. 
 
7.3 Conclusions and Recommendations for Research and Practice 
 
The review of the literature in Chapter 2 on the benefits of GP support for cancer 
patients indicated that research relating to the care of long-term cancer survivors in 
primary care is limited.[221] Clinicians, policymakers and researchers also acknowledge 
that long-term support for cancer survivors must be considered to ensure the optimal 
wellbeing of people with cancer during all stages of their complex disease journey.[38, 
222-224] 
 
Chapter 3 (development of the SATp) adds to this body of knowledge by 
demonstrating that CRC survivors have numerous health needs that must be addressed 
for many years after diagnosis. This thesis also indicates the role of GPs in supporting 
cancer patients. The literature reviewed in Chapter 2 made clear that general practice 
is the first point of contact for healthcare and advice, even for patients under the care 
of specialists.[164] Chapter 4 (predicting the intentions of patients to attend a GP) 
demonstrated that CRC patients trust their GPs to manage their problems following 
treatment. Chapter 5 (evaluating the feasibility and effects of problem-identification 
interventions in general practice) and Chapter 6 (approach to GPs managing CRC 
treatment side-effects) confirmed that general practice is well placed to provide 




The findings of this research can be viewed in the context of Glasziou and Haynes 
model discussed in chapter one of this thesis.[54] According to Glasziou and Haynes, 
even with the best evidence available, there are substantial gaps between the evidence 
and the management patients receive. Further this model states that even when 
clinicians know and accept what to do, they often forget to act on the evidence. 
Omissions are more frequent for long-term and preventive issues because they are not 
the pressing focus of a consultation. [54] Patients on the other hand must contend with 
conflicting advice, adverse effects and sometimes a lack of ability to pay for the tests 
and treatments. Strategies must be trialled to encourage concordance. [54] 
 
 
7.3.1 Evidence Identified by this Thesis Recommendations for Further Research 
 
In Chapter 4 (predicting intentions of CRC patients to attend a GP), attitudes appear 
to be a strong predictor of patients’ intentions to engage with a GP following CRC 
treatment. Consequently, to encourage engagement with general practice among CRC 
patients, interventions would be best advised to create awareness of the CRC services 
that general practice is able to provide. This will generate positive attitudes, rather than 
alter other TPB constructs, such as subjective norms or PBC. The large attitude–
intention relationship suggests that a greater number of individuals made informed 
choices regarding attending a GP for health advice about their CRC needs. 
 
The findings of this study may inform intervention efforts to transfer cancer care to 
GPs. Intervention efforts geared towards strengthening patients’ awareness of the 
issues their GPs can manage may increase confidence in GPs to offer such support. 
Intervention efforts are likely to be most effective by tailoring programs to highlight 
how GPs can support follow-up care. In addition, it may be easier to transfer the care 
of cancer patients who already attend a GP for other chronic illnesses. 
 
Given the importance of attitudes and presence of a chronic illness as predictors of 
intentions to engage with a GP, it is important for future research to assess the 
influence of the properties of attitude—such as levels of knowledge about the CRC 
services provided by GPs—on attitude–intention consistency. More research is 
required to investigate how individuals would react to invitations to attend a GP visit. 
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Other studies that have investigated the use of invitation to screening programs have 
shown that test context and location of recruitment suggest that invitations may be 
viewed differently depending on where the invitation comes from and the nature of the 
test.[57, 58, 225, 226] 
 
Chapters 5 (a pilot evaluation of the feasibility and effect of a problem-identification 
intervention in general practice) found that it is feasible to address patients’ problems 
following treatment via the support of a GP. The literature review in Chapter 2 found 
minimal body of evidence that suggested that this method of supporting patients was 
commonly used in practice. The lack of published documentation for this approach 
was hypothesised to result from the complex nature of these types of interventions, 
which challenge evaluation attempts in practice. Guidance from the Medical Research 
Council and other studies suggest that piloting is essential prior to large-scale 
evaluation and implementation of complex interventions, of which support care is an 
example.[227-229] During piloting, specific attention should be given to examining the 
feasibility, acceptability and potential outcomes of an intervention.[229] Therefore, a 
longitudinal pilot study of SATp intervention was undertaken and reported in Chapter 
5 to confirm the utility of such an approach for CRC patients. 
 
This pilot evaluation used an assessment tool (SATp) developed in Chapter 3. The 
results indicated that using SATp is effective in identifying patients’ needs. These 
results align with other studies which confirm that using a structured symptom 
checklist or screening tool is effective in eliciting the full range of problems for 
patients with other cancers.[193, 194] The SATp was not only structured, but the response 
format was also intended to be a prompt to consultation in order to assist in a thorough 
exploration of possible problems by the GP. 
 
The SATp intervention included a sample of patients who had completed treatment 
and those with Stages I to III CRC. This is likely to have contributed to the variability 
of the scores reported. To reduce this variability, ideally, subgroup analysis would be 
performed to determine whether the SATp intervention benefited patients with 
particular personal or clinical characteristics. However, the sample size of the study 
precluded this analysis. The ability to perform a subgroup analysis to reduce 




Relevant approaches have been tried in the past. Such approaches include using 
computer touchscreen technology to routinely screen patients’ needs in ‘real time’, 
such as QIUCA-TOUCH (Quick, Individually Customised Assessment using 
Touchscreen),[230] the CONNECT intervention[231] and the Supportive Needs 
Screening Tool.[29] Oncology outpatients were screened for pain, distress and other 
common psychopathology using these methods, and then referred to appropriate 
services. Such interventions are useful for screening patients’ needs following cancer 
treatment. The usability of these tools in primary care was not documented. 
 
Chapter 6 (approach to managing CRC treatment–related side-effects and symptoms 
of recurrence—a video vignette study in general practice) found that GPs can 
recognise and manage most of the problems patients present following cancer 
treatment. Although peripheral neuropathy, fatigue, bowel dysfunction, urinary 
dysfunction, tumour recurrence and sexual dysfunction are common presentations of 
patients with CRC in general practice, not all of these symptoms were identified and 
treated as per expert opinion across all categories of management (referral to a 
specialist, order investigations and prescribe medications). For some of the symptoms, 
correct investigations were ordered but participants failed to suggest a referral back to 
the specialist for further management. 
 
A number of approaches have been reported in the literature to promote consistent and 
reliable management of chronic conditions in primary care.[211, 212, 232] A few of these 
have focused specifically on the knowledge of GPs,[190] while others have reported that 
attitudes and beliefs are important in the context of a cancer diagnosis.[213] These issues 
were not evaluated in this study. For example, this study was unable to report the 
participants’ attitudes towards the management of patients following treatment, and 
whether they felt that this role extended to investigating and treating conditions that 
may have resulted from specialist treatment. In addition, this study could not identify 
any practitioners with specialist training in CRC. However, all participants were 
working as GPs when they participated in this study, and it is reasonable to assume 
that there were a negligible number with specialist training in a specific cancer. This 
pilot study had a modest sample size of 240 observations—a number that was assumed 
to be adequate to estimate the proportion of occasions on which at least one problem 
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was correctly identified or managed with reasonable precision (approximately ± 10%). 
This was not true of all management modalities. In some cases, the number of 
observations was very low, as evidenced by the wide confidence limits shown in Table 
6.3. Therefore, a much larger and randomised study is required to robustly test this 
study’s objectives. 
 
Overall, this thesis has demonstrated that using a screening tool (SATp) with 
appropriate support in place (general practice) is a viable method to support CRC 
patients with problems following cancer treatment. The reports of Study 3 showed that 
GPs can recognise and offer appropriate treatment for most of the side-effects of CRC 
treatment and for the symptoms of recurrence. However, more training is required for 
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Appendix 2.1: Main Findings of the Studies Assessing Side-Effects of Colorectal Cancer 
Treatment 
 
Type of Study and 
Study Setting 




Holtedahl et al. 
2005[42] 
Cancer site: Multiple sites 
Length of follow-up: Six months 
Sample size: Int n = 41, hospital n = 50 
Survey response rate: Int 88%, hospital 
90% 
The most prevalent concerns reported one year after diagnosis and 
treatment were fear of recurrence (68%), fatigue (67%), and sleep 





Bergholdt et al. 
2012[36] 
Cancer site: Multiple sites 
Length of follow-up: 14 months 
Sample size: Int n = 486, hospital n = 
469 
Response rate: Overall response rate 
reported = 71% 
Pt psychological distress: fear of recurrence 
The most commonly reported symptoms were fatigue (23%); 
physical discomfort (19%); stomach-ache was more frequent for 




Lindsey I et al 2002 
[236] 
Cancer site: Rectum 
Sample size: Int n = 18, hospital n = 14 




- Male Sexual Dysfunction 
 




- Female Sexual Dysfunction 
Dyspareunia 
    Vaginal dryness 
Case Control Study 
Netherlands 
Peeters et al 2005 [2] Cancer site: Rectum 
Sample size: 597 
Length of follow-up: 7 years 
 
Bowel Dysfunction 
Clustering of BMs 
Night time BM 
Incontinence 
Pad wearing 
Inability to defer BM 
Diarrhoea 
Constipation 
Prospective Cohort study 
United States 
Schneider et al 2007[3]  Cancer site : Colon and Rectum 
Sample size : 474 
Length of follow-up: 4 years 
Urinary Incontinence (Surgery +/− Radiotherapy) 
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Type of Study and 
Study Setting 





Urinary incontinence (38%), difficulties in bladder emptying 
(31%), need to void within two hours of voiding (70%), and need 
for protective pads (57%) 
Difficulty bladder emptying 
Bowel dysfunction  
frequency, urgency, evacuatory difficulties, and inability to 
differentiate stool and gas 
Diarrhoea 
Constipation 
Fear of recurrence 
 
Retrospective cohort study 
Netherlands 
Lange et al 2008 [237] Cancer site: Rectum and colon 
Sample size 785 
Survey response rate: Not specified 
Urinary Incontinence (Surgery +/− Radiotherapy 
Difficulty bladder emptying, 
Need to void within 2 hrs  
Pad wearing 
Prospective cohort study 
United States 
Kurtz, M., et al 2002 
[237] 
Cancer site: Colon and Rectum 
Sample size: 211 
Survey response rate: Not specified 
26–44% of long-term CRC survivors continued to worry about 
cancer recurrence, symptoms as cancer indicators, getting a 
second malignancy, or future diagnostic tests. Cancer-related 
health worries were associated with anxiety and depression, with 
24% of the survivors reporting depression scores that were high 
enough to need evaluation for clinical depression 
Cross-sectional study 
United States 
Haggstrom et al. 
2009[50] 
Cancer type: Colorectal cancer 
Sample size: n = 303 
Survey response rate: Not specified 
- sensory impairment of the peripheral nerves in a stocking-
glove distribution 
o numbness, pain, paresthesias, dysesthesias, and 
changes in proprioception 
- urinary retention 
Cross-sectional study 
United States 
Kaley, T.J. and L.M. 
DeAngelis[238] 
Cancer type: Colorectal cancer 
Sample size: n = 350 
Survey response rate: Not specified 







Appendix 2.2: Main Findings of the RCTs and Observational Studies Assessing the Importance 
of GP Involvement in Cancer Care 
Type of Study and 
Study Setting 




Holtedahl et al. 
2005[42] 
Cancer site: Multiple sites 
Length of follow-up: Six months 
Sample size: Int n = 41, hospital n = 
50 
Survey response rate: Int 88%, 
hospital 90% 
- QoL: No statistically significant difference in QoL between the 
intervention and hospital group 
- Patient satisfaction with care: Improved satisfaction after six 
months of follow-up 
RCT 
Denmark 
Nielsen et al. 2003[46] Cancer site: Multiple sites 
Length of follow-up: Six months since 
diagnosis 
Sample size: Int n = 121, hospital n = 
127 
Questionnaire response rate: Int 78%, 
hospital 64% 
- QoL: No statistically significant difference in QoL between the 
intervention and hospital group 
- Patient satisfaction with care: A statistically significant 
difference in the intervention group for: 
 feeling not being left in limbo: Int 65.49 (n = 65) v. 
hospital 58.55 (n = 77); p = 0.05 
 inter-sectoral cooperation: Int 59.22 (n = 62) v. hospital 
51.71 (n = 62); p = 0.05 
(Statistical test used: Mann-Whitney U test) 
RCT 
Denmark 
Bergholdt et al. 
2012[36] 
Cancer site: Multiple sites 
Length of follow-up: 14 months 
Sample size: Int n = 486, hospital n = 
469 
Response rate: Overall response rate 
reported = 71% 
- QoL: No statistically significant difference in QoL between the 
intervention and hospital group 
- Pt psychological distress: No statistically significant difference 
between the intervention and hospital group 
RCT 
Norway 
Augestad et al. 
2013[168] 
Cancer site: Colon 
Length of follow-up: 24 months 
Sample size: Int n = 55, hospital n = 
55 
Response rate: Overall = 75% 
- QoL: There was a significant improvement in postoperative 
QoL (p = 0.003) at baseline, but no differences between groups 
revealed at the one-, three-, six-, nine-, 12-, 15-, 18-, 21- and 24-
month follow-up appointments) 
- Recurrence: There were no differences in time to recurrent 
cancer diagnosis between Int and hospital groups 
(Estimated mean change for EORTC QLQ-C30 between the 
groups was calculated) 
Cross-sectional study 
United States 
Forsythe et al. 
2012[133] 
Cancer site: Breast and colon 
Sample size: PCPs n = 1,021, ONCs n 
= 1,130 




Type of Study and 
Study Setting 
Author Study Details Main Conclusions 
 
Survey response rate: Not specified - Both PCPs and ONCs saw themselves as providers of 
psychosocial care. The PCPs were confident in providing 
psychosocial care to patients, while the ONCs reported shared 
provision of psychosocial care (p < 0.001) 




Aubin et al. 2010[132] Cancer site: Lung cancer 
Length of follow-up: 18 months 
Sample size: n = 395 
Survey response rate: 56.8% 
- Patient contact with family physician upon cancer diagnosis and 
during treatment, follow-up and terminal care 
- 92% of cancer patients had a regular family physician 
- Extent of family physician involvement in treatment decisions 
(% of patients): At baseline, only 16% of patients perceived a 
shared care pattern between their family physician and 
oncologists; however, this proportion increased with cancer 
progression to terminal care (p < 0.001) 
(Statistical test used: Cochran–Mantel–Haenszel test) 
Retrospective cohort study 
Netherlands 
Roorda et al. 2012[134] Cancer site: Breast 
Sample size: Pts n = 185, Refgrp n = 
585 
- Annual healthcare use in primary care before diagnosis v. since 
diagnosis (%): Pts. with breast cancer had twice as many face-to-
face contacts (p < 0.001) with the GP and a higher number of 
cancer-related medication prescriptions (p < 0.01) than did 
women from the Refgrp 
(Statistical test used: Mann–Whitney test) 
Cross-sectional study 
United States 
Haggstrom et al. 
2009[50] 
Cancer type: Colorectal cancer 
Sample size: n = 303 
Survey response rate: Not specified 
- Pt contact with PCP: 16% of CRC survivors saw PCP, while 
60% saw ONC 
- Survivors most often seen by PCPs were more likely to have 
three or more medical comorbidities (70% v. 51%, p = 0.012) 
than survivors seen by specialist 
- Quality of care/content of follow-up: No significant specialty 
differences in patient-centred quality of follow-up cancer care 
Note: hospital = control group, Int = intervention group (GPs involved in cancer care), Dx = diagnosis, ONC = oncologist, Pts = patients, Refgrp = reference group 




Appendix 2.3: Results Indicating Type of GP Involvement in Cancer Care 
Type of Study and 
Study setting 
Author Study Details Type of GP 
Involvement 
Extent of GP Involvement 
RCT 
Norway 
Holtedahl et al. 
2005[42] 
Cancer site: Multiple sites 
Length of follow-up: Six months 
Sample size: GP group n = 41, hospital n = 50 
Survey response rate: GP group 88%, hospital 
90% 
Formal involvement Patients in the GP group received a 30-
minute invited consultation with the GP and 
an invitation to further GP visits 
RCT 
Denmark 
Nielsen et al. 
2003[46] 
Cancer site: Multiple sites 
Length of follow-up: Six months since diagnosis 
Sample size: GP group n = 121, hospital n = 127 
Questionnaire response rate: GP group 78%, 
hospital 64% 
Formal involvement Patients were encouraged to visit their GP 
RCT 
Denmark 
Bergholdt et al. 
2012[36] 
Cancer site: Multiple sites 
Length of follow-up: 14 months 
Sample size: GP group n = 486, hospital n = 469 
Response rate: Overall response rate reported = 
71% 
Formal involvement GPs were encouraged to contact the patients 
and facilitate the rehabilitation process 
Cross-sectional study 
United States 
Forsythe et al. 
2012[133] 
Cancer site: Breast and colon 
Sample size: PCPs n = 1,021, ONCs n = 1,130 
Survey response rate: Not specified 
Informal involvement Patients attended a GP while still 




Aubin et al. 
2010[132] 
Cancer site: Lung cancer 
Length of follow-up: 18 months 
Sample size: n = 395 
Survey response rate: 56.8% 
Informal involvement Patients attended a GP while still 




Roorda et al. 
2012[134] 
Cancer site: Breast 
Sample size: Pts n = 185, Refgrp n = 585 
Not specified GPs were ‘informally’ involved in the 
follow-up care of cancer patients 
Cross-sectional study 
United States 
Haggstrom et al. 
2009[50] 
Cancer type: Colorectal cancer 
Sample size: n = 303 
Survey response rate: Not specified 
Informal involvement Patients attended a GP while still 
receiving follow-up from the specialists 
Note: hospital = control group, Int = intervention group (GPs involved in cancer care), Dx = diagnosis, ONC = oncologist, Pts = patients, Refgrp = reference group 





Appendix 2.4: Critical Review of RCTs Assessing GP Involvement in Cancer Care Using 
CONSORT 




Nielsen et al. 
2003[46] 






Title and abstract 1a Identified as a randomised trial 
in the title 
1 949 263 
1b Structured summary of trial 
design, methods, results and 
conclusions (for specific 
guidance, see CONSORT for 
abstracts) 
1 949 263 
Introduction 
Background and objectives 2a Scientific background and 
explanation of rationale 
2 949 263 
2b Specific objectives or 
hypotheses 
2 949 263 
Methods 
Trial design 3a Description of trial design 
(such as parallel or factorial), 
including allocation ratio 
2 Not clarified Not clarified 
3b Important changes to methods 
after trial commencement 
(such as eligibility criteria), 
with reasons 
Not clarified  Not clarified 
Participants 4a Eligibility criteria for 
participants 
2 950 264 
4b Settings and locations where 
the data were collected 
2 950 263 
Interventions 5 The interventions for each 
group with sufficient details to 
allow replication, including 
3 950 263–264 
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Nielsen et al. 
2003[46] 






how and when they were 
actually administered 
Outcomes 6a Completely defined pre-
specified primary and 
secondary outcome measures, 
including how and when they 
were assessed 
4 950 264 
6b Any changes to trial outcomes 
after the trial commenced, with 
reasons 
Not clarified Not clarified Not clarified 
Sample size 7a How sample size was 
determined 
4 952 264 
7b When applicable, explanation 
of any interim analyses and 
stopping guidelines 
Not clarified Not clarified Not clarified 
Randomisation 
 Sequence generation 8a Method used to generate the 
random allocation sequence 
4 950 265 
8b Type of randomisation, and 
details of any restriction (such 
as blocking and block size) 
4 Not clarified 265 
 Allocation concealment mechanism 9 Mechanism used to implement 
the random allocation 
sequence (such as sequentially 
numbered containers), 
describing any steps taken to 
conceal the sequence until 
interventions were assigned 
4 950 265 
 Implementation 10 Who generated the random 
allocation sequence, who 
enrolled participants, and who 
assigned participants to 
interventions 
4 950 265 
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Nielsen et al. 
2003[46] 






Blinding 11a If done, who was blinded after 
assignment to interventions 
(for example, participants, care 
providers or those assessing 
outcomes) and how 
4 950 265 
11b If relevant, description of the 
similarity of interventions 
Not clarified Not clarified Not clarified 
Statistical methods 12a Statistical methods used to 
compare groups for primary 
and secondary outcomes 
4 952 264 
12b Methods for additional 
analyses, such as subgroup 
analyses and adjusted analyses 
4 952 Partially 
clarified 
Results 
Participant flow (a diagram is strongly recommended) 13a For each group, the numbers of 
participants who were 
randomly assigned, received 
intended treatment, and were 
analysed for the primary 
outcome 
4 951 266 
13b For each group, losses and 
exclusions after randomisation, 
together with reasons 
2 951 266 
Recruitment 14a Dates defining the periods of 












Baseline data 15 A table showing baseline 
demographic and clinical 
characteristics for each group 
4 952 265 
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Nielsen et al. 
2003[46] 






Numbers analysed 16 For each group, the number of 
participants (denominator) 
included in each analysis and 
whether the analysis was by 
original assigned groups 
5–7 953–954 265, 267–270 
Outcomes and estimation 17a For each primary and 
secondary outcome, the results 
for each group and the 
estimated effect size and its 
precision (such as 95% 
confidence interval) 
5–7 953–954 267–270 
17b For binary outcomes, 
presentation of both absolute 







Ancillary analyses 18 Results of any other analyses 
performed, including subgroup 
analyses and adjusted analyses, 
distinguishing pre-specified 
from exploratory 
5–7 953–954 Partially 
clarified 
Harms 19 All important harms or 
unintended effects in each 
group (for specific guidance, 
see CONSORT for harms) 
Not clarified Not clarified Not clarified 
Discussion 
Limitations 20 Trial limitations, addressing 
sources of potential bias, 
imprecision and (if relevant) 
multiplicity of analyses 
6 955 268 
Generalisability 21 Generalisability (external 
validity and applicability) of 
the trial findings 
6 955 268 
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Nielsen et al. 
2003[46] 






Interpretation 22 Interpretation consistent with 
results, balancing benefits and 
harms, and considering other 
relevant evidence 
6-Aug 955 267–270 
Other information 
Registration 23 Registration number and name 
of trial registry 
Not clarified Not clarified Not clarified 
Protocol 24 Where the full trial protocol 
can be accessed, if available 
Not clarified Not clarified Not clarified 
Funding 25 Sources of funding and other 
support (such as supply of 
drugs) and role of funders 






Appendix 2.5: Critical Review of Observational Studies Assessing GP Involvement in Cancer 
Care Using STROBE 































Title and abstract  a. Indicate the study’s 
design with a commonly 
used term in the title or 
abstract 
Y Y N Y Y N Y Y Y 
b. In the abstract, provide 
an informative and 
balanced summary of 
what was done and what 
was found 
Y Y Y Y Y Y Y Y Y 
Introduction                  
Background Explain the scientific 
background and rationale 
for the investigation being 
reported 
Y Y Y Y Y Y Y Y Y 
Objectives State specific objectives, 
including any pre-
specified hypotheses 
Y Y Y Y Y Y Y Y Y 
  Study design mentioned 
earlier in the paper 
Y Y Y Y Y Y Y Y Y 
Study design Present key elements of 
the study design early in 
the paper 
N N N Y Y Y Y Y Y 
Setting Describe the setting, 
locations and relevant 
dates, including periods of 
recruitment, exposure, 
follow-up and data 
collection 
Y Y Y Y Y Y Y Y Y 
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Participants Give the eligibility 
criteria, and the sources 
and methods of selection 
of participants. Describe 
methods of follow-up 
Y Y Y Y Y Y Y Y Y 
Variables Clearly define all 
outcomes, exposures, 
predictors, potential 
confounders and effect 
modifiers. Give 
diagnostic criteria, if 
applicable 
N N Y Y Y Y Y Y Y 
Data 
sources/measurement 
For each variable of 
interest, give sources of 
data and details of 
methods of assessment 
(measurement). Describe 
comparability of 
assessment methods if 
there was more than one 
group 
Y N Y N Y Y Y Y Y 
Bias Describe any efforts to 
address potential sources 
of bias 
Y Y N N Y Y Y Y N 
Quantitative 
variables 
Explain how quantitative 
variables were handled in 
the analyses. If 
applicable, describe 
which groupings were 
chosen and why 
Y Y Y Y Y Y Y Y Y 
Sample size Explain how the study 
size was reached 
Y N N N Y N N N Y 
Statistical methods (a) Describe all statistical 
methods, including those 
Y Y Y N Y Y Y Y Y 
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used to control for 
confounding 
(b) Describe any methods 
used to examine 
subgroups and 
interactions 
Y Y Y N Y Y Y Y Y 
(c) Explain how missing 
data were addressed 
N N N N N/A N/A N N/A Y 
(d) Cohort study: If 
applicable, explain how 
loss to follow-up was 
addressed 
N/A N/A N/A N Y N/A N/A N/A N/A 
Case-control study: If 
applicable, explain how 
matching of cases and 
controls was addressed 
N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Cross-sectional study: If 
applicable, describe 
analytical methods taking 
account of sampling 
strategy 
Y N/A N N/A Y N/A Y N/A N/A 
(e) Describe any 
sensitivity analyses 
Y N N N N N N Y N/A 
Results                  
Participants (a) Report numbers of 
individuals at each stage 
of study—e.g. numbers 
potentially eligible, 
examined for eligibility, 
confirmed eligible, 
included in the study, 
completing follow-up, 
and analysed 
Y Y Y Y Y Y Y Y Y 
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(b) Give reasons for non-
participation at each stage 
Y Y N Y Y N/A Y N/A N/A 
(c) Consider using a flow 
diagram 
N Y Y Y N N/A Y N N 
Descriptive (a) Give characteristics of 
study participants (e.g. 
demographic, clinical and 
social) and information on 
exposures and potential 
confounders 
Y Y Y Y Y y Y Y Y 
Data (b) Indicate number of 
participants with missing 
data for each variable of 
interest 
Y N N N Y N N N Y 
  (c) Cohort study: 
Summarise follow-up 
time (e.g. average and 
total amount) 
N/A N/A N/A Y N/A Y N/A Y Y 
Outcome data Cohort study: Report 
numbers of outcome 
events or summary 
measures over time 
N/A N/A N/A Y N/A Y N/A Y Y 
Case-control study: 
Report numbers in each 
exposure category, or 
summary measures of 
exposure 
N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Cross-sectional study: 
Report numbers of 
outcome events or 
summary measures 
Y Y Y N/A Y N/A Y N/A N/A 
Main results a) Give unadjusted 
estimates and, if 
applicable, confounder-
Y Y Y Y Y Y Y Y Y 
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adjusted estimates and 
their precision (e.g. 95% 
confidence interval). 
Make clear which 
confounders were 
adjusted for and why they 
were included 
(b) Report category 
boundaries when 
continuous variables were 
categorised  
Y Y Y Y Y N/A Y Y Y 
(c) If relevant, consider 
translating estimates of 
relative risk into absolute 
risk for a meaningful time 
period 
N/A N/A N N Y Y Y Y Y 
Other analyses Report other analyses 




Y Y N Y Y Y Y Y Y 
Discussion            
Key results Summarise key results 
with reference to study 
objectives 
Y Y Y Y Y Y Y Y Y 
Limitations Discuss limitations of the 
study, taking into account 
sources of potential bias 
or imprecision 
Y Y Y Y Y Y Y Y Y 
Discuss direction and 
magnitude of any 
potential bias 
     Y Y Y Y 
Interpretation Give a cautious overall 
interpretation of results 
Y Y Y Y Y Y Y Y Y 
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limitations, multiplicity of 
analyses, results from 
similar studies, and other 
relevant evidence 
Generalisability Discuss the 
generalisability (external 
validity) of the study 
results 
Y Y N Y Y Y Y Y Y 
Other information            
Funding Give the source of 
funding and the role of 
the funders for the present 
study and, if applicable, 
for the original study on 
which the present article 
was based 
N Y Y Y Y N Y Y Y 
Total   27/31 24/31 21/33 24/34 31/33 24/30 30/34 30/33 30/32 




Appendix 2.6: Critical Review of Qualitative Studies Assessing GP Involvement in Cancer Care 
Using Walsh and Downie Criteria 
Stages Essential Criteria Specific Prompts Hudson 
et al. 
2012[137] 





Scope and purpose Clear statement of and 
rationale for research 
questions, aims and 
purposes 
Clarity of focus demonstrated Y Y Y 
Explicit purpose given, such as 
descriptive/explanatory intent, theory building 
and hypothesis testing 
Y Y Y 
Link between research and existing knowledge 
demonstrated 
Y Y Y 
Study thoroughly 
contextualised by existing 
literature 
Evidence of systematic approach to literature 
review, location of literature to contextualise 
the findings, or both 
Y Y Y 
Design Method/design apparent 
and consistent with 
research intent 
Rationale given for use of qualitative design Y Y Y 
Discussion of why particular method chosen is 
most appropriate, sensitive and relevant to 
research questions and aims 
Y Y Y 
Discussion of epistemological/ontological 
grounding 
Y Y Y 
Data collection strategy 
apparent and appropriate 
Were data collection methods appropriate for 
the type of data required and the specific 
qualitative method? 
Y Y Y 
Were they likely to capture the 
complexity/diversity of experience and 
illuminate context in sufficient detail? 
Y Y Y 
Was triangulation of data sources used, if 
appropriate? 
N/A Y Y 
Sampling strategy Sample and sampling 
method appropriate 
Selection criteria detailed, and description of 
how sampling was undertaken 
Y Y Y 
Justification for sampling strategy given N Y N 
Thickness of description likely to be achieved 
from sampling 
Y Y Y 
Any disparity between planned and actual 
sample explained 
Y Y N 
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Stages Essential Criteria Specific Prompts Hudson 
et al. 
2012[137] 





Analysis Analytic approach 
appropriate 
Approach made explicit (e.g. thematic 
distillation, constant comparative method, 
grounded theory) 
Y Y Y 
Was it appropriate for the qualitative method 
chosen? 
Y Y Y 
Were data managed by software package or by 
hand, and why? 
Y Y Y 
Discussion of how coding systems/conceptual 
frameworks evolved 
Y Y Y 
How was context of data retained during 
analysis? 
Y Y Y 
Evidence that the subjective meanings of 
participants were portrayed 
N Y Y 
Evidence of more than one researcher involved 
in stages, if appropriate to 
epistemological/theoretical stance 
Y Y Y 
Did research participants have any 
involvement in analysis (e.g. member 
checking)? 
Y Y Y 
Evidence provided that data reached 
saturation, or discussion and rationale if it did 
not 
Y Y Y 
Evidence that deviant data were sought, or 
discussion and rationale if they were not 
N N N 
Interpretation Context described and 
taken account of in 
interpretation 
Description of social/physical and 
interpersonal contexts of data collection 
Y Y Y 
Clear audit trail given Evidence that researcher spent time ‘dwelling 
with the data’, interrogating it for competing 
or alternative explanations of phenomena 
Y Y Y 
Sufficient discussion of research processes so 
that others can follow the ‘decision trail’ 
Y Y Y 
Data used to support 
interpretation 
Extensive use of field notes entries/verbatim 
interview quotations in discussion of findings 
Y Y Y 
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Stages Essential Criteria Specific Prompts Hudson 
et al. 
2012[137] 





Clear exposition of how interpretation led to 
conclusions 
Y Y Y 
Reflexivity Researcher reflexivity 
demonstrated 
Discussion of relationship between researcher 
and participants during fieldwork 
Y Y Y 
Demonstration of researcher’s influence on 
stages of research process 
Y Y Y 
Evidence of self-awareness/insight Y Y Y 
Documentation of effects of the research on 
researcher 
N N N 
Evidence of how problems/complications were 
managed 
Y Y Y 
Ethical dimensions Demonstration of 
sensitivity to ethical 
concerns 
Ethical committee approval granted Y Y Y 
Clear commitment to integrity, honesty, 
transparency, equality and mutual respect in 
relationships with participants 
Y Y Y 
Evidence of fair dealing with all research 
participants 
Y Y Y 
Record of dilemmas and how they were 
resolved in relation to ethical issues 
Y Y Y 
Documentation of how autonomy, consent, 
confidentiality and anonymity were managed 
Y Y Y 
Relevance and transferability Relevance and 
transferability evident 
Sufficient evidence for typicality specificity to 
be assessed 
Y Y Y 
Analysis interwoven with existing theories and 
other relevant explanatory literature drawn 
from similar settings and studies 
Y Y Y 
Discussion of how explanatory 
propositions/emergent theory may fit other 
contexts 
Y Y Y 
Limitations/weaknesses of study clearly 
outlined 
Y Y Y 
Clearly resonates with other knowledge and 
experience 
Y Y Y 
Results/conclusions obviously supported by 
evidence 
Y Y Y 
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Stages Essential Criteria Specific Prompts Hudson 
et al. 
2012[137] 





Interpretation plausible and ‘makes sense’ Y Y Y 
Provides new insights and increases 
understanding  
Y Y Y 
Significance for current policy and practice 
outlined 
Y Y Y 
Assessment of value/empowerment for 
participants 
Y Y Y 
Outlines further directions for investigation Y Y Y 
Comment on whether aims/purposes of 
research were achieved 
Y Y Y 









































Excluded (22.5% Stage IV and 3–5% unstaged) 
Physical 
Weight loss n = 1–6 (5–55%[1]) 
Peripheral-neuropathy: n = 4 (12%[10]) 
Nausea/vomiting: n = 1–6 (5–55%[1]) 
Fatigue: n = 17 (23%[1]) 
Pain and cramping: n = 5 (7%[1]) 
 
Psychological 
*Negative body image: n = 6 (25%) 
*Sexual dysfunction: n = 6 (26%[1, 5, 6]) 
Depression: n = 19 (25%[7]) 
Fear of recurrence: n = 50 (67–68%[6-8]) 
Anxiety: n = 5 (7%[7]) 




Diarrhoea: n = 10 (13–14%[1-4]) 
Constipation: n = 5 (7%[1]) 
BO urgency: n = 15 (20–22%[2, 3]) 
Faecal incontinence: n = 10 (14–16%[2, 3]) 
Urine incontinence: n = 9 (38%[1]) 
Urine retention: n = 7 (31%[1]) 
 
Social 
Activity limitation: n = 11 (15%[3]) 












Please rate the following questions based on the level of importance. 
 
e.g. Extremely unimportant    1 ☐    2 ☐      3 ☒      4 ☐   5 ☐    Extremely important 
 
RE: PATIENTS TREATED FOR LOWER BOWEL CANCER 
 
The following issues/problems have been identified from the literature as being important side-
effects in the years after active treatment (usually more than one year). Such problems or issues 
may be raised by patients during their follow-up appointments. 
 
From your experience, please indicate how important each issue is for patients to raise with 
their doctor. 
 
1. Diarrhoea (loose, watery bowel motions)  1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 
 ☐ 
 2. Inability to defer a bowel movement for more               1 ☐ 2 ☐ 3 ☐     4  ☐    5 
     than 15 minutes 
 
3. Leakage of stool  1 ☐ 2 ☐ 3  ☐     4  ☐    5 
 ☐ 
 4. Need to wear protective pads due to leakage  1 ☐ 2 ☐ 3  ☐     4  ☐    5 
 ☐ 
     of stool 
 5. Frequent bowel movements during the night  1 ☐ 2 ☐ 3  ☐     4  ☐    5 
 ☐ 
     (three times or more) 
 6. Frequent bowel movements during the day  1 ☐ 2 ☐ 3  ☐     4   ☐   5 
 ☐ 
     (three times or more) 
 7. Abdominal pain  1 ☐ 2 ☐ 3   ☐    4   ☐   5 
 ☐ 
 8. Constipation  1 ☐ 2 ☐ 3   ☐    4   ☐   5 
 ☐ 
 9. The need to spend money managing 1 ☐ 2 ☐ 3   ☐    4   ☐   5 
 ☐ 
      bowel issues 
 10. Feeling nauseous or vomiting  1 ☐ 2 ☐ 3   ☐    4   ☐   5 
 ☐ 
 11. Poor appetite  1 ☐ 2 ☐ 3   ☐    4   ☐   5 
 ☐ 
 12. Feeling more tired than usual (fatigued)  1 ☐ 2 ☐ 3   ☐    4   ☐   5 
 ☐ 
 13. Pain and tingling sensations in the fingers  1 ☐ 2 ☐ 3   ☐    4   ☐    5 
 ☐ 
        and toes  14. Difficulties starting to pass urine  1 ☐ 2 ☐ 3   ☐  4 ☐ 5 
 ☐ 









Please rate the following questions based on the level of importance. 
 
e.g. Extremely unimportant    1 ☐    2 ☐      3 ☒      4 ☐   5 ☐    Extremely important 
16. Need to wear protective pads due to 1 ☐ 2 ☐ 3  ☐  4 ☐ 5 
 ☐ 
        leakage of urine 
17. (For women ) 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 
 ☐ 
        Pain or discomfort during intercourse 
and/or vaginal dryness 
18. (For men)  1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 
 ☐ 
        Difficulties getting or maintaining an 
        erection and/or ejaculation problems 19. Difficulty sleeping  1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 
 ☐ 
20. Feeling anxious  1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 
 ☐ 
21. Feeling depressed  1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 
 ☐ 
22. Unintentional weight loss  1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 
 ☐ 
23. Negative body image  1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 
 ☐ 
24. Fear of recurrence  1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 
 ☐ 
25. Need for dietary advice  1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 
 ☐ 
26. Financial difficulties  1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 
 ☐ 
27. Difficulties driving a car 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 
 ☐ 
28. Inability to do things around the house  1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 
 ☐ 







29. Inability to go shopping  1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 
 ☐ 
 
Other symptoms you think are extremely important (5 ☒ )and have been left out: 
 
 
1. Enter symptom here 
2. Enter symptom here 
3. Enter symptom here 
4. Enter symptom here 
5. Enter symptom here 
 
 





Appendix 3.3: Participant Information Sheet and Consent 
Forms 
   
 




Colorectal Cancer Follow-up: An Intervention to Support Patients Following Treatment 
 
Investigators: Ms Irene Ngune, Professor Moyez Jiwa, Professor Alexander McManus, Professor 
Jeff Hughes and Dr Rupert Hodder. 
 
 
Please take time to read the following information carefully and to discuss it with your 
family, friends and general practitioner, if you wish. If any part of the information is not clear to 
you, or if you would like more information, do not hesitate to ask us to explain it more fully. 
Make certain you do this before you sign the consent form to participate in this study. 
 
Who is funding this study? 
Primary Health Care Research Evaluation and Development 
 
Contact people: 
If you have any questions about the study, you can contact: 
 
Irene Ngune: telephone—08 9266 9213 or email—I.ngune@curtin.edu.au 
 
Decision to participate: 
Your decision to participate in this study is voluntary— that is, you may decide to be in this 
study or not take part in it at all. If do you decide to participate, you are able to change your mind 
at any time during the study. However, before you make any decision, it is important that you 
understand why this study is being done and what it will involve, including your rights and 
responsibilities. You will be given a copy of this Participant Information Sheet and Consent Form 
to keep for your personal record. 
 
Any decision you make will not affect your regular medical care or any benefit to which you 
would otherwise be entitled. 
 
The Participant Information Sheet explains the study and includes details such as: 
 why this study might be suitable for you 
 possible benefits and risks of the study 
 what your rights and responsibilities are if you agree to participate. 
 
What is the purpose of this study? 
You are invited to participate in a study that assesses health issues that may come up after 
completing colorectal cancer treatment. A self-assessment form will be developed that will assist 
patients to be able to identify symptoms or issues they may experience during follow-up, keep a 
record of these issues/symptoms, and use the form as a guide to consult their clinician. We wish to 
identify the benefits patients may receive after being provided with this additional support (self-
assessment tool) during follow-up. 
 
Why is this study suitable to me? 
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You are eligible to participate in this study because you have completed colorectal cancer 
treatment and are receiving follow-up care. 
 
How long will I be in this study? 
If you agree to participate, you will be enrolled for a period of six months. This study does not 
prevent you from seeking healthcare or attending medical appointments you may have with 
your clinician/specialist. 
 
What will happen if I decide to be in this study? 
If you agree to participate, you may be given an assessment tool that you will use to record 
any issues you experience while receiving follow-up, and you can use it when you visit your 
general practitioner (GP). 
 
Also, at the beginning of the study and at several points within the six months, you will be sent 
surveys and/or you will be telephoned by a researcher to ask questions about your health. All your 
details will remain confidential and will only be known by the researcher. 
 
Your GP will also be asked about symptoms you may have reported to him or her and the 
investigations that your GP may have done over the six months. 
 
Are there any reasons I should not be in this study? 
You should not participate in this study if you have not completed treatment for colorectal cancer. 
Eligible participants will be those who are receiving or have completed follow-up with their 
clinician/specialist. 
 
What are the costs to me? 
We do not anticipate there will be any costs associated with this study. 
 
What are the possible benefits of taking part, to me and to the wider community? 
This study will enable us to determine whether colorectal cancer patients and their 
clinicians would benefit from using this self-assessment form during consultation. Your 
involvement may benefit you, but it may also be of benefit to other patients like yo u who will 
use the form. 
 
How will my safety be ensured? 
No harm is expected to result from your involvement in this study. The surveys may contain 
questions that are personal or private. If for any reason you find these upsetting, you may choose 
not to answer the question or you may choose to speak with your doctor. If for any reason 
you choose to withdraw from the study, you are free to do so without having to give a reason. 
 
What are my alternatives if I do not want to participate in this study? 
If for any reason you choose not to participate in this study, you are free to do so without giving a 
reason to the researcher. This will not affect your treatment or medical appointments in any way. 
 
What are the possible side-effects, risks and discomforts of taking part? 
The researchers will need to collect personal data about you, which may be sensitive. Examples of 
such data include your name, contact details, date of birth and relevant health information. 
 
However, any personal or health information will be kept private and confidential. It will be stored 
securely, and only authorised people who understand that it must be kept confidential will have 
access to it. Your study details will be given a number so that your identity will not be apparent. 
The data collected will be stored securely, then archived and destroyed according to the Sir 
Charles Gardner Hospital and Curtin University policies. 
 
All electronic records will be identified by a unique study number. The database will be protected 
from unauthorised access and will not be available to anyone other than the researchers involved in 
this study. The results of the research will be made available to other health professionals 
through medical journals or meetings, but you will not be identifiable. 
 
What if new information comes along during the study? 
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We do not anticipate the study will have any new information that will affect your treatment. 
However, if for any reason new information becomes available that may affect whether you wish 
to continue with the study, you may be asked to sign a new consent form. 
 
Could the study be stopped early? 
Sometimes a study may need to be stopped. The reasons a study may end early include safety 
concerns for the participants, because the researcher chooses to stop the study early, or for other 
reasons. If this does occur, you will be notified of the reasons, if known. 
 
What happens at the end of the study? 
At the end of the study, the participants will retain a copy of the self-assessment tool and use it if 
they wish. Participants will continue  with their usual follow-up care as scheduled by their 
clinicians. 
 
Will my taking part in this study be kept confidential? 
The researchers will need to collect personal data about you, which may be sensitive. Examples of 
such data include your name, contact details, date of birth and relevant health information. 
 
However, any personal or health information will be kept private and confidential. It will be stored 
securely and only authorised people who understand that it must be kept confidential will have 
access to it. Your study details will be given a number so that your identity will not be apparent. 
All electronic records will be identified by a unique study number. The database will be protected 
from unauthorised access and will not be available to anyone other than the researchers involved in 
this study. The results of the research will be made available to other health professionals 
through medical journals or meetings, but you will not be identifiable. 
 
How can I find out the results of this study? 
In due course, the researchers will send you information about the results of the study. The results 
of the study will also be published in peer-reviewed journals and presented at national and 
international conferences. You may find out about the study results by reading these articles or by 
contacting the researcher directly. 
 
Who has reviewed this study? 
The Sir Charles Gardner Group and Curtin University Human Research Ethics Committees have 
reviewed this study and given approval for the conduct of this research study. In doing so, this 
research conforms to the principles established by the National Statement on Ethical Conduct in 
Human Research, and abides by the Good Clinical Practice Guidelines. 
 





























Colorectal Cancer Follow-up: An Intervention to Support Patients Following Treatment 
 
Investigators: Ms Irene Ngune, Professor Moyez Jiwa, Professor Alexander McManus, Professor 





Date of Birth:    
 
Name of your GP: 
  
 




NOTE: If you are still unclear about anything you have read in the Participant Information 
Sheet and Consent Form, please speak to your doctor before signing this Consent Form. 
 
1. I have been given information, both verbally and in writing, about this study and, 
having had time to consider it, am now able to make an informed decision to participate. 
 
2. I have been told about the potential benefits and known risks of taking part in this study 
and I understand what this means to me. 
 
3. I was given the opportunity to have a family member or friend with me when this study was 
being explained to me. I have been able to ask questions and have had all my questions 
answered. 
 
4. I know that I do not have to take part in this study, and that my decision to take part is 
voluntary. I understand that I can withdraw from this study at any time without this decision 
affecting my medical care. 
 
5. I understand that participating in this study does not affect any right to compensation, which I 
may have under statute or common law. 
 
6. I accept that by taking part in this research, any information obtained about me during the study 
may be published, provided that my name and other identifying information are not used. 
 
 




Name of Researcher Signature of Researcher Date 
The Sir Charles Gairdner Group Human Research Ethics Committee has granted approval for the conduct of 
this study. If you have any concerns about the ethics or code of practice of the study, please contact the 
Executive Officer of the Sir Charles Gairdner Group Human Research Ethics Committee on (08) 9346 2999. 
 
This study has also been approved by the Curtin University Human Research Ethics Committee (Approval 
Number HR 42/2012). If needed, the verification of approval can be obtained by writing to the Curtin 
University Human Ethics Committee (c/- Office of Research and Development, Curtin University, GPO Box 







Appendix 3.4: Self-assessment Tool for Patients (SATp) 
These questions relate to issues that you might experience as a result of your colorectal 










1. I have had diarrhoea (loose watery bowel motions)   
2. I have been unable to defer a bowel movement for more than 15 minutes   
3. I have needed to wear protective pads due to leakage of stool   
4. I have had frequent bowel movements (3 or more) during the night and/or day   
5. I have had abdominal pain   
6. I have had flatulence   
7. I have spent money managing my bowel issues   
8. I have felt nauseous (sick) or vomited   
9. I have had a poor appetite   
10. I have been feeling more tired than usual (fatigued)   
11. I have had pain and/or tingling in my fingers and toes   
12. I have had difficulties starting to pass urine   
13. I have needed to wear protective pads due to leakage of urine   
14. I have had difficulty sleeping   
15. I have been anxious   
16. I have been feeling depressed   
17. I have had sexual problems (vaginal dryness for women, or ejaculation and 
erection problems for men) 
  
18. During the past month, my cancer treatment has caused me to lose weight that 
concerns me 
  
19. I have been concerned about how my body looks since having my treatment   
20. During the past month, I have been worried that my cancer will return   
21. I have needed advice about what I should be eating   
22. My cancer treatment has caused me some financial difficulties   
23. Since having my treatment, I have had difficulties driving my car   
24. Since having my treatment, I have been unable to do things around the house 
(gardening, cleaning, working in the shed) 
  
25. I have been unable to go shopping because of the effects of my treatment   
26. Have you shown this form to your GP?   




Appendix 3.5: SATp Instruction Manual 
Dear Participant 
 
Thank you for choosing to participate in this study. 
 
1. In this booklet there are 10 sets of forms. 
2. Each set contains three forms (white, yellow and blue). The white form is the original and the 




3. Before filling out the forms, please flip the first set (white, yellow and blue) over onto the 
purple cover (the right hand flap of the purple folder). This is to protect the set underneath. 
 
    
 
 
Once you have completed the first set: 
 Please send the white copy back to me. There is a reply-paid envelope attached. 
 Please give the yellow copy to your GP whenever you visit him or her, even if your 
reason for the visit is not bowel cancer. This is to keep your GP updated of the issues you 
are experiencing while you are receiving follow-up. Your GP is aware that you are 
participating in this study. 
 The blue copy is for your records, and you are welcome to use it during your follow-up 
clinic appointments at Sir Charles Gairdner Hospital. 
 
Please fill out a set once every month and any other time before you visit your GP. 
 
Thank you for your participation. 
 










Appendix 3.6: Letter of Acceptance for Publication of the 
SATp Manuscript 
 
Quality in Primary Care ~ Acceptance ~ Development of a patient-administered self-assessment tool (SATp) 
for follow-up of CRC patients in general practice 
Susan Bowler <sbowler@lincoln.ac.uk> 
Fri 17/10/2014 11:32 AM 
Inbox 
To: Irene Ngune <I.Ngune@curtin.edu.au>; 
Cc: Niro Siriwardena <nsiriwardena@lincoln.ac.uk>; 
 
Dear Dr Ngune, 
 
Development of a patient-administered self-assessment tool (SATp) for follow-up of colorectal cancer 
patients in general practice 
 
Thank you for submitting the above paper. I am pleased to confirm that your article has been accepted for 
publication in Quality in Primary Care. Please send me the contact details for your co-authors in order that I 
can contact them directly. 
 
As you will know from my recent e-mail, Quality in Primary Care has been bought by OMICS and the new 
arrangements for publishing the journal have not yet been finalised. This is causing delays in our usual 
processes and we apologise for this. We aim to keep you informed of future developments but in the 
meantime if you have any queries, please do not hesitate to contact me. 
 
I should like to thank and congratulate you for the work which you and your colleagues have done and look 






Sue Bowler (Mrs) 
Editorial Assistant/Research Administrator 
CaHRU—Community and Health Research Unit www.cahru.org.uk 
University of Lincoln 
School of Health and Social Care 
Tel: 44 (0) 1522 886949 
 
For and on behalf of: 
 
Prof Niroshan Siriwardena 
Editor, Quality in Primary Care 
School of Health & Social Care University of Lincoln Brayford Pool Lincoln LN6 7TS 
Email: nsiriwardena@lincoln.ac.uk 
Web: http://staff.lincoln.ac.uk/nsiriwardena http://www.cahru.org.uk/staff/ 
Journal: http://www.ingentaconnect.com/content/rmp/qpc 














Appendix 4.2: TPB Survey 
Section A 
 
Instructions: Please answer every question by ticking () your response in the box next to 
the answer that best applies to your experience 
 
OR write your answer in the box provided 
 
 
This questionnaire is anonymous and the responses you provide will be kept 
confidential. Thank you for your participation. Please complete the questions below. 
 
1. Are you male or female? 
a) Male 
b) Female 
2. What is your date of birth or age in years on your last birthday? ___________________ 
3. Where do you live? 
a) Suburb 
b) Postcode 
4. What is your present marital status? 
a) Never married 
b) Widowed 
c) Married 
d) Separated, but not divorced 
e) Divorced 
f) De facto partner 
5. What is the highest level of formal education you have completed? 
a) Primary school 
b) Year 10 or equivalent 
c) Year 12 or equivalent 
d) Trade certificate/TAFE 
e) University /CAE (College of Advanced Education) 
Which of the following best describes your current employment status? (Tick one option) 
a) Self employed 
b) Employed for wages, salary or payment in kind 
c) Engaged in home duties 
d) Student 
e) Unable to work 
f) Unemployed 
g) Retired 




The following questions are about your medical care 
 
Check-up(s) in this section refer to a visit to your general practitioner (GP), specialist or 
other health professional. 
 
 
6. How often did you visit a GP during the last 12 months for any reason? 
___ ___ ___ (estimate the number of times) 
 
 




Written response goes here 
 
180 
8. Since you were first diagnosed with colorectal cancer, who have you discussed it with? (Tick 








9. Thinking about the last 12 months, how often have you had a medical check-up for your 
colorectal cancer? 
a) Every week 
b) At least once a month 
c) Every two to three months 
d) Every four to six months 
e) Once during the last 12 months 
f) I did not have regular check-ups 
 
 
10. When is your next check-up about your colorectal cancer? 
a) ______________________________________(month/year) 
b) I do not have a check-up scheduled 
 
 
11. Do you visit a GP for any other health conditions? 
a) Yes 
b) No  (if no, please go to Section C) 
 
 





The following questions ask about choices of medical care during the next six months. 
 
 
Please circle the number that best describes your level of agreement with the following statements 
 
e.g. Likely     1     2     3     4     5     Unlikely 
 
It is important that the doctors I 
see have all the information 
about my colorectal cancer and 
treatment 
Strongly disagree 1 2 3 4 5 Strongly 
agree 
Attending a GP about my 
colorectal cancer is likely to 
detect problems and side-
effects early 
Not likely  1 2 3 4 5 Likely 
Attending a GP about my 
colorectal cancer will reassure 
me 
Strongly disagree 1 2 3 4 5 Strongly 
agree 
 
Please circle the number that best describes your level of agreement with the following statements 
 




Making a routine appointment 




1 2 3 4 5 Extremely 
easy 
For me to travel to see a GP 
about my colorectal is 
Extremely 
difficult 
1 2 3 4 5 Extremely 
easy 
It is easy for me to attend a GP 
about my colorectal cancer 
Strongly 
Disagree  
1 2 3 4 5 Strongly 
agree 
It is affordable for me to attend 




1 2 3 4 5 Strongly 
agree 
 
Please circle the number that best describes your level of agreement with the following statements 
 
e.g. Strongly disagree     1     2     3     4     5     Strongly agree 
 
My family members think I should 
attend a GP about my colorectal 
cancer 
Strongly disagree 1 2 3 4 5 Strongly 
agree 
My close friends think I should attend 
a GP about my colorectal cancer 
Strongly disagree 1 2 3 4 5 Strongly 
agree 
My specialist thinks I should attend a 
GP about my colorectal cancer 
Strongly disagree 1 2 3 4 5 Strongly 
agree 
My cancer care nurse at the hospital 
thinks I should attend a GP about my 
colorectal cancer 
Strongly disagree 1 2 3 4 5 Strongly 
agree 
Most people who are important to me 
think I should attend a GP about my 
colorectal cancer 
 
Strongly disagree 1 2 3 4 5 Strongly 
agree 
 
Please circle the number that best describes your level of agreement with the following statements 
 
e.g. Strongly disagree     1     2     3     4     5     Strongly agree 
 
In the next six months, I am likely to attend a GP Very 
unlikely  
1 2 3 4 5 Very likely 
In the next six months, I am likely to talk about 
my colorectal cancer with a GP 
Very 
unlikely  
1 2 3 4 5 Very likely 
In the next six months, I intend to only visit a 














Appendix 4.3: TPB Questionnaire Score Sheet 
 
 
Questions measuring attitudes towards attending a GP for colorectal cancer care 
 
It is important that the doctors I see 
have all the information about my 
colorectal cancer and treatment 
Strongly 
disagree 
1 2 3 4 5 Strongly 
agree 
Attending a GP about my colorectal 




1 2 3 4 5 Likely 
Attending a GP about my colorectal 
cancer will reassure me  
Strongly 
disagree 
1 2 3 4 5 Strongly 
agree 
Scoring: Record negatively worded end points (‘bad’ and ‘unpleasant [for me]’) to reflect lower 
scores. E.g. bad = 1 and good = 5, while the middle score = 3. Calculate the mean of the score to 
give an overall attitude score. 
 
Questions measuring intentions of attending a GP for CRC care 
 
In the next six months, I am likely to attend a 
GP  
Very unlikely  1 2 3 4 5 Very likely 
In the next six months, I am likely to talk 
about my colorectal cancer with a GP  
Very unlikely  1 2 3 4 5 Very likely 
In the next six months, I intend to only visit a 
specialist for my colorectal cancer  
Strongly 
disagree 
1 2 3 4 5 Strongly 
agree 
Scoring: Calculate the mean of the three intention scores.
 
 
Questions measuring PCB 
Making a routine appointment with a 
GP about my colorectal cancer is 
Extremely 
difficult 
1 2 3 4 5 Extremely 
easy 
For me to travel to see a GP about my 
colorectal cancer is 
Extremely 
difficult 
1 2 3 4 5 Extremely 
easy 
It is easy for me to attend a GP about 
my colorectal cancer 
Strongly disagree  1 2 3 4 5 Strongly 
agree 
It is affordable for me to attend a GP 
about my colorectal cancer  
Strongly disagree 1 2 3 4 5 Strongly 
agree 
Scoring: Record negatively worded end points to reflect lower scores. E.g. bad = 1 and good = 5, 
while the middle score = 3. Calculate the mean of the score to give an overall PCB score. 
 
Questions measuring PCB 
My family members think I should attend a GP 
about my colorectal cancer 
Strongly 
disagree 
1 2 3 4 5 Strongly 
agree 
My close friends think I should attend a GP 
about my colorectal cancer 
Strongly 
disagree 
1 2 3 4 5 Strongly 
agree 
My specialist thinks I should attend a GP 
about my colorectal cancer 
Strongly 
disagree 
1 2 3 4 5 Strongly 
agree 
My cancer care nurse at the hospital thinks I 
should attend a GP about my colorectal cancer 
Strongly 
disagree 
1 2 3 4 5 Strongly 
agree 
Most people who are important to me think I 
should attend a GP about my colorectal cancer  
Strongly 
disagree 
1 2 3 4 5 Strongly 
agree 
Scoring: Recode negatively worded endpoints on the right, so that high scores consistently reflect 
greater social pressure to do the target behaviour. Calculate the mean of the item scores to give an 








Patient study ID  
 
 
Name of the GP  
 
 




If SATp presented Yes  1 
No  2 
Not indicated 3 
 




Referred to  Specialist 1 
 AHW 2 
 Other 3 
 
Investigations offered Radiological 1 
 Laboratory 2 
 Other 3 
 
Prescription offered Analgesics 1 
 Antibiotics 2 
 Aperients 3 
 Bulk forming agents 4 
 Mood stabilisers 5 
 Sedatives 6 
 Other  7 
 
If health advice offered Yes  1 














Appendix 6.2: Details of Patients Presented in the Video 
Vignettes 
Details of patients presented in the video vignettes 
 
Case 1: ‘James’—58 years of age, married and works as a plumber. Has high blood pressure, but 
now stable. Diagnosed with bowel cancer (splenic flexure mucinous adenocarcinoma, no 
metastases in 21 lymph nodes, pT4b, N0, M0) 18 months ago and completed treatment 12 months 
ago (treatment offered—left hemi-colectomy, chemotherapy [Flurouracil + Leucovorin + 
Oxaliplatin FOLFOX]). 
 
Presents with pain and tingling sensation in his fingertips and toes that has markedly interfered 
with his work. He complains of having trouble grasping items with his fingers. On examination, 
there is no jaundice, anaemia, cyanosis, oedema or lymphadenopathy. Neuro examination—
normal; upper limbs sensation—moderately on light touch; reduced from 5 cm below elbow; 
reflex—absent wrist, elbow +; temp—reduced from 5 cm below elbow; position sense—
abnormal; coordination—poor fine motor movements, unable to unbutton buttons. 
 
Diagnosis: Chemotherapy-induced peripheral neuropathy. 
 
Case 2: ‘David’—60 years of age, maintenance worker at a school, previously divorce and in a 
new relationship for the last six months. Presented with erectile dysfunction that is affecting his 
relationship. He was aware such a problem would occur following surgery. His urine stream is 
normal. He was diagnosed with rectal cancer (mid to lower rectal mass, T3, N2, M0) and 
completed treatment 12 months ago (treatment offered—anterior resection, ostomy, radiotherapy 
long course [5/52]). He has no family history of diabetes. Random blood sugars—normal; full 
blood count—normal; and urea/electrolyte/creatinine—normal. Recent carcinoembryonic 
antigen—3 ng/ml and CT scan abdomen—normal. On examination, normal: perianal reflexes 
intact. No jaundice, anaemia, cyanosis, oedema or  l ymphadenopathy. Vital signs are within 
normal ranges. 
 
Diagnosis: Erectile dysfunction secondary to lower anterior resection. 
 
Case 3: ‘Margaret’—45 years of age, peri-menopausal and has been on hormonal replacement 
therapy. Diagnosed with rectal cancer (low rectal mass rT3,N0, M0) two years ago and completed 
treatment about 18 months ago (treatment offered—low anterior resection with ostomy). 
Generally feeling well, but finds it difficult to cope with urinary urgency and incontinence. 
 
Recent follow-up investigations: Pap smear—normal;  thyroid function tests—normal; liver 
function tests—normal; Vitamin D—normal; recent carcinoembryonic antigen—3 ng/ml; CT 
scan abdomen—normal. No evidence of urinary tract infection. On examination, no jaundice, 
anaemia, cyanosis, oedema or lymphadenopathy. No abdominal tenderness; small uterus—no 
mass or tenderness; no per vaginal bleeding; mucosa appears normal; no punch tenderness over 
the kidneys. However, pelvic floor is weak. 
 
Diagnosis: Urinary dysfunction secondary to lower anterior resection/radiation. 
 
Case 4: ‘Doreen’—54 years of age. Over the past two months, she has been feeling nauseous and 
sick and having lower back pain (waking her at night) and weight loss that concerns her. She was 
diagnosed with sgmoid adenocarcinoma T2N1m0 2.5 years ago and completed treatment two 
years ago (laparoscopic anterior resection and neo‐adjuvant therapy). Six months ago, 
carcinoembryonic antigen levels—11 ng/ml and CT scan of pelvis/abdomen—small area of low 
attenuation near the left lateral margin of the suture line fluid collection. PET—no evidence of 
distant metastatic disease; CXR—clear; pap smear and liver function tests—normal. On 
examination, there is mild lower abdominal distension; tenderness of lower abdomen (diffuse 
non-specific); bowel sound +++; per rectal examination—red blood and stool on glove. 
 
Diagnosis: Tumour recurrence. 
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Case 5: ‘Joan’—68 years of age, retired nurse. She has noninsulin-dependent diabetes mellitus, 
but blood sugars are under control. She has been on Metformin 500mg BD for her diabetes for 
many years. She can no longer take her dog for a walk. She is easily exhausted. She completed 
treatment for colon cancer (caecal cancer T3N0M0) one year ago, but has been feeling tired most 
of the time. Treatment offered: laparoscopic right hemi-colectomy; adjuvant chemotherapy 
(Flouroracil + leucovorin—six months). Recent carcinoembryonic antigen levels—normal; recent 
HbA1c 5.4—5.6%; pap smear—normal;  thyroid function tests—normal; liver function tests—
normal; Vitamin D—normal; mammogram—normal; ophthalmologist review—normal. On 
examination, there is good eye contact and emotional response is congruent. 
 
Diagnosis: Chemotherapy-induced fatigue. 
 
Case 6: ‘Kerry’—77 years of age, retired. She is asthmatic, but the asthma is under control. She 
was treated for upper rectal cancer T3, N1, M0 one year ago. Her bowels have not settled since 
she completed the treatment—she has been experiencing diarrhoea, which has significantly 
affected her social life. Treatment offered: pre‐operative chemo/radiotherapy 5/52 and post-
operation adjuvant chemotherapy. Recent carcinoembryonic antigen—3 ng/ml and CT scan 
abdomen—normal. Pap smear,  thyroid function tests, liver function tests, Vitamin B levels, full 
blood count, and urea/electrolyte/creatinine levels—normal. On examination, there is no evidence 
of jaundice, anaemia, cyanosis, oedema, lymphadenopathy or dehydration. Per rectal examination 
reveals watery stool and no blood. 
 







Appendix 6.3: Questionnaire GP Video Vignette Study 
Internet-based GP Questionnaire 
 
Welcome to the Colorectal Cancer Study and thank you for your interest in participating. Your 
involvement is important in improving the management of colorectal cancer patients who have 
completed treatment. We hope you will enjoy taking part in this unique method for testing 
innovations in general practice. 
 
Before proceeding, you are required to read the participant information (on the next page) about 
the study, and give consent to participate. 
 
If you need further information about this study, please contact Irene on 92669213 or 
chiriestudies@curtin.edu.au. 
 
Colorectal Cancer Study 
Chief investigators: Irene Ngune and Professor Moyez Jiwa 




Instructions for Participating 
 
Participant Information Sheet 
 
You have been asked to volunteer for a research study that aims to explore the approach to 









You will be invited to view six simulated (1.5 minutes each) standardised consultations that 
portray patients presenting to the GP with complications associated with colorectal cancer 
treatment. 
 
You will be asked to make a decision about the management of each patient and to submit 
details of your decision at the time of viewing the video. 
 
Number of Phases in this Study 
 
This study has only one phase 
 
Payment for Participation 
 
To compensate for the time required to review the case scenarios and complete the associated 
tasks, a reimbursement of $50 will be awarded to you upon completion of the study.  
 
Privacy and Confidentiality 
 
We believe it is extremely important to keep your personal information confidential. Any 
information you provide will be kept strictly confidential. 
 
The information provided will be used for the purpose of this project only and individual results 








Participation in this study is voluntary. You may decline to take part or withdraw from this 
study at any time. 
 
Risks, Benefits and Research Outcomes 
 
There are no risks associated with your participation and any information gained from you will 
be treated as confidential. 
 





Irene Ngune: I.ngune@curtin.edu.au 
 
Professor Moyez Jiwa: m.jiwa@curtin.edu.au 
 
Professor Alexandra McManus: A.Mcmanus@curtin.edu.au 
 




This study has been approved by the Curtin University Human Research Ethics Committee 
(study no. HR42 2012). The committee is comprised of members of the public, academics, 
lawyers, doctors and pastoral carers. Its main role is to protect participants. If needed, 
verification of this approval can be obtained by writing to the Curtin University Human Ethics 
Committee (c/- Office of Research and Development, Curtin University, GPO Box U1987, 





You have been asked to volunteer for a research study that aims to explore the approach 
to management of colorectal cancer patients who have completed treatment. 
 
Please note: It is important t h a t  we are able to contact you by email, so please ensure these 
details are complete and correct. 
 
Click to write the question text 
 
Surname First Name Email address 
Telephone Number 
 
By completing the consent form below you certify that you: 
 
 Are a general practitioner practising in Australia. 
 Have read the Participant Information Sheet and have had any questions answered to your 
satisfaction by the researcher. 
 Have been informed of the benefits and risks associated with this research study. 
 Understand that you are free to withdraw from the study at any time, for any reason and 
without prejudice. 
 Agree to take part in this research study, and for the data obtained to be published, provided 





Internet-based GP Questionnaire 
 
If you are unclear about anything you have read in the Participant Information Sheet or 
this Consent Form, please speak to the researcher before signing this Consent Form. 
 
 Yes, I agree with the points above and consent to participate in this study 
 
 No, I have decided not to participate 
 
This study has been approved by the Curtin University Human Research Ethics Committee 
(Approval study no. HR42 2012). The committee is comprised of members of the public, 
academics, lawyers, doctors and pastoral carers. Its main role is to protect participants. If 
needed, the verification of approval can be obtained by writing to the Curtin University Human 
Ethics Committee (c/- Office of Research and Development, Curtin University, GPO Box 






The study requires you to view videos of simulated consultations. Play the test video below to 
ensure you can see and hear video on this website. If the video does not play, review the video 
troubleshooting instructions (below) for further support. 
 




Video troubleshooting steps 
 
Download and install the Adobe Flash player 
The latest Adobe Flash player for your web browser can be downloaded from the Adobe website 
(free download). Once you have the Flash player installed, you can use the link in your study 
invite email to return to this page. 
 
Enable Javascript 
Javascript must be enabled in your web browser for the video to appear. Complete the steps for 
your web browser on the Google website and return to this page. 
 
Check if YouTube works 
Go to the YouTube website and try playing a few videos. If the videos work there, they should 
also work on the study website. 
 
Try a different web browser or different computer 
If your computer has a second web browser, you can try it with this site and see if the video 









Internet-based GP Questionnaire 
 





Have you previously participated in any of our Curtin Health Innovation Research Institute 
(CHIRI) e-studies (Referral Writer Study, Discharge Summary Study, Prostate Cancer Study & 




















What year did you graduate from medical school? 
 
 
How many years have you been practising as a GP? 
 
 












 New South Wales 
 Queensland 
 Victoria 
 South Australia 
 Tasmania 
 Western Australia 
 Australian Capital Territory 








Name of city/town 
 
 
Select from the list the most appropriate description of where your practice is located by 
rural, remote and metropolitan area classification (RRMA) 
 Capital 
 Other metropolitan 
 Large rural  Small rural  Other rural  Remote centre   Other remote 
 
Select from the list the most appropriate description of where your practice is located 
according to the Australian Standard Geographical Classification (ASGC) remoteness 
structure 
 Major cities  Inner regional  Outer regional  Remote   Very remote 
 
How many GPs are in your practice? 
 




What is your position in the practice? 
 Principal 
 Non-principal 
 Other (please describe) 
 
 
How many general practice sessions you do per week? (1 session = approx 4 hours) 
 
 
How many patients do you see per week? 
 less than 100  100–149  150–199   more than 199 
 
How many direct patient care hours do you work per week? 
 less than 11  1–20   21–40   41–60   more than60 
 
Do you conduct any of your consultations in a language other than English? 
 No 
 Yes, less than 25% of consultations 
 Yes, 25–50% of consultations 




There are six patient/actor-GP consultations to view. Please treat this consultation as if a patient 
has come to your clinic. Take notes if you wish (you can download partly completed Patient 
Health Summaries and Physical Examination pro-forma below, or at each consultation). Your 
progress through the survey is saved after each consultation. If for some reason you have 
problems viewing a video, you will be able to view it again in this survey. 
 
After viewing each consultation, decide what you would do with this patient if they had come 
to you. You will be given three options—to refer the patient to a specialist, prescribe something 
to the patient, or send the patient for a test (you can chose more than one option). For any of 
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these options, you will need to fill out a form (referral letter, test order form or prescription 
sheet), as you normally would in practice, and these will be available in subsequent pages of the 
survey (online). 
 
Patient Health Summary pro-forma downloads 
Patient health summary consultation one 
Patient health summary consultation two 
Patient health summary consultation three 
Patient health summary consultation four 
Patient health summary consultation five 
Patient health summary consultation six 
 
Physical Examination pro-forma downloads 
Doctor's exam consultation one 
Doctor's exam consultation two 
Doctor's exam consultation three 
Doctor's exam consultation four 
Doctor's exam consultation five 
Doctor's exam consultation six 
 
 
Consultation 1: Mr James Spears, age 58 years 
 
Download: 
1. Patient health summary consultation one (pdf) 




If a pop-up window appears, please click no to enable you to watch the video. 
 
Adobe Flash plugin version 9.0.115 or later required for video playback. 
 
Download the Adobe Flash player to play the consultation video. 
 
What is your differential diagnosis? 
 
Your decision (multiple choices can be selected with each management following in 
subsequent pages). 
 Refer to a specialist  Prescribe something  Order tests 
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 Health advice 
 
Would you prescribe something? If so, what would you prescribe? 
 
Would you refer the patient? If so, to whom? 
 
Would you order tests? If so, which tests? 
 
 
Consultation 3: Mrs Margaret Howard, age 45 years 
 
Download: 
1. Patient health summary consultation three (pdf) 




Your decision (multiple choices can be selected with each management following in 
subsequent pages). 
 Refer to a specialist  Prescribe something  Order tests 
 Health advice 
 
Would you prescribe something? If so, what would you prescribe? 
 
Would you refer the patient? If so, to whom? 
 




Consultation 2: Mr David Simpson, age 60 years 
 
Download: 
1. Patient health summary consultation two (pdf) 








If a pop-up window appears, please click no to enable you to watch the video. 
 
Adobe Flash plugin version 9.0.115 or later required for video playback. 
 




Image correlating to the symptom mentioned above by the patient. 
 
Your decision (multiple choices can be selected with each management following in 
subsequent pages). 
 Refer to a specialist  Prescribe something  Order tests 
 Health advice 
 
Would you prescribe something? If so, what would you prescribe? 
 
Would you refer the patient? If so, to whom? 
 




Consultation 4: Ms Doreen Furby, age 54 years 
 
Download: 
1. Patient health summary consultation four (pdf) 
2. Doctor's exam consultation four (pdf) 
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If a pop-up window appears, please click no to enable you to watch the video. 
 
Download the Adobe Flash player to play the consultation video. 
 
Your decision (multiple choices can be selected with each management following in 
subsequent pages). 
 Refer to a specialist  Prescribe something  Order tests 
 Health advice 
 
 
Would you prescribe something? If so, what would you prescribe? 
 
Would you refer the patient? If so, to whom? 
 
Would you order tests? If so, which tests? 
 




Are you registered with the Australian Taxation Office to charge GST? 
 Yes, I have an ABN and I am registered to charge GST 
 No, I do have an ABN and I am not registered to charge GST 









Appendix 6.6: Actor Consent Form for GP Video Vignette 
Study 
Talent release form 
 
 
 
 
